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MECHANISMS OF TYPE-I IFN INHIBITION: EQUINE HERPESVIRUS-1 
ESCAPE FROM THE ANTIVIRAL EFFECT OF TYPE-1 INTERFERON 
RESPONSE IN HOST CELL 
Equine herpesvirus-1 (EHV-1) is one of the most important and prevalent 
viral pathogens of horses causing a major threat to the equine industry 
throughout most of the world. EHV-1 primarily causes respiratory disease but 
viral spread to distant organs enables the development of more severe sequelae; 
abortion and neurologic disease. In order to produce disease, EHV-1 has to 
overcome the innate barrier of the type-I interferon (IFN) system in host cells. 
However, the underlying mechanisms employed by EHV-1 to circumvent the 
type-I IFN response in host cells are not well understood. In this project study, 
using molecular techniques, we explored how EHV-1 is able to escape the type-I 
IFN response in host cells during infection. We also investigated whether EHV-4, 
a closely related but less pathogenic virus, has similar effects on type-I IFN as a 
clue to understanding how widespread IFN suppressive function is found among 
equine alphaherpesviruses. 
 
Our data showed that inhibition of the type-I IFN response in host cells is 
not a function of neuropathogenicity of EHV-1 strains. However, a reduced type-I 
IFN response correlated with pathogenicity as EHV-4, unlike EHV-1, was unable 
to down-regulate the type-I IFN response in equine endothelial cells (EECs). 
Investigation of the mechanisms employed by EHV-1 to suppress type-I IFN 
revealed that the virus sequentially prevented outside-in signaling events that 
lead to type-I IFN production. Specifically, EHV-1 blocked the expression of Toll-
like receptors (TLR) 3 and TLR4 at 6 hours post-infection (hpi) and 12 hpi. EHV-1 
also prevented the transcription of IRF7 and IRF9 at different time-points during 
infection. The virus also perturbed the JAK-STAT signaling pathway by 
negatively regulating the cellular levels of TYK2 and phosphorylation-mediated 
activation of STAT2 molecules. Immunofluorescence data revealed that during 
infection, EHV-1 was able to sequester STAT2 molecules from nuclear 
translocation. This may be a limiting step preventing the formation of interferon-
stimulated gene factor 3 (ISGF3) whose nuclear translocation is required to 
transactivate interferon-stimulated genes (ISGs) including IRF7. 
Further investigation showed that unlike EHV-1, EHV-4 only interfered 
with phosphorylation-mediated activated STAT1 and STAT2 molecules at 3 and 
6 hpi. EHV-4 was unable to block TLR3/4 and IRF7/9 mRNA expression at any 
time-point. Intriguingly, while viral late gene of EHV-1 mediates inhibition of STAT 
phosphorylation, our data showed that for EHV-4, a virus late gene did not 
mediate the inhibition of STAT phosphorylation. The findings from this study help 
illuminate how EHV-1 strategically interferes with limiting steps required for type-I 
IFN response in host cells to promote pathology. Our data also strengthen the 
hypothesis that the ability to shut off host factors required for type-I IFN 
production might be directly related to the degree of pathogenicity of the EHV 
subtypes.  
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CHAPTER 1: LITERATURE REVIEW 
1.1 Research overview 
Equine herpesvirus 1(EHV-1) was first described by Dimock and Edwards 
in the early 1930s (1). Since then, EHV-1 infection and immunity have gained 
prominence in the literature (2-6). However, over 80 years after its first 
description and despite many vaccine trials, the virus remains one of the most 
important and prevalent viral pathogens of horses and a major threat to the 
equine industry (7). Almost all domesticated horses are repeatedly exposed to 
this virus and, as a result, may experience significant morbidity and even 
mortality (8). Depending on host or viral factors, exposure to EHV-1 can result in 
respiratory disease, sporadic abortion during the third trimester of gestation, 
neonatal deaths, chorioretinitis, and neurologic disease (9-11). Additionally, the 
disease is highly contagious among horses. One of the most devastating 
manifestations of EHV-1 infection is the neurologic form - equine herpesvirus 
myeloencephalopathy (EHM). Although EHM is not new, more outbreaks are 
being recognized with more horses seeming to be affected in each outbreak, 
causing concern among many horse owners. 
This viral infection is unique in its ability to escape the host immunity and 
progress to latency after primary infection within the first weeks or months of life 
(12), leading to a carrier state in infected horses. Most horses acquire the 
infection at a young age and remain latent carriers for the rest of their lifetimes 
(5, 10). Latent infection occurs in the trigeminal ganglion and lymphoreticular 
system (13). The latent virus can recrudesce into full-blown productive infection, 
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typically when the animals are under stress, with the potential for subsequent 
shedding and infection of other susceptible horses, or abortion in the latently 
infected horse itself (14). Additionally, the disease is highly contagious among 
horses. One of the most devastating manifestations of EHV-1 infection is the 
neurologic form - equine herpesvirus myeloencephalopathy (EHM). Although 
EHM is not new, more outbreaks are being recognized with more horses 
seeming to be affected in each outbreak, causing concern among many horse 
owners.    
Interferons (IFN) are a group of biological regulatory proteins, or 
cytokines, which act as an early line of defense against viral infections (15). 
Three classes of IFN, Type-I, II and III, have been characterized (15). In general, 
type-I IFNs which include multiple IFN-β and IFN-α species, along with IFN -ε, -δ, 
-ω, and -κ (16) are produced by a wide variety of cells including fibroblasts, 
epithelial cells, monocytes, macrophages, leukocytes and dendritic cells after 
viral infection. Type-II interferon on the other hand includes IFN-γ and it is 
produced by activated NK, NKT cells and macrophages after viral invasion of the 
host cell (17, 18). In 2003, a third type of interferon response (IFN-λ) against viral 
infection was identified in the host cell (19, 20) and it utilizes a heterodimeric 
receptor that is different from the receptors of either type-I or type-II interferons. 
Of the three types of IFN response, the type-I IFN system is potentially the most 
important host defense against a systemic viral infection. Upon viral infection of a 
susceptible cell, type-I IFN (IFN-β) is induced in the infected cell which then binds 
to cognate interferon α receptors (IFNAR1 and IFNAR2) on both the infected and 
 3 
 
uninfected cells (21). This triggers a signaling cascade that subsequently leads to 
the activation of the transcription factors which are responsible for the production 
of a diverse variety of antiviral genes called interferon stimulated genes (ISGs) 
(22). The release of ISGs helps to create a global antiviral environment in the 
infected host animal to curtail viral replication and viral cell-to-cell spread. The 
importance of the type-I IFN response is not only explained by its function in the 
immediate early phase of the nonspecific cellular response but also in serving as 
a link between the innate and the adaptive arms of the host immunity (23-25). 
For instance, IFN-α/β induces natural killer cell cytotoxicity and up-regulates 
expression of major histocompatibility complex class I on most cells and 
costimulatory molecules on antigen-presenting cells (26, 27). Furthermore, type-I 
IFNs enhance cross-presentation of exogenous antigen in major 
histocompatibility complex class I and promote T-cell expansion (28-30). 
Over the years, many research studies have focused on the role of the 
adaptive immune response in curtailing the replication cycle of EHV-1, but little is 
known about the ways by which EHV-1 can manipulate and overwhelm the host 
type-I IFN response prior to disease progression. In addition, the biological 
functions of most of the EHV-1 viral proteins in the infected host cell remain 
poorly understood. Recently, Sarkar et al reported that EHV-1 gene expression 
was necessary to interfere with STAT-1 phosphorylation and nuclear 
translocation (31). The nature or the identity of the viral genes involved in the 
prevention of key steps of type-I IFN induction is yet to be determined. In order to 
come up with the development of viable interventions that will limit the scourge of 
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this infectious disease, detailed knowledge of how the virus outsmarts the host 
type-I IFN system is highly fundamental. The central focus of this research 
hinged on identifying the key pathways of the type-I IFN response that are 
downregulated by EHV-1 in the course of an infection using an equine 
endothelial cell model. The next section describes what is currently known about 
equine herpesviruses with a central focus on EHV-1, its disease manifestations, 
and host immunity against EHV-1 with particular emphasis on type-I IFN system. 
1.2 Historical perspectives of the herpesviruses 
Within the virus kingdom, Herpesvirales is a huge order that includes 
numerous viruses infecting humans and almost all animal species, including 
insects, fish, mollusks, reptiles, birds, and mammals (32). The first written 
documentation of the word herpes was by Hippocrates (460 BC-377 BC) (33-35) 
and possibly most of the disease conditions now designated as being herpes 
would not have been called by that name before Hippocrates’ documentation. In 
ancient time, the word ‘herpes’ became commonly used to describe a diverse 
range of spreading cutaneous lesions of varied etiology (36). It is known that the 
word ‘herpes’ has been used in human medicine for at least 2,600 years due to 
early descriptions of the disease-causing eczema and cancer of the skin (33). 
With time, the term was restricted to skin eruptions with a vesicular component, 
and by the latter part of the nineteenth century, a distinction was made between 
lesions caused by poxviruses and herpesviruses based on clinical and 
epidemiologic features (37). The term ‘herpes’ comes from the Greek word 
herpein which implies to creep or crawl beneath the skin and therefore 
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herpesvirus derived its name from this word as a result of the characteristic 
nature of the disease which involves spreading of cutaneous lesions. Different 
scientists have provided a fascinating history of the usage of the terms (33, 35) 
and selected usage was illustrated by Onions (38), but of the many clinical 
conditions, only a few, i.e., herpes simplex, herpes labialis, herpes genitalis, and 
herpes zoster are still designated by this term (39). 
The earliest herpesviruses were named after the clinical conditions or the 
diseases they cause. Herpes simplex virus, herpes zoster virus, Aujesky’s 
disease virus (pseudorabies), and Marek’s disease virus are examples of such 
designations. The modern notion of herpes probably began with the definitions of 
Willan and Bateman (40). The term was restricted to conditions characterized by 
the appearance of localized groups of vesicles, a short self-limiting course, and 
the absence of more than mild constitutional symptoms (41). The species of 
herpes included zoster, labial herpes, and genital herpes; also included were 
ringworm (H. circinatus) and erythema multiforme (H. iris) (41). These later 
conditions were still classified as species of herpes until as late as 1880 and 
appear at least as late as 1938 in the “American Illustrated Medical Dictionary” 
(42). Vidal was able to demonstrate the infectious nature of herpes simplex in 
humans (43). Similarly, herpes zoster was shown to be infectious by Von Bokay 
(44), who also suggested as early as 1888 that zoster and chickenpox were 
related. Even though the genomes of sequenced mammalian herpesviruses 
differ widely, there is a subset of around 40 genes that are conserved by criteria 
of encoded amino acid sequences and local preservation of gene layout (45-48). 
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This suggests that these viruses evolved from common ancestors but have 
diverged to a greater extent over time. While herpesviruses have been 
considered to be evolving along with their hosts over about 400 million years, the 
subgroup alphaherpesviruses, to which EHV-1 belongs, diverged only 180-210 
million years ago (49, 50). Thus, equine herpesvirus 1 likely has been plaguing 
wild or domestic equid populations much earlier than the first written 
documentation of the disease which occurred in the early 1930s. 
1.3 EHV-1 infection of horses: How it all began 
The discovery of the first virus, Tobacco Mosaic Virus, is attributed to the 
work of Dmitry Iosifovich Ivanovsky, a Russian-Ukrainian scientist considered the 
father of Virology (51). However, after that discovery, fifty years passed before 
William Wallace Dimock and Philip Edwards in 1932 first showed that a different 
kind of microorganism, other than bacteria, was causing contagious epizootic 
abortion in mares (52). In the same year, the disease was reproduced by 
experimental inoculation of materials from aborted fetuses into mares. Their 
research indicated that a filterable viral agent was causing abortions in pregnant 
mares, and they coined the term “viral abortion” to refer to the syndrome (1). 
They went further to describe the gross pathological changes of aborted fetuses, 
including intranuclear inclusion bodies in the fetal pneumocytes and hepatocytes, 
and defined the clinical observations of ‘equine viral abortions’ (53). Later, the 
‘equine abortion virus’ (EAV) was cultivated in laboratory animals and in tissue 
culture (54-56), and more extensive pathological findings were published (57). 
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Around the same period, Manninger and Csontos in Hungary also 
documented the same symptoms of viral abortions as in Kentucky, along with 
additional syndromes of respiratory diseases including mild fever (58). They 
observed the development of symptoms resembling that of mild influenza when 
bacteriological sterile filtrate from the aborted fetuses with lesions of viral 
abortion was inoculated into pregnant mares (58). Salyi also demonstrated that 
the observed gross and microscopic lesions in fetal abortion material were 
identical with those reported in Kentucky (59). Kress further suggested that the 
abortion virus was pneumotropic because of occurrence of bronchopneumonia in 
horses that had been in contact with aborted mares and fetuses (60). This led 
Manninger to conclude that viral abortion was due to infection of pregnant mares 
with equine influenza virus (61). 
The respiratory infection associated with EAV was first studied 
experimentally by Doll et al. (62), and the symptomatology produced in 
inoculated young horses was again similar to that described as equine influenza 
whose cause had not yet been identified. The evidence from their study showed 
that EAV was the etiological agent of an epizootic respiratory disease of young 
horses (62). It remained for Doll and associates to prove that several putative 
influenza virus isolates were identical with EAV (63-65). In another study, Bryans 
and co-workers suggested that the causative agent previously known as EAV 
should be regarded as a respiratory virus because the principal histological 
lesions in young horses and aborted foals occur in the respiratory tract (66). 
Accordingly, the authors designated the disease caused by the virus as viral 
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pneumonitis and the agent as an equine viral pneumonitis virus. In 1963, the 
virus was shown by electron microscopy to be a member of the herpes group 
(67). 
1.4 Classification of herpesviruses 
In the course of their evolution, herpesviruses have undergone 
considerable diversification with respect to virion morphology, biological 
properties, and virion antigenic properties (39). The members of the 
Herpesviridae family are divided into three subfamilies: Alphaherpesvirinae, 
Betaherpesvirinae, and Gammaherpesvirinae (68) based on their morphology 
and biological properties. 
Alphaherpesviruses are found in a wide range of host species. They 
undergo efficient and relatively short replicative cycle, and they establish latency 
in the sensory neurons or lymphocytes of their hosts (69). They spread well from 
cell to cell but they also are easily released from infected cells, in which they 
multiply causing cytopathic effect and formation of eosinophilic intranuclear 
inclusion bodies (70). In vitro, they can often infect cells originating from varying 
species of animals. Although in vivo the alphaherpesviruses can infect various 
host species, there is always a specie to which each virus has been adapted 
(70). In such a host, they have the propensity to undergo latency, during which 
viral pathogenicity is absent. Within the host, the alphaherpesviruses are 
believed to spread best along the nerves, where intra-axonal transmission 
predominates (70). Members of Alphaherpesvirinae subfamily include four 
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different genera; Simplexvirus, Varicellovirus, Mardivirus, and Iltovirus (71). EHV-
1 is classified as a member of the Varicellovirus genus. 
Unlike alphaherpesviruses, betaherpesviruses have a restricted host 
range and a long reproduction cycle (72). In vitro, members of the 
Betaherpesvirinae only replicate in cells derived from their specific host, further 
underscoring their narrow host range (70). Their replication cycle is slow (lasts 
several days) and their release from infected cells is inefficient (70). 
Betaherpesvirus infection slowly progresses in tissue culture and the infected 
cells become larger rather than lyse and contain intranuclear inclusion bodies 
(70, 73). Latent infection is established predominantly in monocytes or 
macrophages (72). Because they do not show the preferential neural spread, 
they usually persist in leukocytes, in cells of the reticuloendothelial system and 
also in epithelial cells of renal tubuli and salivary gland ducts (70). The viruses in 
this subfamily are subdivided into four genera namely Cytomegalovirus, 
Muromegalovirus, Roseolovirus, and Proboscivirus (74).  
The members of the subfamily Gammaherpesvirinae are slow replicating 
viruses with lymphotropic properties and limited host ranges (70). In contrast to 
both alpha- and betaherpesviruses, gammaherpesviruses seem to initially favor 
the establishment of latency in either T or B cells, while only a subset of cells 
supports lytic replication (75). There are more homolog genes conserved within 
members of the subfamily Gammaherpesvirinae than members of the other two 
subfamilies (72). In addition to the genes conserved between herpesviruses, 
each gammaherpesvirus also contains a set of unique genes which are usually 
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present at the terminal regions of the genome and which are important for viral 
pathogenesis (72). This subfamily consists of four genera: Lymphocryptovirus, 
Rhadinovirus, Macavirus, and Percavirus (74).  
1.5 Equine herpesviruses  
To date, all the nine equid herpesviruses isolated belong to either the 
alphaherpesvirinae or gammaherpesvirinae subfamilies (Table 1.1). The 
members of the subfamily of alphaherpesviruses include EHV-1, EHV-3, EHV-4, 
EHV-6, EHV-8, and EHV-9 (76). The members of the gammaherpesviruses 
include EHV-2, EHV-5, and EHV-7. Only five of the nine herpesviruses (viz. 
EHV-1, 2, 3, 4 and 5) can produce disease in horses (77). EHV-6 to 8 infect 
donkeys and are also called asinine herpesvirus (AHV, AHV-1 to 3), while EHV-9 
or gazelle herpesvirus (GHV) infects Thomson’s gazelles (78-80).  
1.6 Genomic structure and gene functions of EHV-1 
The complete genome sequence of EHV-1 has been published (81, 82) 
making information regarding the genomic organization of EHV-1 available. EHV-
1 has a linear dsDNA molecule of about 150.2 kbp in size with base 
compositions of about 56.7% G+C content (73). The genome is composed of a 
long unique region (UL, 112,870 bp) flanked by a small inverted repeat sequence 
(TRL/IRL, 32 bp) and a short unique region (US, 11,861 bp) that is flanked by a 
large inverted repeat (TRS/IRS, 12,714 bp) (73). The genome contains 80 open 
reading frames (ORFs), which encode 76 unique genes, with four duplicated 
ORFs present in the terminal repeat sequence (TRS) (82, 83). The four 
duplicated ORFs in the EHV-1 genome are ORF 64, 65, 66, and 67 which are 
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present in the sequences flanking the unique short segment (77). The inverted 
repeats allow the short components to give rise to virion populations which exist 
in two orientations, resulting in the formation of two isomeric DNA molecules (84-
88). The gene layout of EHV-1 reveals tightly arranged ORFs with little 
intervening sequence, the absence of extensive ORF overlap, and few instances 
of exon splicing (77). Generally, this gene arrangement of EHV-1 is similar to 
other sequenced herpesviruses with the only difference being that EHV-1 
encodes five genes ORF 1, 2, 67, 71, and 75 which have no structural homolog 
when compared to all other herpesviruses sequenced to date (77). The functions 
of some of these genes remain unknown but have been predicted to exert major 
influence in the unique biology of EHV-1 enabling them to adapt to the horse as 
their natural host (77). The genomic details of EHV-1 ORFs including the 
functions of individual genes are listed in Table 1.2.  
1.7 Biological functions of EHV-1 proteins 
The structural architecture of a purified EHV-1 particle (Fig. 1.1) is made 
up of about 30 discrete kinds of polypeptides (89-93). It consists of a genomic 
core made up of a linear double-stranded DNA neatly packed within an 
icosahedral capsid of T=16 with an approximate diameter of 100 to 110 nm (72). 
The nucleocapsid, which houses the viral genome, is in itself made up of six 
proteins encoded by ORFs 22, 25, 35, 42, 43, and 56 (77, 90). All herpesviruses 
have a similar capsid structure composed of 162 capsomers (12 pentons and 
150 hexons) (94). The nucleocapsid contains a ring structure made up of 12 
portal proteins which enables viral DNA to enter into the capsid (95, 96). 
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Although their names vary between herpesvirus families, the structure and 
arrangement of capsid proteins are conserved across all herpesviruses (97, 98). 
The amorphous tegument layer, which corresponds to the area between the 
nucleocapsid and the envelope, comprises about twelve different proteins 
encoded by ORFs 11, 12, 13, 14, 15, 23, 24, 40, 46, 49, 51, and 76 (77). These 
tegument proteins and enzymes are critically involved in very early events during 
infection which are required for initiating viral replication (94, 99, 100). The large 
tegument protein, UL36, interacts with the pentons (VP5) of the capsid and this 
interaction gives the innermost part of the tegument an icosahedral symmetry 
(101-103). The outermost part of the tegument interacts with the virus envelope 
membrane and may sometimes come in contact with the transmembrane 
domains of envelope glycoproteins.  
The nucleocapsid and the tegument are surrounded by an envelope from 
patches of the altered host-derived cell membrane (104). Embedded in the EHV-
1 envelope are about eleven glycoproteins which are functional homologs of 
those found in HSV-1. The eleven glycoproteins of EHV-1 (i.e. gB-gp14, gC-
gp13, gD-gp18, gE, gG, gH, gI, gK, gL, gM and gN) are conserved across all 
alphaherpesviruses and therefore named according to the nomenclature 
established for HSV-1 (94). As with other herpesviruses, the envelope 
glycoproteins of EHV-1 are critical determinants of virus entry into a susceptible 
host cell, host range, virus cell-to-cell spread, pathogenicity, and immunologic 
responses to infection. EHV-1 encodes an additional gp2, which has homologs 
present only in EHV-4 and AHV-3 (94). The inclusion of tegument and viral 
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envelope enables the virion size to markedly increase from 120 nm to 
approximately 300 nm (73).  
1.8 Epidemiology and transmission of EHV-1 
It is estimated that between 80 to 90% of horses have been exposed to 
either EHV-1 or its close relative EHV-4 by the time they are 2 years of age (7). 
The great level of antigenic similarity between EHV-1 and EHV-4 often 
complicates seroepidemiological data as a result of lack of type-specific 
antibodies and extensive antigenic cross-reactivity that exists in natural infection 
(105). In the early 1990s, evidence became available that the envelope 
glycoprotein, gG, of EHV-4 elicits a type-specific antibody response, which for 
the first time provided the opportunity to differentiate between antibodies present 
in polyclonal sera from mixed cases of infection involving both EHV-1 and EHV-4 
(106). The epitopes present in the carboxyl domain, a variable region of the gG’s 
of both viruses, were identified as useful tools for differentiating between EHV-1 
and EHV-4 based on distinct type-specific humoral responses that they elicit in 
their natural hosts (106, 107). The annual incidence of EHV-1 is not well defined, 
as a result of mixed infection with EHV-4 and the ability of both viruses to 
undergo latency. Latency is an important pathological strategy employed by 
alphaherpesviruses for continuous survival and spread within the natural host 
population (108). The virus can be reactivated at any time during the life of the 
infected host to promote a clinical course of the disease and virus shedding.  
EHV-1 is a highly contagious viral infection and is easily spread by direct 
contact, fomites, and aerosols after shedding from the nasal cavity or by the high 
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virus loads present in aborted materials including placenta (109). Transmission of 
the virus to susceptible horses is facilitated by contact with an acutely infected 
horse or a reactivated virus-shedding horse or from contact with aborted fetuses 
or placenta which is rich in infectious virus particles (77). Extensive work 
investigating the transmission cycle of EHV-1 has identified mare and foal 
populations as important reservoirs enabling virus transmission before and after 
weanling, with foals becoming infected as early as 30 days of age (110). In 
another study, EHV-1 shedding was reported in 22 day-old foals even after a 
widespread vaccination of mares (12). Evidence suggests that infected mares, 
especially the latently infected ones, serve as a continuous source of EHV-1 
exposure to foals by horizontal transmission when contact is established 
between foals and the nursing dam. Broodmares may undergo recrudescence of 
latent viral infection as a result of stress resulting from pregnancy/parturition 
which may expose young foals to EHV-1 infections from mares that are actively 
shedding the virus (94). Overall, available data suggest a cyclic but mostly quiet 
epidemiologic pattern of EHV-1 infection with the dams serving as a continuous 
source of infectious virus particles to their foals between breeding seasons.  
1.9 Cell infection and virus replication 
The viral life cycle can be divided into the following major steps: entry into 
a permissive host cell, uncoating of viral nucleocapsid, expression of viral genes, 
viral DNA replication, virion assembly, and egress of newly produced virion 
particles (Fig.1.2). In horses, EHV-1 can infect at least three distinct cell types in 
three different organ systems including epithelial cells, mononuclear cells in 
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lymphoid tissue and peripheral blood (PBMCs), and endothelial cells of inner 
organs (5). Cells are either infected by direct contact with an infectious EHV-1 
particle or by cell-to-cell spread following contact with an infected cell in the same 
host (94). As with herpes simplex virus 1 (HSV1) and most other 
alphaherpesviruses including EHV-1, productive infection is initiated by a 
relatively unstable attachment to heparan sulfate moieties on cell surface 
proteoglycans that is mediated by gC and gB, followed by binding of gD to one of 
the specific receptors expressed on the cell surface (111-113). Receptor 
engagement leads to conformational changes enabling complex interactions 
between gB and gH/gL (113). However, for virus entry into host cells, EHV-1 also 
utilizes a unique receptor that is different from those described for other 
alphaherpesviruses (114). Equine Major Histocompatibility Complex I (MHC-I) 
molecules serve as entry receptors that bind gD of EHV-1 to facilitate virus entry 
into equine dermal (ED) cells as well as equine brain microvascular endothelial 
cells (115, 116).  
EHV-1 can enter permissive cells either by fusion of its envelope with the 
host cell membrane or by cell-mediated endocytosis, producing a productive 
infection in both cases (117). Both entry pathways facilitate the release of viral 
nucleocapsid and tegument proteins into the infected host cell. As with other 
alphaherpesviruses, once the virus is released inside the host cell, the tegument 
proteins dissociate from the nucleocapsid and the capsid is transported along 
microtubules via dynein, a minus-end-director motor protein, to the nucleus of the 
cell (94). This mechanism of capsid transport is important especially in the 
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infection of cells such as neurons where the virus may have to travel a long 
distance away from the site of the infection to reach the nucleus (94, 118). 
Following the arrival of the capsid at the nucleus, the capsid directly binds to the 
nuclear pore complex (NPC) and extrudes its content into the nucleus leaving the 
capsid behind in the cytoplasm (119, 120). For HSV-1, the inner tegument 
protein UL36 (ICP1/2) which bears a nuclear localization signal (120), together 
with nucleoporins Nup358 and Nup214 which both bind either directly or 
indirectly to the capsid, facilitate this process (118). Seemingly, all these 
associations and interactions are necessary for the nuclear import of the viral 
DNA by importin β (121).  
Transcription and replication of the viral genome, as well as the assembly 
of progeny virus, takes place within the nucleus (118). These events lead to the 
reorganization of the nucleus causing an increase in the size of the nucleus and 
disruption of the nucleolus and nuclear domain-10 (ND-10), and chromatin 
condensation and its subsequent destruction together with the destruction of the 
nuclear lamina in the late steps of infection (122-124). The coordinated 
transcription of EHV-1 genes is regulated by six regulatory proteins that are 
expressed as: one IE protein (IEP), four early proteins (EICP22P, EICP27P, 
EICP0P, and IR2P), and the late protein EHV-1 α-gene trans-inducing factor 
(ETIF or VP16) (125-130). This cascade starts with the tegument VP16 (HSV) 
homolog protein of EHV-1 acting as a transactivator of an IE (α) gene expression 
(131). During viral entry, VP16 is carried into the infected cell as a tegument 
protein and is required for efficient initiation of the lytic replicative cycle of the 
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virus (94, 132). The IE protein is encoded by ORF64 and synthesized by host cell 
RNA polymerase II (128, 133). The IE of EHV-1 is a 1487-amino acid (aa) 
polypeptide which lies within each of the two inverted repeats (134) and is 
essential for replication of the virus (135). During initial stages of infection, IE 
protein activates the expression of heterologous viral promoters, auto-regulates 
its own expression, and acts synergistically with the EICP22 and EICP27 to 
activate the expression of early (E or β) and late (L or γ) viral genes (136-139). 
For the transcription of IE genes of HSV-1, the cellular transcription factor Oct-1 
binds to a unique consensus sequence: 5′-GyATGnTAATGArATTCyTTGnGGG-
3′ (where y is a pyrimidine base, r is a purine base, n is any base) that overlaps 
the transcription initiation site of the IE promoter (118, 140). VP16 protein then 
interacts with Oct-1 and together with HCFC1 protein form a complex which 
activates transcription of IE genes (118).  
The next set of genes to be transcribed during EHV-1 infection are the E 
genes which encode additional viral regulatory proteins (EICP0, EICP22, and 
EICP27), as well as proteins required for replication of the viral genome (125, 
129, 136, 141, 142). Early gene transcription occurs before the initiation of viral 
DNA synthesis and it is tightly regulated by IE protein (126). The IR2 gene is 
embedded within the IE gene and encodes an early protein that is a truncated 
form (aa 323 to 1,487) of the IE protein (143). Although IR2 protein can trans-
repress the IE gene expression, it is unable to trans-activate E and L gene 
expression due to lack of a trans-activation domain of the IE protein encoded by 
amino acid residues 3 - 89 (144). The EICP0 gene encodes an early nuclear 
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phosphoprotein, about 419 bp, that can trans-activate all classes of EHV-1 
promoters (125, 126). This EICP0 contains a conserved cysteine-rich zinc RING 
finger (C3HC4 type) near the N terminus that is essential for activation of the E 
(β) and L (γ1 and γ2) promoters (126). The EHV-1 IE and EICP0 proteins are 
potent trans-activators of EHV-1 promoters, but unlike in HSV-1, they do not 
function synergistically but exhibit an antagonistic relationship (126, 145). The E 
genes encode proteins involved in enhancing viral replication while the late 
genes encode the viral structural proteins (94). Following the model of HSV-1, it 
is known that once the E proteins are synthesized, viral DNA replication will be 
started. This involves the interplay of at least seven early proteins including the 
gene products of UL5, UL8, UL9, UL29, UL30, UL42 and UL52 (146-148). The 
initial step of HSV DNA replication involves the unwinding of the double-stranded 
helix by UL9 and/or ICP8 (UL29) proteins in the AT-rich regions of the oriL or 
oriS origins of replication (118). The latter has one copy in UL of the herpesviral 
genome and two copies in US of the genome respectively (118). ICP8 binds 
ssDNA fragments, and UL9 binds specifically to oriS and unwinds it enabling the 
helicase-primase complex composed of UL5, UL8, and UL52 proteins to be 
loaded (118). Following unwinding of the dsDNA, a complex of viral DNA 
polymerase (UL30) and processivity factor UL42 synthesize the leading and the 
lagging strand of the DNA (118). This replication occurs in a rolling circle form 
termed ‘theta form of replication’, the mechanism of which has not yet been 
identified. This replication ensures the formation of long head-to-tail concatemers 
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of viral DNA which are then cleaved into individual units during packaging of viral 
DNA into capsids (149). 
In addition to the seven viral proteins, some other cellular factors involved 
in the replication of the viral genome include DNA ligase, topoisomerase II, and 
various components of the DNA repair and homologous recombination systems 
(150). Another important factor for viral DNA replication is cellular chaperone 
protein Hsp90 which is essential for intranuclear localization of viral DNA 
polymerase (151). Some viral proteins such as thymidine kinase (UL23), 
ribonucleotide reductase (UL39, UL40), deoxyuridine triphosphatase (UL50), 
uracil N-glycosylase (UL2), and alkaline nuclease (UL12) participate in nucleotide 
metabolism, viral DNA synthesis, and DNA repair (118).  
The production of late (γ) viral genes peaks only after viral DNA replication 
has commenced and requires ICP4, ICP27, and ICP8 for efficient levels of 
transcription (152). γ1 (leaky-late) genes such as major capsid protein ICP5, gB, 
gD, and ICP34.5, are expressed throughout infection, increasing in transcription 
only a few fold after DNA replication has occurred (152) while expression of γ2 
(true-late) genes such as gC, UL41 (VHS), UL36, UL38, UL20, and gK, does not 
accumulate in appreciable amounts until after DNA replication (152). The 
increase in the expression levels of the late genes, especially those encoding for 
viral capsids, just after DNA replication has been initiated enables the assembly 
of progeny virion particles (118).  
Figure 1.3 illustrates the pathway involved in herpesviral capsid formation. 
The assembly of the herpesviral nucleocapsid occurs in the nucleus first as a 
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DNA-free precursor capsid in the presence of scaffolding proteins just before 
viral DNA encapsidation (94, 153-155). The first step in the capsid formation 
involves the auto-catalytic assembly of a procapsid following the interaction of 
pUL19 and pUL6 with a scaffold composed of conserved pUL26 and pUL26.5 
proteins (156). These proteins associate to form angular segments of the 
spherical procapsid with binding enhanced by scaffold-scaffold interactions and 
by the triplexes which link VP5 molecules (97). This is then followed by 
progressive enlargement of the angular segments, called partial procapsids, to 
form an enclosed spherical procapsid (102). Although the procapsid appears to 
be spherical rather than being polyhedral, it has the same diameter as the 
mature capsid (125nm), and the same T=16 icosahedral symmetry (97). In a 
similar fashion as the major capsid protein, the portal is thought to be integrated 
into the developing procapsid by forming a complex with scaffold proteins (157-
160). Following the formation of the procapsid, the viral dsDNA genome is then 
packaged into the capsid mediated by a three subunit-complex of a virus-
encoded protein called terminase (161).The transport of the virion genome into 
the capsid marks the exit of the scaffold proteins from the procapsid creating the 
polyhedral shape of the mature capsid.  
An early step in the nuclear egress of herpesviruses is the budding 
process at the inner nuclear membrane where the capsid, surrounded by 
tegument proteins, acquires an envelope derived from the inner leaflet of the 
nuclear membrane (162). After the viral genome has been packaged and 
assembled, the nucleocapsid travels within the nucleus with the aid of actin 
 21 
 
filament (163) to establish contact with the inner nuclear membrane before 
primary envelopment (Fig. 1.4.). Intimate contact with the inner nuclear leaflet is 
attained once the nuclear lamina has softened and at least partially dissolved 
requiring two virally encoded proteins, pUL31 and pUL34 (164) that are 
structurally and functionally conserved across herpesviruses (156). Complex 
formation between these two proteins is a prerequisite for primary envelopment 
and the absence of either protein stalls the process of nuclear egress 
tremendously (165-169). The association of the pUL31-pUL34 complex with 
nuclear lamins A/C or B (164, 170) leads to the recruitment of cellular protein 
kinase C (PKC) which then phosphorylates intranuclear lamins A/C and/or B 
(171). This complex interaction results in the dissolution of the nuclear lamin 
network and the underlying chromatin layer (124, 164), enabling the 
nucleocapsid to make contact with the inner nuclear membrane (156). Although 
the nucleocapsid acquires its primary envelope through the process of budding 
from the inner nuclear membrane, there is a striking difference in morphology 
and protein content when compared to the mature virus (172, 173). While the 
primary envelope contains both pUL31 and pUL34 proteins (164, 166), the 
mature virus particle lacks these two proteins demonstrating the differences in 
composition between primary and matured virions (156). The underlying 
mechanism by which the enveloped nucleocapsid gain access into the cytoplasm 
is not well understood. However, it has been shown that access to the cytoplasm 
is by fusion of the enveloped nucleocapsid with the outer nuclear membrane 
(156) rather than exit through the nuclear pore. This eventually leads to loss of 
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envelope (de-envelopment) enabling the naked nucleocapsid to acquire 
tegument proteins once inside the cytoplasm (162). The phosphorylation of a 
component of primary-enveloped virions achieved by the kinase activity of pUS3, 
a component of these particles in itself, is required for a successful de-
envelopment process (174-176).  
Final tegumentation and secondary envelopment occur in the cytoplasmic 
compartments and require a highly coordinated network of protein-protein 
interactions (156). The herpesviral tegument proteins interact with the capsid on 
one side and with the cytoplasmic tails of the envelope glycoproteins on the other 
side enabling the structural integrity of the matured virus particle (162). Two 
subassemblies, the capsid and the future envelope, are distinct sites where final 
tegumentation takes place and they efficiently combine to produce the mature 
virion (156). The capsid proximal proteins consist of conserved pUL36 and 
pUL37 that contribute to the physical structure of the tegument, the conserved 
pUL25, and pUS3 which remains closely associated with the capsid (156). 
Except for pUS3, the other identified components of the inner tegument are 
conserved in the Herpesviridae. Both pUL36 and pUL37 remain closely 
associated with the incoming capsid until they dock at the nuclear pore (177, 
178) and also serve as a vehicle for intracytoplasmic transport of the capsid 
during entry and exit of the cytoplasm (179, 180). Besides these conserved 
components, additional non-conserved proteins may be associated with inner 
tegument (156). Strikingly, the level of the inner tegument proteins pUL36 and 
pUL37 in the virion is strictly regulated unlike those of the outer tegument which 
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vary extensively (181). The addition of the outer tegument is accompanied by 
virion secondary envelopment. This process of final envelopment occurs within 
the trans-Golgi network, where glycoproteins together with a subset of tegument 
proteins (182), like pUL46, pUL47, and pUL49 for the alphaherpesviruses, are 
incorporated (156). Two conserved proteins playing major roles in this process, 
glycoprotein M and pUL11, have been identified. Glycoprotein M, an envelope 
protein of matured virion, helps in retrieving envelope glycoproteins from the cell 
surface and retaining them at the envelopment site (183), while pUL11, a small 
myristoylated protein, directs envelope protein to future envelope sites (184, 
185). At this stage, complex associations between many different tegument 
proteins, between tegument proteins and the nucleocapsid, and between 
tegument proteins and the cytoplasmic tails of various conserved and non-
conserved envelope proteins (186, 187) are required for the ultimate assembly of 
a mature herpes virion (188). Following secondary envelopment, a mature 
herpesviral particle within a cellular vesicle is formed and transported to the 
plasma membrane (156), by anterograde cellular microtubule-dependent 
molecular motor kinesin (189). The newly produced virion particles are then 
released into the extracellular spaces following the fusion of vesicles with the 
plasma membrane (190).  
1.10 Establishment of latency 
EHV-1, like other herpesviruses, can establish a lifelong presence within 
cells of a susceptible host following primary infection. The initial stages of EHV-1 
infection of the upper respiratory epithelial tract (URT) are accompanied by 
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progression into a stage of latency in which infected horses show no clinical 
signs of the disease, virus shedding, or cell-associated viremia (77, 94). While 
productive infection by EHV-1 leads to active viral gene expression in a well-
coordinated manner as described above, the hallmark of latency is the restriction 
of viral gene expression which culminates in failure to synthesize viral factors and 
absence of infectious virus particles. The primary site of latency establishment by 
EHV-1 in the horse has been a subject of debate. While some studies have 
demonstrated that latency of EHV-1 occurs in lymphocytes, both circulating and 
those in draining lymph nodes (191-193), others have shown that the sensory 
nerve cell bodies within the trigeminal ganglia are the preferred primary site of 
latency for EHV-1 (13, 194). While about 80% of CD5+/CD8+ T- lymphocyte 
population have been demonstrated as the predominant site of latency in 
lymphoid cells, a smaller sub-population of 20% CD5+/CD8-/CD4- cells have also 
been found to support latency of EHV-1 (195). Regardless of the site of 
establishment, it appears that the ability of EHV-1 to pass into a latency stage is 
a deliberate biological behavior that the virus utilizes to perpetuate itself in the 
host and this enables viral spread to susceptible horses upon reactivation. During 
latency, the expression of the EHV-1 genome is repressed and only the latency-
associated transcripts (LATs) antisense to either the immediate-early viral gene 
(ORF 64) or a regulatory early gene (ORF 63) are present in infected cells (94, 
193, 194). The exact molecular and physiological mechanisms that direct latency 
in EHV-1 infected horses are poorly understood. However, latency has been 
much better studied in HSV-1 and findings reveal that the major detectable 
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transcript lies within an 8.6-kb sequence antisense to and overlapping the 
immediate-early (IE) gene IE-1 (ICP0) (193). The LAT gene itself is a 2.0 kb 
transcript lacking a polyadenylation site and found mostly in the nuclei of infected 
neurons (193). In HSV, LAT can promote latency but is dispensable for 
maintenance or viral reactivation from latency (196).  
It has been reported that reactivation of latent EHV-1 is possible following 
exposure to stressful conditions such as transportation, handling, re-housing, and 
weaning or following the administration of corticosteroids (197-199). The fact that 
EHV-1 has been experimentally reactivated from cases of natural infection and in 
experimentally infected cases following administration of immunosuppressant 
(13, 192, 199) suggests that horses harboring latent EHV-1 could periodically 
shed the virus following exposure to stressors. Also, viral factors such as a 
defective thymidine kinase in several alphaherpesviruses, including EHV-1, have 
been shown to cause impaired ability to reactivate from latency following 
experimental infection (197, 200-202).  
As a result, the cycle of persistent latent infection followed by reactivation 
of the virus with shedding into nasal mucus may enable virus propagation and 
disease spread to susceptible uninfected horses. In certain instances, the 
characteristic respiratory illness followed by nasal shedding is absent following 
EHV-1 reactivation and such horses are therefore silent virus shedders (199). It 
has been reported that during the reactivation process a small fraction of 
lymphocytes carrying the latent EHV-1 genome can progress towards active 
transcription resulting in DNA revival and fusogenic viral glycoprotein expression 
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on their cell surfaces ultimately leading to active virus replication (197, 199). The 
fine details of the molecular mechanism underlying reactivation of EHV-1 from its 
quiescent state to a lytic productive infection remain elusive. However, it has 
been suggested that the IE gene promoter of a latent EHV-1 can be trans-
activated by the presence of another equine herpesvirus, EHV-2, in a mixed 
infection (203).  
1.11 The Economic importance of EHV-1 to the US horse industry 
About 10 million of the world horse population resides in the United States 
(204). The horse industry is a large and economically diverse industry which 
accommodates a wide array of economic activities. It has been reported that in 
the US, the horse industry generates annually an income of about $102 billion 
when considering both direct and indirect spending (205). With such enormous 
revenue generated from the horse industry in the US, an outbreak of any disease 
affecting its horse population is likely to perturb the economic health of the 
industry. The relevant effects of EHV-1 on the equine industry have been 
summarized (109). Firstly, EHV-1 outbreaks may result in cases of subclinical to 
mild respiratory illness especially with young athletic horses developing pyrexia 
and thus leading to interruptions of training programs. This is considered the 
least important economic effect of EHV-1 disease. Secondly, the incidence of 
abortion during the third trimester of gestation in pregnant mares results in major 
losses to the growth of the industry. Thirdly, outbreaks of the neurologic form of 
the disease, EHM, are very severe and may lead to deaths of horses, disruption 
of breeding or training schedules, cancelation of horse events, and extensive 
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movement restrictions with consequent management difficulties at racetracks, 
training centers, and other horse events. Even though horses may recover from 
the disease, their productivity is usually compromised and huge sums of money 
are expended in the care and management of horses infected with EHV-1.  
1.12 Pathogenesis and disease manifestations 
The pathogenesis of EHV-1 infection has been described by the study of 
an experimental model of infection using the EHV-1 strain, AB4 (94). EHV-1 is a 
highly contagious viral pathogen of horses usually transmitted following direct 
contact with infectious materials such as nasal discharges and materials from 
aborted fetuses or indirectly by fomites (77). In horses lacking protective mucosal 
immunity, nasal and mucosal epithelial cells are the primary sites of replication of 
EHV-1 (206, 207). Subsequently, virus replication is quickly followed by erosions 
of epithelial cells of the URT due to necrosis and inflammatory cellular responses 
which ultimately lead to nasal shedding of infectious virus (94). Once in the URT, 
EHV-1 can spread quickly utilizing and hijacking infected mucosal monocytes to 
invade the deeper connective tissues (208, 209). As a result, EHV-1 can cross 
the basement membrane, infecting leucocytes in the lamina propria and 
endothelial cells of blood and lymphatic organs (209). Within 24 h of infection, 
infected mononuclear leucocytes could be found present in the sinuses and 
parenchyma of respiratory tract-associated lymph nodes (207). Here, EHV-1 
undergoes a second round of replication and viral particles are significantly 
amplified culminating in infected leucocytes escaping, via the efferent lymph, into 
the blood-vascular circulation leading to a state of cell-associated viremia (206, 
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210-212). The ability to establish viremia is key and defines the outcome of EHV-
1 pathogenesis produced from the second round of replication. Viremia facilitates 
the dissemination of the virus to tertiary replication sites in the endothelium of the 
pregnant uterus or the central nervous system (77) leading to two clinically 
important sequelae of EHV-1 respiratory infection, namely abortion or a 
neurological syndrome (197, 213).  
1.12.1 Respiratory disease 
Equine herpesvirus type 1 (EHV-1) is one of the leading causative agents 
of equine respiratory disease, an infection of the upper airway mucosal 
epithelium seen primarily in young horses. The virus is highly ubiquitous among 
horse populations causing an epidemic disease early in life with an estimated 80 
- 90% of horses being infected by 2 years of age (7). Following contact with an 
infectious viral particle, the mucosal epithelial cells of the URT of an infected 
horse are the prime target of EHV-1 where the virus undergoes its first round of 
replication (Fig. 1.5). Within 12 h post-infection, progeny virus and viral antigen 
are detectable in the respiratory epithelium of an infected horse (94) and the 
virus can quickly spread to the respiratory endothelium within 24 hours of 
infection (214). Besides, leucocytes in the adjacent lamina propria and 
endothelial cells of blood and lymphatic vessels are also infected due to a cell-to-
cell spread of the infectious virus from the respiratory epithelium facilitating viral 
spread throughout the body (94, 215). 
Subsequently, erosions due to epithelial cell necrosis and an acute 
inflammatory response may occur usually within the first week of the respiratory 
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disease leading to shedding of infectious virus particles (94). Depending on the 
pathogenicity of the EHV-1 strain, the incubation period of infection may either be 
short (one to three days) (216-218) or prolonged (up to ten days) (79). EHV-1 
primarily results in respiratory tract disease (rhino-pharyngitis and tracheo-
bronchitis) (219) presenting a clinical picture similar to other viral respiratory 
pathogens of the horse (e.g., equine influenza virus, adenovirus, rhinovirus, or 
arteritis virus) (7). Although a majority of such respiratory infections run a 
subclinical or mild course, and a large number of foals seroconvert without 
manifesting clinical signs, there may be visible signs of nasal discharge and 
coughing in some young naively exposed horses (77, 219). Previously exposed 
horses have immune memory that helps reduce the clinical severity of the 
disease and are infected for only a short duration (7, 207, 214). Depending on 
the age and the immune status of the infected horse, the respiratory infection 
may be mild in older horses, pregnant mares, and previously exposed horses 
even following virus reactivation from latency (77). Experimental infection using 
the virulent Ab4 strain of EHV-1 revealed a biphasic pattern of pyrexia which may 
last for up to ten days (216-218). The clinical picture of the disease includes 
moderate depression and anorexia, conjunctivitis and serous ocular discharge, 
and notably a serous nasal discharge which rapidly progresses to mucoid and 
mucopurulent discharge (77). The presence of mucopurulent discharge can be 
associated with a secondary bacterial infection which may exacerbate the 
disease. There is progressive lymphadenopathy mainly affecting submandibular 
lymph node (LN) (77) and evidence of leukopenia (both lymphopenia and 
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neutrophilia) have also been reported (6, 220, 221). Occasionally, 
retropharyngeal LN may also be enlarged and become palpable for some days 
(77). Lymph nodes may reach maximum size between three to ten days and may 
remain enlarged for several weeks following infection (77). In some infected 
foals, EHV-1 may reach the lungs inducing bronchopneumonia as a result (83). 
While infected horses may occasionally cough, the severity and duration 
of clinical signs of the disease in a horse are influenced by proper hygiene and 
rest from exercise or training (222). Generally, the upper respiratory tract disease 
(URTD) associated with infection by EHV-1 is short-lived and of acute course 
with clinical signs and virus shedding manifesting for the first few days following 
infection (7). Although the prognosis of URTD from EHV-1 is good with 
spontaneous recovery by the end of the second week of onset of infection, 
severe secondary bacterial infections can prolong the illness and compromise 
the prognostic outlook for survival (7). Upon recovery from URTD caused by 
EHV-1, some horses may develop non-specific bronchial hypersensitivity, 
resembling chronic obstructive pulmonary disease, which may hinder their 
performance and lead to poor performance syndrome (222). 
1.12.2 Abortion, neonatal and perinatal disease 
The potential health consequences of EHV-1 extend beyond URTD and 
the virus may invade other organs causing more pronounced disease 
manifestations (7). One of the sequelae of EHV-1 URTD is abortion in which the 
virus travels to distant sites such as the reproductive tract by cell-associated 
viremia or latent viral reactivation (223) thereby inducing premature detachment 
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of the fetus from the placenta, stillbirth, or weak neonatal foals (224). Pregnant 
mares infected with the virus may abort spontaneously without prior signs of 
primary URTD by EHV-1 (53, 225-228). The important roles exerted by host 
immune and inflammatory responses, and vascular coagulation cascades 
mediating EHV-1-induced abortion have not been fully elucidated (77). However, 
EHV-1 infection of the endothelial cells of a pregnant uterus results in vasculitis 
that particularly affects the small arteriolar networks of the glandular layer of the 
endothelium at the base of microcotyledons (228-231). Within 9 to 13 days post-
infection, endothelial cell infection becomes widespread resulting in multifocal 
vasculitis of the affected blood vessels (77). The appearance of microthrombosis 
within blood vessels may sometimes promote thrombo-ischemic necrosis of the 
cotyledons and intercotyledonary stroma causing the fetus to detach from the 
placenta (231). The aborted fetus dies from anoxia during a rapidly progressive 
placenta-endometrium separation that immediately precedes the event of 
expulsion (7). Widespread vascular endothelial damage may cause the fetus to 
be aborted even before any detectable level of virus is transferred via the 
placenta to the fetus (228).  
Experimentally induced abortions by EHV-1 in which virus was not 
recovered from the aborted fetus have been reported to be as a result of either 
maternal stress or pyrexia (232, 233). In another experimental study, the extent 
of uterine vasculitis and intercotyledonary necrosis corresponds to reduced viral 
burden in the aborted fetus with fewer lesions found in mares aborting virus-
positive fetuses (231, 234). The severity of the disease (abortion) usually 
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depends on some factors such as the pathogenicity of the EHV-1 strain involved, 
the level and magnitude of viremia, and the hormonal state of the pregnant mare. 
More virulent strains of EHV-1 such as Ab4 have been reported to produce more 
pathologies including abortion at a higher rate in pregnant mares than the less 
virulent strains like V592 (213). The pathogenesis of EHV-1-induced abortion by 
the less virulent strains of EHV-1 is not clear but it appears that those strains 
have reduced affinity for endothelial cell invasion (77). It has also been reported 
that the magnitude rather than the duration of viremia is a significant correlate of 
abortion induced by EHV-1 during an experimental challenge (213). Similarly, 
hormones such as prostaglandin and chorionic gonadotrophin (CG) released by 
the placenta have been reported to exert some roles in reactivating the virus and 
initiating abortion (77, 94). EHV-1 may be transferred by the placenta to the fetus 
thereby inducing multi-organ pathologies. EHV-1-infected fetuses born alive 
become sick either at birth or within one to two days of parturition (235-238). 
However, such foals do not live long because they consequently die as a result 
of the rapid deterioration of their health (94). Infected foals show severe 
respiratory distress that amplifies the risk of viral pneumonia or secondary 
bacterial infection, which lead to respiratory failure within a few days (83, 239). 
EHV-1 infected foals may also display signs of gastrointestinal disease 
(manifested in excreting watery diarrhea) and neurological signs such as visual 
and vestibular defects (236). Prognosis is grave and no treatment is available to 
stop the fatal clinical deterioration of health in infected foals. It has been reported 
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that congenital EHV-1 infection can be epizootic and may occur in association 
with an outbreak of EHV-1 abortion (7). 
1.12.3 Myeloencephalopathy 
Another clinical sequel of EHV-1 respiratory disease is the neurological 
form of the disease termed equine herpesviral myeloencephalopathy (EHM), 
sometimes appearing after one week of infection (83, 240-242). Neurologic 
symptoms may be simultaneously present with respiratory illness or abortion or 
may occur independently (243, 244). Fundamentally important in the spread of 
EHV-1 is cell-associated viremia which effectively disseminates the virus to the 
vasculature of the CNS. The immunologically privileged intracellular location of 
the virus appears to protect it from inactivation by circulating antibody and 
permits dissemination to other tissues, including the CNS, even in the presence 
of high levels of antibody (245). Similar to other herpesviruses, EHV-1 is capable 
of a direct cell-to-cell spread without establishing an extracellular phase (246). 
The vascular endothelium serves as the initial site of infection in the CNS and 
appears to be the preferred site for replication of EHV-1 after the transfer of the 
virus from circulating leukocytes (241). The infection of the endothelial cells and 
the accompanying inflammation of the vasculature of the CNS is central to the 
neurological syndrome caused by EHV-1 (206, 210, 230, 247). The vasculitis of 
the endothelium caused by EHV-1 may be as a result of two different 
mechanisms; the first being the direct damage of the endothelial lining of the 
blood vessels during EHV-1 replication and the second, a result of immune 
complex formation between EHV-1 and antibody (Arthus-type reaction) (224). 
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The development of vasculitis with or without hemorrhage and thrombo ischemic-
necrosis of small blood vessels in the brain or CNS is a common feature of the 
neurological form of EHV-1 (77). The observed clinical signs in infected horses 
are a culmination of the vasculitis, hemorrhage, edema, necrosis, and ischemia 
that can result from the virus having a profound predilection for the vascular 
endothelium (224). Indeed, the ability of certain EHV-1 strains to inflict damage 
on the CNS is not reflective of their neurotropism but rather a marked 
endotheliotropism (210, 229, 230, 247, 248). However, the finding of 
chorioretinopathy and neural lesions in some experimentally infected, specific 
pathogen-free ponies suggests that at least some strains of EHV-1 may exhibit 
neurotropism (249). There seems to be no satisfactory scientific explanation for 
the variable incidence of EHM and different clinical manifestations observed 
during outbreaks of EHV-1 (238, 250). Several factors including age, sex, 
reproductive status (including the stage of pregnancy), immune status of the 
horse, the magnitude of the challenge, strain variations, and perhaps the route of 
infection influence the clinical outcome of EHV-1 infection (238, 250, 251).  
Clinical signs of the neurologic disease may become apparent within 2 
weeks of URTD or may occur without any antecedent sign of the disease (241). 
Clinical signs are highly variable and widespread depending on the location of 
the neurologic lesions and usually peak between two to three days of onset (77). 
Generally, there is fever, inappetence, distal limb edema, abortion, fetal death, or 
neurologic disease which are usually variable in different groups of horses on a 
particular farm (238). The extent of neurological dysfunction ranges from 
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temporary ataxia with an abnormal gait to complete paralysis. Conscious 
proprioceptive deficits have also been observed (77). The neurological disorders 
affect mainly the hind limbs, although complete recumbency or tetraplegia have 
also been observed (77, 238, 252). In some cases, there are signs of bladder 
dysfunction with accompanying urinary incontinence and scalding of the perineal 
area or urinary retention which may lead to colic (253). The prognosis for non-
recumbent horses is favorable but not so much for recumbent horses which may 
develop complications such as pneumonia, colic or bladder rupture (77, 238, 
254) and are generally euthanized. 
1.12.3.1 Recent Outbreaks of EHM 
Outbreaks of EHM, among domestic horse populations, have been 
recorded for centuries. Today, a resurgence in the number of EHM cases across 
the world has necessitated the classification of this syndrome as an emerging 
disease of the horse. According to the Center for Emerging Issues report of 
2007, EHM met the requirement for an emerging infectious disease based on (1) 
the more virulent nature of the circulating EHV-1 strains than previously reported 
and (2) increased incidence of the disease with heightened case fatality rate 
(255). Increased outbreaks of EHM were reported not only in North America and 
Europe, but also in Africa, Oceania, and Asia (256-266). The recent increased 
incidence of EHM during EHV-1 outbreaks supports the observation that the 
currently circulating neuropathogenic EHV-1 strain has evolved into a more 
virulent strain producing higher morbidity and mortality than in the past 
(267). EHM has been associated with an A2254G2254 mutation in the viral DNA 
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polymerase (ORF30). Generally, neuropathogenic strains have aspartic acid at 
position 752 whereas non-neuropathogenic strains possess asparagine (268, 
269). In field outbreaks, this association is strong but not absolute, and there are 
other factors that could contribute to neuropathogenicity (109, 270). 
Approximately, 14 percent to 24 percent of EHV-1 isolates from horses with EHM 
lack this neurological marker suggesting that the so-called non-neuropathogenic 
genotype of EHV-1 can also cause EHM (271, 272). This disease condition is a 
major concern for the horse industry considering its negative impact on the 
economic health of the industry. 
The associated risk factors for this increased incidence of EHM are still 
poorly defined. However, outbreaks have been reported mostly at places such as 
riding schools, racetracks, and veterinary hospitals where horses from different 
origins congregate (256, 262, 273). The high stocking density of stabled horses 
during events such as horse racing may facilitate the quick spread of EHM by 
direct contact when outbreaks occur. International movement of horses has also 
played a role in some recent outbreaks of EHM (267, 274). Other factors that 
have been reported to facilitate increased incidence of EHM include poor 
biosecurity measures and presence of stressors (256, 275) along with other ill-
defined environmental and host factors (276). Finally, the mutant EHV-1 (G2254) is 
now widely distributed within horse populations which would tend towards the 
increased incidence and severity of recent EHM outbreaks. 
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1.12.4 Ocular disease 
Occasionally and particularly in foals, respiratory tract infection with 
hypervirulent strains of EHV-1 is accompanied by severe ocular disease such as 
uveitis or chorioretinitis (277). Within three to five weeks of URTD by EHV-1, 
foals may develop three distinct types of chorioretinal lesions (focal, multifocal or 
diffuse) without uveitis (249). Although the first report of EHV-1 associated 
chorioretinitis was in Ilamas and alpacas (278, 279), the disease condition has 
also been reported in natural outbreaks of paralytic EHV-1 infection involving a 
mare and foal (250). More recently, an incidence rate of 50-90% of horses was 
shown to develop chorioretinal lesions during an experimental challenge with 
EHV-1 (280). Similar to the pathogenesis of EHV-1 induced abortion and 
neurologic syndromes, replication of EHV-1 in the vasculature of the chorioretina 
may result in ischemic necrosis resulting in visual impairment (281). Apart from 
chorioretinitis, uveitis is another ocular condition seen in some foals following 
outbreaks of EHM in mares and stallions (238). Young foals that come in close 
contact with EHM-infected mares and stallions are at high risk of developing 
ocular disease associated with EHV-1 (238). 
1.13 Laboratory diagnosis 
A rapid diagnosis of URTD associated with EHV-1 within a group of 
horses is highly desirable to aid therapeutic decisions and shape future control 
strategies to prevent an epidemic outbreak of the disease (7). Usually, the 
presenting clinical sign alone is not sufficient to reach a precise diagnosis as the 
initial clinical presentation may also resemble that of equine influenza, 
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adenovirus, etc. As a result, laboratory diagnostic confirmation of EHV-1 induced 
URTD is predicated on the ability to isolate the virus from submitted clinical 
materials. Polymerase chain reaction (PCR) is a useful diagnostic tool for rapid 
identification and detection of genomic materials of EHV-1 in clinical or 
pathological specimens such as aborted fetus, placenta, nasal swabs, nasal 
discharges, brain and spinal cord, paraffin-embedded archival tissues, and 
infected cell cultures (282-286). Perhaps the most sensitive diagnostic tool for 
EHM is the RT-PCR which can discriminate isolates possessing single nucleotide 
polymorphism (SNP) in the ORF30 gene associated with the neurologic 
phenotype of the disease (287). One major caveat to the use of PCR is that it is 
not able to distinguish nucleic acid from a viable virus from that of a non-viable 
virus. It has been reported that the agreement between PCR and virus isolation 
is about 85-90 percent (77).  This may be a particular concern when interpreting 
the presence of extremely low levels of viral DNA in clinical samples. 
Direct detection of viral antigen from clinical samples using 
immunofluorescence staining also provides for rapid diagnosis of EHV-1. Cells 
from nasopharyngeal secretions can be stained with fluorescent antibodies 
against viral antigens for demonstration of a positive EHV-1 disease outbreak 
(77, 219). However, it is also important to confirm such results by virus isolation 
from submitted clinical specimens. Using type-specific antigen, Serological 
diagnostic tests such as virus neutralization (VN), complement fixation (CF), and 
enzyme-linked immunosorbent assay (ELISA) can also be employed on paired 
serum samples to differentiate EHV-1 from EHV-4. Immunohistochemically, 
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EHV-1 antigens can be detected in paraffin-embedded tissues from infected 
horses using immunoperoxidase staining (77). Histopathological examination of 
paraffin-embedded tissue sections can also be employed to identify 
pathognomonic lesions typical of EHV-1 infections.  
The gold standard technique for laboratory diagnosis of EHV-1 is virus 
inoculation of cell cultures for isolation of the virus. The virus can be isolated from 
a variety of cell lines including those derived from the horse (EEC), rabbit (RK-
13), monkey (Vero), and cattle (MDBK) (77, 152). The cytopathic effect (CPE), 
develops rapidly in cell cultures as clusters of rapidly enlarging, rounded, and 
detached cells which are characteristically herpetic in appearance (77). Virus 
culture and isolation should be carried out concurrently with rapid diagnostic 
testing (PCR), to retrospectively be able to biologically and molecularly 
characterize the virus isolate. Confirmatory diagnosis of EHV-1 should rule out 
other differentials such as EHV-4, influenza virus, adenovirus, rhinovirus, equine 
arteritis virus, and Sarcocystis neurona infection which may all present disease 
phenotypes that mimic EHV-1 infection. 
1.14 Current treatment and control recommendations 
There is no specific drug effective against EHV-1 disease conditions. 
However, good hygiene and management practices together with symptomatic 
treatment of infected horses may help curtail the spread of the viral infection. The 
current recommendations for treatment of horses include offering supportive care 
in cases of recumbency, nutritional care and hydration, frequent bladder and 
rectal evacuation to prevent colic, and reduction of CNS inflammation (288, 289). 
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Symptomatic treatment with non-steroidal anti-inflammatory agents as an adjunct 
therapy may be helpful (109, 224). Similarly, corticosteroids and 
immunomodulatory agents may be used to symptomatically treat early signs in 
cases of EHM. However, there is no evidence-based study to support the 
effectiveness of either drug class and caution must be applied not to reactivate 
virus shedding in latently infected horses (109, 152). Corticosteroids are thought 
to be protective against the cellular response to the infection of CNS thereby 
preventing the development of vasculitis, hemorrhage, thrombosis, and edema 
that are prominent early lesions of EHV-1 myeloencephalopathy, and their use is 
only reserved for severe cases of EHM (109). 
Similarly, the administration of immunostimulants before horses are 
exposed to stressors could help prevent viral reactivation and replication but their 
value for treating EHV-1 infection is yet to be ascertained (109). Antiviral drugs 
especially virustatic agents like acyclovir derivatives are of theoretical value for 
the treatment of EHV-1 infection as they demonstrated in vitro efficacy (290). 
Beside acyclovir, prophylactic administration of valacyclovir hydrochloride has 
been tried in experimentally infected horses with demonstrable benefits (291). 
Ganciclovir has been demonstrated to be the most potent inhibitor of EHV-1 
infection in an in vitro study that investigated the efficacy of many antivirals 
against EHV-1 (290), and in a more recent study, it also offers a much-improved 
bioavailability, in vivo (292) compared to acyclovir. 
EHV-1 infection, as with other herpesviruses, is more complicated than 
most other viral infections; the ability of the virus to establish persistent latent 
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infection ensures that the virus is naturally maintained in horse populations all 
year-round. Also, EHV-1 has evolved a plethora of strategies to evade many 
components of the host innate and adaptive immune responses (293). As a 
result, an efficient EHV-1 vaccine must be able to invoke strong and sustained 
levels of humoral and cell-mediated immunity against the virus. In addition, since 
the establishment of cell-associated viremia is a prerequisite for the development 
of abortion and EHM, an effective vaccine candidate must, also, be able to 
stimulate those immune responses needed to block the development of cell-
associated viremia. The currently available commercial vaccines against EHV-1 
in North America are in the form of modified live vaccine (MLV) and inactivated 
whole virus vaccine. Both the Rhinomune (Boehringer Ingleheim), an MLV, and 
Pneumabort K-1B (Zoetis), an inactivated vaccine, reduced the clinical incidence 
of disease in an EHV-1 vaccine challenge study with the former offering better 
protection (294). However, the effectiveness of either vaccine in preventing EHV-
1 induced abortion or EHM is still far from proven. EHV-1 antigen is also 
incorporated in some multivalent vaccines marketed across the US in their 
inactivated forms. Recombinant vaccine models expressing EHV-1 gB, gC, and 
gD reduced the initial nasal viral shedding in vaccinates but offered less 
protection against cell-associated viremia and clinical signs of disease (295, 
296). Intriguingly, a recombinant vaccine expressing EHV-1 IE significantly 
reduced cell-associated viremia in vaccinated ponies however, its effect on EHV-
1 induced abortion and EHM remains inconclusive (297). There is currently no 
available vaccine that completely prevents EHV-1 infection, or the development 
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of viremia or the establishment of latency, and EHM has been observed in 
vaccinated horses (252, 289, 298, 299). Despite that, it is recommended that all 
horses at risk of EHV-1 exposure should be vaccinated to help reduce the 
severity of clinical diseases associated with EHV-1. The updated version of 
AAEP guidelines for vaccination for adult horses provides a detailed 
recommendation for vaccinating against EHV-1 (300). 
Control measures for curtailing EHV-1 infection are aimed at reducing the 
spread of the virus to susceptible horses and also at preventing the reactivation 
of the virus in latently infected horses (79, 246, 301). Infected sick horses are 
primary sources of infectious EHV-1, and as such, should be isolated from the 
rest of the herd to prevent direct contact with un-infected horses. Also, infected 
materials such as aborted fetus, placenta and uterine fluids from mares that have 
aborted should be disposed of appropriately to curtail the spread of EHV-1 (224). 
High-level biosecurity measures should be put in place in farms and all visitors 
should be encouraged to use a footbath and wash their hands before entering or 
leaving horse farms. Infected equipment must be disinfected or disposed of, and 
separate equipment and personnel should be engaged to work on affected and 
unaffected horses to prevent horizontal transmission of the disease (246). 
Movement of horses and visitors should be restricted onto and off the infected 
farm premises until laboratory tests indicate negative results for EHV-1 infection. 
Newly acquired horses should be quarantined from the rest of the herd for at 
least three weeks and must be certified negative for EHV-1 before being allowed 
to join the resident population. Horse owners and horse farmers should 
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immediately report EHM outbreaks to relevant government agencies to contain 
the spread of the disease and to help formulate policies against future outbreaks.  
1.15 The type-I IFN system 
Mammals are constantly exposed to a wide array of pathogens and have 
evolved a systematic approach to remain protected in most instances against 
invading pathogens such as viruses. As the specific adaptive arm of the immune 
response requires days to several weeks to become fully activated, the non-
specific innate arm plays a central role in immediately combating viral invaders 
(302). In the absence of pre-existing adaptive immunity, the innate immune 
function of the host immune response is immediately triggered to recognize 
incoming viruses and curtail their replication and spread to uninfected cells (302). 
The first line of defense against viral pathogens in a mammalian host consists of 
a soluble class of cytokines called interferon (303). IFN was first described in the 
early 1950s as an important host factor that is rapidly produced in virus-infected 
cells and whose release enables protection of neighboring cells against virally 
induced cell-to-cell spread (304). To date, three types of IFN, namely type-I, 
type-II, and type-III, have been recognized to be produced by different cell types, 
bind different receptors, and mediate different biological functions (15, 305). 
Although structurally unrelated and operating through distinct receptors, these 
cytokines are classified as IFNs on the basis of their partially overlapping 
activities (306). The type-I IFN of mammals comprises a large group of 
molecules, but only eight classes have been recognized in horses to date: IFN-α, 
IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-ω, IFN-ν, and IFN-µ (307). They are produced by 
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different types of host cells including epithelial, fibroblast, and dendritic cells to 
mediate distinct roles during viral infection, cell growth, and pregnancy. While 
IFN-α/β, hereafter referred to as the type-I IFN, are virally induced cytokines, 
IFN- κ, ε, δ, and ω act as regulators of maternal recognition of pregnancy (15).  
Type-I IFN induction by virus-infected cells occurs in 3 phases- 
sensitization, induction and amplification (302). In the immediate early or 
sensitization phase (Fig. 1.6.A.), innate immune sensors known as pattern 
recognition receptors (PRRs) interact with conserved viral motifs resulting in the 
coordinate activation of cellular transcription factors such as nuclear factor-κB 
(NF-κB), interferon-regulatory factor 3 (IRF3), IRF1, and ATF-2/c-Jun. Activated 
transcription factors collectively called the ‘enhanceasome’ then induce the 
production of low levels of IFN-β (23, 306, 308, 309). The mediators of viral 
recognition that lead to the production of IFN-β consist of a group of PRR located 
either in the cytoplasm or in the transmembrane of cell surface/endosomes; 
areas that allow these receptors to efficiently detect viral invasion. These 
receptors include toll-like receptors (TLRs) which recognize a variety of viral 
structures, retinoic acid-inducible gene-I (RIG-I)-like receptor (RLR) family which 
recognizes intracellular dsRNA, and the recently identified cytosolic DNA sensor- 
DNA-dependent activator of IFN-regulatory factors (DAI) receptor (310-312). 
Following ligand binding, PRRs recruit and interact with the appropriate adaptor 
protein which plays an essential role by phosphorylating and activating several 
constitutively expressed transcription factors for a low-level IFN-β transcription. 
While TLRs majorly interact with Toll/IL-1 receptor (TIR) containing adaptors 
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such as MyD88, TIR-domain-containing adapter-inducing IFN-β (TRIF), Mal and 
TRIF related adaptor molecule (TRAM), RLRs interact with either stimulator of 
interferon genes (STING) or mitochondrial antiviral signaling protein (303, 313). 
In resting cells, NF-κB is constitutively present in the cytoplasm in its inactive 
state, forming a complex with its inhibitor IκBα (314). Following PRR activation, 
IκBα becomes phosphorylated (mediated by I-kappa-B kinases (IKK) recruited by 
the adaptor proteins) and undergoes subsequent degradation thereby releasing 
NF-κB to translocate to the nucleus and induce target genes (303). Similarly, 
IRF3, which is also constitutively expressed in resting cells, is phosphorylated by 
IKK-related kinases IKKε and TBK-1 upon pathogen-associated molecular 
pattern (PAMP)-PRR interaction causing IRF3 to homodimerize and undergo 
nuclear translocation (303). There, they could either interact with histone acetyl 
transferases such as CREB-binding protein (CBP) and p300, initiating their 
immediate association with IFN-β promoter (303), or they could directly activate a 
subset of ISGs even in the absence of IFN (315, 316). Not much is known about 
the roles of ATF-2/c-Jun, but it is suggested that the complex is inherently 
intranuclear even in its inactive form, and is stimulated by phosphorylation of its 
activation domain (317).  
In the subsequent early or inductive phase (Fig. 1.6.B.), secreted IFN-β 
binds to its cognate receptors present ubiquitously on cell surfaces initiating IFN 
signaling. The major components of this cross-talk leading to type-I IFN signaling 
include two receptor subunits, two Janus-activated kinases (JAKs), two signal 
transducers and activation of transcription (STATs) and the IRF- family 
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transcription factor IRF9. This signaling pathway can be summarized in five main 
steps (27): (a) the extracellular IFN-driven dimerization of IFN-α/β receptor 
(IFNAR) induces (b) phosphorylation-activation events in the cell, resulting in (c) 
heterotrimeric, STAT-IRF, complex formation activating them for (d) nuclear 
translocation where they (e) bind specific DNA sequences and stimulate 
transcriptional processes. The receptor has two subunits: IFNAR1 and IFNAR2c 
hereafter referred to as IFNAR2. These two subunits are required for a high-
affinity binding of secreted IFN-β as neither subunit alone binds effectively to IFN 
(318, 319). Upon ligand binding, a signaling cascade commences with the 
phosphorylation of TYK2 following its interaction with the cytoplasmic domain of 
IFNAR1 (320, 321). JAK1 then interacts with IFNAR2 inducing the 
phosphorylation and activation of TYK2 (322) which in turn cross-activate JAK1 
to activate it further (27). A series of well-coordinated events lead to the 
phosphorylation of IFNAR1, STAT2 and STAT1 in that order. Firstly, TYK2 
phosphorylates IFNAR1 at tyrosine residue 466 (Y466) creating a docking site for 
STAT2 (320). This is then followed by the phosphorylation of STAT2 at tyrosine 
690 (Y690) by TYK2 creating a new docking site for STAT1 (323, 324). STAT1 is 
subsequently phosphorylated at tyrosine 701 (Y701) by IFNAR2-bound JAK1 
(325). Upon phosphorylation, STAT1 and STAT2 then dimerize and bind to IRF9 
to form a heterotrimeric complex termed interferon stimulated gene factor 3 
(ISGF3) (326). The newly formed heterotrimer then translocates to the nucleus 
and binds to the promoter regions of ISGs (327), including IRF7, enhancing their 
transcription (328). Activated IRF3 forms a heterodimer with IRF7, translocates 
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into the nucleus and binds to the promoter of IFN-α genes resulting in the 
production of IFN-α species as well as a greater number of ISGs (15, 302, 328).  
In the delayed early or amplification phase (Fig. 1.6.C.), IFN-α/β further 
induce a greater range of ISGs and the protein products of these ISGs help 
restrict viral replication and spread leading to the establishment of a global 
antiviral state within the host cell (329). 
1.15.1 ISG expression and function 
ISGs have been described as the workhorse of the type-I IFN system 
(330, 331) whose antiviral effects block the transcription and translation of viral 
genes and also promote the apoptosis of virally infected cells (302, 332). The 
inhibitory effects of IFN on a wide range of mammalian DNA and RNA viruses 
have been described by using both in vitro and in vivo models (333-335). 
Prominent antiviral ISGs induced by IFN in virus-infected cells are protein kinase 
R (PKR), 2’, 5’-oligoadenylate synthetase (OAS) and RNase L, RNA-specific 
adenosine deaminase (ADAR), and myxovirus-resistance (Mx) protein GTPases 
(330). It has been reported that dsRNA exert a major modulatory effect on 
protein phosphorylation, RNA editing, and RNA degradation that is catalyzed by 
actions of PKR kinase, OAS synthetase, and ADAR1 deaminase (336, 337). 
PKR is an intracellular sensor of dsRNA that is induced by IFN, and elicits an 
antiviral effect by inhibiting protein translation (338, 339). Although this enzyme is 
predominantly found closely associated with ribosomes in the cytoplasm of IFN-
treated cells (340-342), small amounts of PKR has also been demonstrated by 
cell fractionation and immunofluorescence to be localized in the nucleus (342, 
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343). PKR contains several functional domains (344) such as the N-terminal 
domain that binds dsRNA and the C-terminal domain that possess kinase 
activities (329). Following dsRNA-mediated autophosphorylation of PKR (341, 
345, 346), activated PKR catalyzes additional phosphorylation events of at least 
6 proteins: the PKR protein itself (347, 348); the α subunit of eukaryotic initiation 
factor 2, eIF-2α (349); the transcription factor inhibitor IκB (350, 351); the Tat 
protein encoded by human immunodeficiency virus (HIV) (352); the 90-kDa 
NFAT protein (353); and the M-phase specific dsRNA-binding phosphoprotein 
MPP4 (354). Among the many substrates of PKR, eIF-2α remains the best 
characterized. Serine phosphorylation of eIF-2α, which occurs at position Ser-51 
(349, 355), negatively regulates cellular pathways including primarily mRNA 
translation and protein synthesis (330) by impairing the eIF-2B-catalyzed guanine 
nucleotide exchange reaction (341, 345, 356, 357). Studies suggest that changes 
in IFN-inducible PKR phosphorylation play an important role in the antiviral 
actions of IFN and regulation of cell growth by IFN (341, 345, 358, 359). 
In its inactive state, OAS is constitutively expressed in the cytoplasm of 
resting cells but becomes induced upon IFN treatment (360). It was initially 
thought that this enzyme primarily targets only the viral RNA for degradation as 
part of the antiviral IFN-mediated response, however, cellular RNAs have also 
been reported as targets of this pathway indicating its role in regulating cellular 
functions and apoptosis (329, 361). This pathway seems to be activated by 
dsRNA and requires two enzymes namely; OAS and RNase L for mRNA 
degradation (330). The synthesis of oligoadenylates (commonly referred to as 2-
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5A) by OAS triggers the activation of RNase L, a latent endoribonuclease, by the 
binding of 2-5A oligoadenylates (330). A third enzymatic event involves the 
hydrolysis of oligonucleotides possessing 2’, 5’-phosphodiester bonds, by 
phosphodiesterase thereby attenuating the 2-5A response (330). There is no 
structural homology between the dsRNA-binding domains of OAS and those of 
PKR and ADAR (362, 363), however, OAS, like PKR and ADAR (341, 345, 364), 
possesses separate subdomains for its dsRNA binding and catalytic activity (365, 
366). Convincingly, this pathway has been demonstrated to regulate cellular 
processes and also restrict viral replication in in vitro and in vivo experiments 
(367-370). 
The myxovirus-resistance (Mx) proteins were among the first IFN-
inducible gene products to be studied in the context of a virus infection (371). 
Experimental evidence obtained from animal models revealed that Mx alone has 
the ability to restrict viral replication in the absence of any other IFN-α/β-inducible 
proteins (372, 373). Mx proteins are IFN-inducible GTPases and belong to the 
superfamily dynamin-like GTPases (374, 375). The intrinsic GTPase activity of 
Mx proteins indicates that their antiviral activity requires an enzymatic function 
(361). The highly conserved GTP binding activity is located within the N-terminal 
region of the protein (372-374). Mx proteins associate with themselves and 
importantly, with viral protein complexes mediated by the central and the C-
terminal region of Mx (376, 377). The antiviral significance of Mx proteins was 
first demonstrated in influenza- and Thogoto-virus systems (361). The spectrum 
of antiviral activity and the underlying mechanisms of Mx proteins are dependent 
 50 
 
on the phenotype of the Mx protein induced, its subcellular localization and the 
challenge virus (330). It has been demonstrated that MxA protein associates with 
the nucleocapsid of bunyaviruses promoting the redistribution of the viral capsid 
proteins in an attempt to inhibit bunyavirus replication (378). Similarly, the 
presence of Mx proteins either in the cytoplasm or nucleus of IFN-treated virus 
infected host cells determines whether viral nucleocapsid transport or viral RNA 
synthesis is blocked by Mx proteins (372, 374, 379, 380).  
The functionality of both viral and cellular RNAs can be changed by 
posttranscriptional modifications such as deamination of adenosine to yield 
inosine enabling certain biological processes to be affected (381-384). ADAR1 
deaminase is an example of an enzyme that is able to edit viral RNA transcripts 
and cellular pre-mRNAs (364, 385, 386). This enzyme was first identified to 
possess dsRNA-unwinding activity in Xenopus oocytes (387, 388) and it is 
known to catalyze deamination of adenosine to yield inosine in RNA substrates 
(330). The resultant effect of A to I transition creates an instability in the dsRNA 
helix by disrupting the base pairing making them become single stranded in 
character (387, 389). The catalytic domain of ADAR1 is situated in the C-terminal 
region of the deaminase (390-392) while the nucleic acid binding region is 
located in the N-terminal region of the catalytic domain (330). The biological 
significance of RNA editing by ADAR1 is in the potential to alter the protein 
coding capacity of the edited RNA transcript and sequence of replicated RNAs 
(330). Adenosine deamination is proposed as the mechanism underlying how 
RNA transcripts expressed early during polyomavirus infection are inactivated 
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after viral replication (393). Similarly, an A to I editing at specific sites of 
neurotransmitter receptor pre-mRNAs by ADAR have been reported to alter 
receptor function (384, 392). 
IFN can also shape the host’s immune response to infection by inducing 
nitric oxide synthase (iNOS2), and the MHC class I and II molecules (330). While 
nitric oxide produced by iNOS2 plays a key role in immunological defenses as an 
antimicrobial and antiviral agent, elevated MHC class I and II antigen levels 
mediated by IFN are believed to increase the efficiency of cellular immune 
responses to infections in the intact animal (330). 
1.16 Viral evasion of type-I IFN response  
Due to the importance of the type-I IFN system in restricting viral 
replication both in infected and uninfected cells, many viruses have adapted 
mechanisms to counteract the antiviral effect of the type-I IFN response. The 
mechanisms used by various viruses to inhibit the type-I interferon system 
involve: (1) mechanisms that interrupt the upstream mediators of viral recognition 
(394, 395) (2) mechanisms that circumvent the signaling pathways leading to 
interferon production (21, 31, 396), and (3) mechanisms that inhibit interferon-
induced antiviral proteins (397).  
1.16.1 Viral mechanisms that inhibit the upstream mediators of IFN production 
Certain viral factors target PRRs in infected host cells to evade an early 
innate immune detection thereby escaping the antiviral effect of the type-I 
response during infection. For example, the US3 gene of HSV-1 interferes with 
TLR3-mediated signaling that enables the virus to evade type-I IFN response in 
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an infected host cell (398). Similarly, HSV-1 deletion mutants of the US3 gene 
express elevated levels of TLR3 and type-I IFN activity in infected monocytic 
cells when compared with the WT virus (399). In a different study, Schlender et al 
reported that respiratory syncytial virus (RSV) strain A2 and measles virus strain 
Schwarz block type-I IFN production in a plasmacytoid dendritic cell model 
mediated by inhibition of both TLR 7 and TLR 9 signaling (394). Multiple viral 
proteins have also evolved to specifically inhibit cytosolic viral sensors in order to 
avoid an immediate innate immune detection and activation. For instance, the 
US11 protein of HSV-1 binds to RIG-I and MDA-5 in order to inhibit their 
downstream signaling pathways, thereby preventing the production of IFN-β 
(395). Similarly, the nonstructural 1(NS1) protein of the influenza A virus has 
been shown to inhibit the tripartite motif containing 25-caspase activation and 
recruitment domain (TRIM25-CARD) interaction which is required for the 
activation of RIG-I (400). 
1.16.2 Mechanisms that circumvent the signaling pathways leading to IFN     
production 
The two most common mechanisms employed by viruses to inhibit type-I 
IFN signaling are (1) virally derived proteins that inhibit the IRF3, IRF7, NF-κB, 
and the activator protein 1 (AP-1) signaling pathways and (2) virally derived 
proteins that inhibit the JAK-STAT signaling pathway. It has been shown that 
human papillomavirus encodes a protein, E6, that interacts with IRF3 affecting its 
ability to transactivate IFN- induction (401). Recently, our laboratory 
demonstrated that the molecular mechanism for EHV-1 suppression of type-I IFN 
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induction involves interference with the IRF-3 signaling pathways (402). In a 
different study by Ciancanelli et al. the IRF-7 gene was shown to be defective in 
patients with severe susceptibility to H1N1 influenza, while susceptibility to other 
viral diseases such as CMV, RSV, and parainfluenza was unaffected (403). 
Different viruses have been reported to encode viral factors that targets different 
steps of JAK-STAT signaling pathway. The ICP 27 of HSV-1 has been shown to 
prevent phosphorylated-dependent activation and nuclear translocation of STAT1 
molecules (404). Cellular expressions of V proteins from simian virus 5 and type 
II human parainfluenza virus have been reported to induce polyubiquitination of 
STAT1 and STAT2 targets (396). In another study, Human metapneumovirus 
decreases cellular levels of JAK1 and TYK2 by targeting them for proteasomal 
degradation leading to a consequential effect on IFN- signaling (21). Our 
laboratory also reported that the molecular mechanism employed by EHV-1 to 
down-regulate type-I IFN production involves interference with the activation and 
nuclear translocation of STAT1 molecules in infected EECs (31). The important 
function played by the JAK and TYK2 kinases, and STAT proteins in antiviral 
response makes them attractive targets for viral proteins to evade type-I IFN 
biological effects.  
1.16.3 Mechanisms that inhibit IFN-induced antiviral proteins    
The end-products of type-I IFN signaling ensures that virally infected cells 
and bystander uninfected cells are protected from the damaging effects of viral 
infection. However, many viruses encode proteins that enables them to 
outmaneuver the global anti-viral effect of ISGs. The RING finger domain of 
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HSV-1 ICP0 has been reported to inhibit IRF3- and IRF7-mediated activation of 
ISGs (405). Similarly, it has been reported that dengue virus encodes some non-
structural proteins, such as NS4B, NS2A, and NS4A, that down-regulate ISGs in 
human A549 cells (397). Yokota et al. also showed that herpes simplex virus 
induces suppressor of cytokine signaling 3, a negative regulator of JAK-STAT 
pathway, as early as 2 hpi in human amnion cells (Yokota et al., 2003). More 
recently, our laboratory reported that EHV-1 infection of EECs suppresses the 
expression of an IFN induced antiviral protein, viperin (‘virus inhibitory protein’, 
‘endoplasmic reticulum-associated’, ‘interferon-inducible’) (406).  
1.17 Statement of problems and hypothesis 
EHV-I causes a disease condition worrying to many horse owners not only 
because of its tendency to affect reproduction but also because of its capability to 
progress to a neurological form, which affects horses’ well-being and their 
abilities to be utilized for sport and recreation. Outbreaks are costly for the equine 
industry-quarantines and tracing efforts funded by the government to curtail the 
spread of the disease amount to millions of dollars annually in the United States 
(407). In the same vein, horses are confined to stalls to prevent direct spread 
between horses and horse race events are canceled leading to a huge loss in 
revenue. The highly infectious nature of EHV-1 imposes an urgent need to 
develop a more effective vaccine than the ones presently available commercially. 
Additionally, there is no report of an effective vaccine against the neurological 
form of the disease.    
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Multicellular organisms possess sophisticated defense mechanisms, 
innate and adaptive immunity, that are immediately activated to counter the 
invasion of a wide array of pathogens within the body of a vertebrate host (408). 
However, successful pathogens such as EHV-1 have evolved a range of anti-
immune strategies to overcome both innate and acquired immunity (31, 402, 406, 
409-412), which play critical roles in their ability to cause disease. Over the 
years, several studies have investigated the underlying mechanisms employed 
by EHV-1 to counteract the adaptive immune arm of the host immunity. 
Unfortunately, studies investigating the impact of EHV-1 infection on the innate 
immune response of the host appear to be rudimentary. The type-I IFN system is 
a critical component of the host’s innate immunity against viral infection. It plays 
a dual role in the signaling pathway to preventing viral replication. Firstly, type-I 
IFN is responsible for inducing transcription of a large group of genes, which 
makes the host cells develop resistance to viral infections (15, 302, 328). 
Secondly, it can activate key components of both the innate and adaptive 
immune systems (413). Type-I IFN has applications in immunotherapy against 
viral infections and also in cancer treatment. Despite the recent increase in 
interest from researchers to decipher the intricate interaction between EHV-1 and 
the type-I IFN response, a lot of information is still missing. Characterization of 
type-I IFN response during EHV-1 infection using an appropriate experimental 
model will furnish explanations to questions on why the host is unable to induce a 
protective immunity against EHV-1.   
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Furthermore, a detailed knowledge of how the virus outsmarts the host 
type-I IFN system is highly fundamental in order to come up with the 
development of viable interventions that will limit the scourge of this infectious 
disease. Identifying certain critical steps in the virus replication cycle which are 
indispensable for its ability to infect host cells and dampen the host type-I IFN 
response will go a long way towards developing effective vaccines and 
therapeutic interventions against EHV-I infection. This is an ongoing line of 
research, and our study aims to expand prior knowledge on the underlying 
molecular mechanisms employed by EHV-1 to down-regulate type-I IFN 
response in host cells. The central hypothesis of this dissertation is that highly 
pathogenic EHV-1 and low pathogenic EHV-4 differentially alter type-I IFN 
signaling molecules. To test this hypothesis, the specific aims are: 
(A) To investigate the relationship between neuropathogenicity of EHV-1 
and suppression of IFN-α/β response. 
(B) To investigate the effect of EHV-1 infection on signaling events leading 
to IFN-α/β response in vitro. 
(C) To investigate the effect of EHV-4 infection on signaling events leading 
to IFN-α/β response in vitro. 
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Table 1. 1 Known equine herpesviruses 
Subfamily of 
Herpesviridae 
Equus species 
 
Gazella 
thomsoni 
 Domestic horse 
(Equus caballus) 
Donkey 
(Equus asinus) 
Zebra 
(Equus grevyi) 
Onager 
(Equus 
hemionus 
onager) 
 
Alphaherpesvirinae: 
a. Viscerotropic 
subgroup 
 
Equine herpesvirus 1
a
 
(Equid herpesvirus 1)
b
 
Equine herpesvirus 4 
(Equid herpesvirus 4) 
Asinine 
herpesvirus 3 
(Equid 
herpesvirus 8) 
Zebra 
herpesvirus 
isolates 
Onager 
herpesvirus 
isolates 
Gazelle 
herpesvirus 
1 
( Equid 
herpesvirus 
9) 
b. Dermatotropic 
subgroup 
Equine herpesvirus 3 
(Equid herpesvirus 3) 
Asinine 
herpesvirus 1 
(Equid 
herpesvirus 6) 
   
Gammaherpesvirinae Equine herpesvirus 2 
(Equid herpesvirus 2) 
Equine herpesvirus 5 
(Equid herpesvirus 5) 
Asinine 
herpesvirus 2 
(Equid 
herpesvirus 7) 
   
Adapted from Allen et al. (77).  
a
Viruses located in the same horizontal row of the table represent closely related equid herpesviruses exhibiting minor 
genetic and antigenic divergence induced by natural adaptation of a common progenitor to different equid or animal 
species.  
b
Virus names in parentheses are nomenclatural designations assigned by the Herpesvirus Study Group of the 
International Committee on Taxonomy and Nomenclature of Viruses (ICTV) (414, 415).  No ICTV designations have at 
this date been assigned by the Study Group to the zebra or onager herpesviruses (414).
 
A neurotropic herpesvirus isolate 
from captive gazelle closely related to Equid herpesvirus 1 has provisionally been designated Equid herpesvirus 9 (80, 
414, 416). 
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Table 1. 2 EHV-1 and EHV-4 gene products and their functions 
ORF 
# 
EHV-1 
 
 
EHV-4 
 
 Functional class of HSV 
homolog (core genes) 
 
Gene products and proposed functions 
 
 
Start 
 
 
Stop 
 
Start 
 
Stop 
     Capsid protein assembly  
43 Ϯ 82083 83027 81661 82605 UL18 VP23, involved in intercapsomeric 
formation with VP19c 
42 Ϯ 77703 81832 77301 81428 UL19 VP5, major capsid protein 
35 Ϯ 67093 65153 66770 64827 UL26 VP24 and VP21 are products of self-
cleavage of UL26, serine protease 
35.5 
Ϯ 
66142 65153 65822 64827 UL26.5 VP26, scaffolding protein 
25 Ϯ 47311 46952 47068 46709 UL35* VP26, capsid protein 
22 Ϯ 32916 31519 32355 30967 UL38 VP19c, a component of intercapsomeric 
complex 
     DNA replication  
57 Ϯ 102375 105020 101875 104517 UL5 DNA helicase-primase, DNA replication 
54 Ϯ 97069 99324 96626 98881 UL8 DNA helicase-primase, DNA replication 
31 Ϯ 55453 59082 55178 58804 UL29 ICP8, Single stranded DNA-binding protein 
30 Ϯ 55184 51522 54924 51262 UL30 DNA polymerase, DNA replication 
18 25696 24479 25222 24002 UL42 Double-stranded DNA binding protein, DNA 
polymerase subunit 
7 Ϯ 10301 7056 9900 6658 UL52 DNA primase, DNA helicase-primase 
subunit 
     DNA cleavage/packaging  
56 Ϯ 102391 100130 101891 99648 UL6 Associated with capsids, a subunit of portal 
1 complex 
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Table 1. 3 EHV-1 and EHV-4 gene products and their functions (continued) 
44 Ϯ 84320 83148 83875 82703 UL15 DNA terminase activity, involved in DNA 
packaging 
45 Ϯ 84480 86600 84037 86157 UL17  
36 Ϯ 68975 67212 68648 66885 UL25 Capsid protein, involved in packaging of 
cleaved viral DNA 
32 Ϯ 59243 61570 58964 61285 UL28 ICP18.5, pac motif-specific DNA binding 
activity, DNA packaging protein 
28 Ϯ 48763 50625 48515 50365 UL32 Cytoplasmic/nuclear protein involved in 
DNA cleavage/packaging 
27 Ϯ 48791 48369 48543 48124 UL33 DNA packaging protein involved in capsid 
assembly 
     Nucleic acid metabolism  
61 Ϯ 108144 107206 107640 106696 UL2* Uracil-DNA glycosylase 
50 Ϯ 91135 92832 90699 92396 UL12* Alkaline nuclease, involved in viral DNA 
processing 
21 Ϯ 31276 28904 30732 28363 UL39* ICP6, ribonucleotide reductase large 
subunit involved with protein kinase activity  
9 Ϯ 12115 11135 11702 10722 UL50* Deoxyuridine triphosphate 
     Envelope glycoprotein  
62 Ϯ 108843 108147 108296 107637 UL1 gL, forms complex with gH to direct viral 
entry, egress and cell-to-cell spread 
52 Ϯ 94472 93120 94033 92681 UL10* gM, involved in viral cell-to-cell spread 
39 Ϯ 71192 73738 70858 73425 UL22 gH, forms complex with gL to direct viral 
entry, egress and cell-to-cell spread 
33 Ϯ 61432 64374 61147 64074 UL27 gB, VP7, required for viral entry into a cell, 
forms a dimer and induces neutralization 
antibody 
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Table 1. 4 EHV-1 and EHV-4 gene products and their functions (continued) 
     Others  
55 Ϯ 100332 99421 99850 98942 UL7* Associated with intracellular capsids, 
involved in DNA packaging? 
51 Ϯ 92784 93008 92348 92575 UL11* Myristoylated viral protein involved in 
efficient capsid envelopment and egress 
49 Ϯ 89369 91153 88921 90717 UL13* UL13 PK, tegument protein with protein 
kinase activity 
48 Ϯ 88947 89900 88499 89464 UL14* Tegument protein with molecular 
chaperone function 
46 Ϯ 86620 87732 86176 87285 UL16* Tegument protein, located within the intron 
of UL15, involved in DNA packaging? 
37 Ϯ 69897 69079 69567 68749 UL24* Non-glycosylated membrane-associated 
protein, neuropathogenic virulence factor? 
29 Ϯ 50618 51598 50358 51338 UL31* Nuclear matrix binding protein, interacts 
with UL34 
26 Ϯ 48230 47403 47980 47156 UL34* Associate with inner nuclear membrane  
24 Ϯ 36588 46853 36006 46610 UL36 ICP1/2, largest tegument protein, involved 
in both uncoating and egress 
23 Ϯ 33292 36354 32712 35777 UL37 ICP32, Tegument protein with nuclear 
export signal, involved in egress and virion 
maturation 
NA     UL49.5* Small membrane-associated protein 
8Ϯ 10300 11037 9899 10633 UL51* Palmitoylated virion protein, associated 
with the Golgi 
5 Ϯ 5874 4462 5484 4081 UL54 ICP27, regulation of gene expression at the 
post-translational level 
     Non-core essential genes  
53 94390 97053 93951 96614 UL9 Replication origin-binding protein 
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Table 1. 5 EHV-1 and EHV-4 gene products and their functions (continued) 
12 13595 14944 13173 14519 UL48 VP16, tegument protein involved in 
(immediate early) IE gene expression 
64 118591 
144569 
114128 
149032 
117422 
140628 
113093 
144956 
RS1 ICP4, major regulatory protein 
72 131583 132791   US6 gD, required for virus entry 
     Non-core accessory genes  
NA     RL1* ICP34.5, protein synthesis regulator 
63 111985 110387 111713 110103 RL2* ICP0, promiscuous transactivator with E3 
ubiquitin ligase domains involved in gene 
regulation 
60 107116 106478 106606 105971 UL3* Nuclear phosphoprotein, involved in 
nucleolar localization 
58 105070 105747 104567 105250 UL4* Nuclear protein, co-localized with UL3 and 
ICP22 
41 76793 77512 76399 77112 UL20* Virion protein, essential for viral exocytosis 
40 76224 74632 75832 74243 UL21* Tegument protein, associated with 
microtubules 
38 69910 70968 69582 70640 UL23* ICP36, thymidine kinase (TK) required for 
nucleotide metabolism 
20 28859 27894 28324 27362 UL40* Ribonucleotide reductase small subunit, 
involved in nucleotide metabolism 
19 26262 27755 25765 27255 UL41* VHS, virion host shut-off protein, causes 
non-specific cellular mRNA degradation 
17 24234 23029 23786 22575 UL43* Membrane-associated protein 
16 22851 21445 22396 20939 UL44* gC, VP7.5, involved in cell attachment and 
adsorption, C3b-binding activity 
15 21170 20487 20698 20018 UL45* Virion protein, type-II membrane protein 
involved in virus egress 
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Table 1. 6 EHV-1 and EHV-4 gene products and their functions (continued) 
14 18083 20326 17633 19864 UL46* VP11/12, tegument protein, interacts with 
UL48 (VP16) 
13 15317 17932 14890 17484 UL47* VP13/14, tegument protein, enhances 
immediate early gene expression 
11 12549 13463 12128 13042 UL49* 
 
VP22, tegument protein with intercellular 
trafficking activity 
6 7042 6011 6649 5618 UL53* gK, required for efficient viral exocytosis 
4 4249 3647 3864 3262 UL55* Nuclear protein, nuclear matrix-binding 
protein 
NA     UL56* Type-II membrane protein, associated with 
intercellular trafficking 
65 121368 
141792 
122249 
140911 
120069 
137981 
120923 
137127 
US1* ICP22, regulatory protein involved in the 
expression of late genes 
68 126275 125019 124559 123585 US2* Virion protein, interacts with cytokeratin 
69 126411 127559 124695 125849 US3* US3 PK, has anti-apoptotic activity 
70 127681 128916 125970 127277 US4* gG, involved in viral entry and egress 
71 129097 131490 127455 129707 US5* gJ, protects from Fas-mediated apoptosis 
73 132899 134173 131111 132373 US7* gI, interacts with gE, involved in cell-to-cell 
spread 
74 134406 136058 132593 134239 US8* gE, forms complex with gI, Fc receptor 
activity, cell-to-cell spread 
NA     US8.5* Localized in nucleoli of infected cells 
76 136783 137442 134911 135573 US9* Type-II membrane protein, involved in 
anterograde transport of envelope 
glycoprotein? 
66 122862 
140298 
123572 
139588 
121447 
136603 
122133 
135917 
US10* Tegument protein, tightly associated with 
capsids 
NA     US11* Tegument protein, RNA-binding activity, 
and intercellular trafficking 
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Table 1. 7 EHV-1 and EHV-4 gene products and their functions (continued) 
NA     US12* TAP-binding protein, involved in MHC class 
I downregulation 
1 1298 1906 944 1543 NA Downregulates MHC class I 
2 2562 1945 2206 1580 NA Virion virulence factor  
3 2841 3614 2457 3227 NA Unknown 
34 64578 65060 64268 64750 NA Unknown 
47 Ϯ 88917 87886 88469 87438 NA Unknown 
10 Ϯ 12084 12386 11671 11973 UL49A gN, Envelope protein 
59 106416 105877 105918 195358 NA V57, virion morphogenesis? 
67 125194 
124376 
137966 
138784 
123491 122631 NA VP67, co-localizes with nuclear lamin 
75 136055 136447 134273 134605 NA US8A, unknown function 
Table 1.2 was prepared according to available data published in Allen et al (77), Nishiyama et al (417), Davison et al 
(146), Sarkar (418), Roizman (419), Kasem et al (420), Telford et al (81), Ma et al (421), and Ma et al  (422). * indicates 
that the gene is dispensable for replication in cell culture; NA= Not available; Ϯ indicates conserved genes across all 
mammalian herpesviruses. 
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Figures. 
 
Figure 1. 1 Schematic illustration of herpesvirus structure. The basic herpesviral 
structure consists of an envelope, a tightly woven dsDNA genome enclosed within the 
capsid, and a tegument layer. Several glycoproteins are present on the surface of the 
envelope. 
 
Figure 1. 2 Lytic life cycle of EHV-1. The virus enters susceptible cells either by fusion 
at the cell membrane or by the non-classical endocytosis pathway. This is followed by the 
release of nucleocapsid into the cytoplasm of an infected cell. The nucleocapsid, which is 
transported to the nucleus via dynein, docks at the NPC and extrudes the viral DNA 
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directly into the nucleus. This initiates viral gene expression beginning with the 
transcription of IE (α) gene. Immediate early proteins are then synthesized in the 
cytoplasm and migrates to the nucleus where they direct the transcription of E (β) gene. 
Early protein, synthesized in the cytoplasm, translocates to the nucleus to initiate virus 
DNA replication and virus L (γ) gene expression. Next, some of the L proteins 
synthesized in the cytoplasm, migrate to the nucleus to form the capsid before 
encapsidation of the new virus DNA. The newly assembled virion then migrates through 
the nucleus and the cytoplasmic membranes before it is eventually released outside of 
the cell. 
 
 
Figure 1. 3 Herpesvirus capsid formation. The basic assembly of a matured capsid 
consists of complex formation between major capsid protein and scaffold protein with the 
incorporation of a portal protein. An early step in the formation of a spherical procapsid 
(partial procapsids) involves complex interactions between the major capsid protein and 
the scaffold protein to produce what, first, looks like an angular segment. A complex of 
portal and scaffold protein is incorporated with the progressive enlargement of the partial 
procapsid. Once the procapsid is formed, virus DNA is packaged marking the exit of the 
scaffolding proteins creating a polyhedral shape. 
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Figure 1. 4 Herpesvirus egress pathway. Following intranuclear encapsidation of the 
virus genome, the herpesviral nucleocapsid will bud through the inner nuclear membrane 
resulting in perinuclear localization of an enveloped primary virion. This primary envelope 
becomes lost (de-envelopment) as the virus translocates into the cytosol where the 
nucleocapsid acquires tegument proteins. Final (secondary) envelopment then occurs in 
the cytoplasm derived from the TGN and the enveloped virion is transported in a vesicle 
to the plasma membrane for release.  
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Figure 1. 5 Schematic illustration of EHV-1 pathogenesis. EHV-1 primarily 
infects the respiratory epithelial cells. The virus is able to cross the basement 
membrane and invade the lamina propria where it infects circulating leucocytes. 
The virus then travels through the lymphatic system to regional lymph nodes 
where it undergoes amplification and infects peripheral blood mononuclear cells 
leading to a state of cell-associated viremia. The cell-associated viremia ensures 
that EHV-1 is disseminated to distant sites such as the endometrium of the 
pregnant uterus and the CNS causing inflammatory responses that culminate in 
the development of pathologies; abortion and EHM. 
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Figure 1. 6 Virus-mediated IFN production. A. In the immediate early/sensitization 
phase, viral conserved motifs (PAMPs) interact with host innate immune sensors (PRR) 
leading to the production of low levels of IFN-β. B. In the early or inductive phase, 
released IFN-β bind to IFNAR1 and IFNAR2 triggering the activation of the JAK-STAT 
signaling pathway leading to the induction of ISGs including IRF7. With subsequent viral 
infection, activated IRF3 and IRF7 form heterodimers and translocate to the nucleus to 
upregulate the transcription of IFN-α species. C. In the delayed early or amplification 
phase, the synergistic effect of IFN-α and IFN-β induces enhanced transcription of a 
diverse set of ISGs creating a global antiviral environment. Illustration was based on 
Mossman and Ashkar (302) . 
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CHAPTER 2: ABSENCE OF RELATIONSHIP BETWEEN TYPE-I 
INTERFERON SUPPRESSION AND NEUROPATHOGENICITY OF EHV-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Fatai S. Oladunni, Sanjay Sarkar, Stephanie Reedy, Udeni B.R. 
Balasuriya, David W. Horohov, Thomas M. Chambers. Veterinary Immunology 
and Immunopathology. 2018. 197 (24-30). 
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Abstract                     
Equine herpesvirus-1 (EHV-1) infection is an important and highly 
prevalent disease in equine populations worldwide. Previously we have 
demonstrated that a neuropathogenic strain of EHV-1, T953, suppresses the 
host cell’s antiviral type-I interferon (IFN) response in vitro. Whether or not this is 
unique to EHV-1 strains possessing the neuropathogenic genotype has been 
undetermined. Here, we examined whether there is any direct relationship 
between neuropathogenic genotype and the induced IFN-β response in equine 
endothelial cells (EECs) infected with 10 different strains of EHV-1. The extent of 
virus cell-to-cell spread following infection in EECs was also compared between 
the neuropathogenic and the non-neuropathogenic genotype of EHV-1. We then 
compared IFN-β and the total type-I IFN protein suppression between T953, an 
EHV-1 strain that is neuropathogenic and T445, an EHV-4 strain mainly 
associated only with respiratory disease. Data from our study revealed no 
relationship between the neuropathogenic genotype of EHV-1 and the induced 
IFN-β mRNA by the host cell. Results also indicate no statistically significant 
difference in plaque sizes of both genotypes of EHV-1 produced in EECs. 
However, while the T953 strain of EHV-1 was able to suppress IFN-β mRNA and 
type-I IFN biological activity at 12 hours post-infection (hpi), EHV-4 weakly 
induces both IFN-β mRNA and type-I IFN biological activity. This finding 
correlated with a statistically significant difference in the mean plaque sizes 
produced by the two EHV subtypes in EECs. Our data help illuminate how EHV-
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1, irrespective of its genotype, evades the host cell’s innate immune response 
thereby enabling viral spread to susceptible cells. 
Keywords: Neuropathogenic; Viral pathogenesis; Herpesvirus; Interferon; 
Equine; Genotype. 
2.1 Introduction 
EHV-1 infection is an important disease of equids that was first 
documented in the early 1930s (1). The viral infection is known for its clinical 
manifestations including respiratory disease, sporadic abortion during the third 
trimester of gestation, birth of weak newborns, chorioretinitis and neurological 
disease (11, 79, 105, 230, 423-425). Like most other herpesviruses, EHV-1 has 
the ability to establish latency after primary infection, leading to a carrier state in 
infected horses. Additionally, the disease is highly contagious among horses and 
one of the most devastating manifestations of EHV-1 infection is the neurologic 
form termed equine herpesvirus myeloencephalopathy (EHM). Although EHM is 
not new, there has been an increase in the outbreak of the disease condition 
since the year 2000 (105, 411, 426-428). 
It has been suggested that distinct strains of EHV-1 differing in 
pathogenicity circulate in the field (272). Strains of EHV-1 have been broadly 
classified neuropathogenic and non-neuropathogenic, based on the presence of 
a single nucleotide polymorphism (A2254→G2254) in the viral DNA polymerase with 
G2254 associated with neuropathogenic strains (272). Generally, the EHV-1 
strains possessing the neuropathogenic genotype are involved in neurologic 
outbreaks while those with the non-neuropathogenic genotype are predominantly 
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isolated from cases of sporadic abortions in pregnant mares (206, 210, 213, 239, 
250). It is, therefore, noteworthy that some of the EHM cases are associated with 
the A2254 non-neuropathogenic genotype, and the G2254 neuropathogenic 
genotype does not necessarily lead to EHM (276, 429-432), indicating that other 
viral and host factors are involved in EHM. 
Equine herpesvirus-4 (EHV-4) is a different virus type but closely related 
to EHV-1 with nucleotide sequence identity within individual homologous genes 
ranging from 55 to 84 percent and amino acid sequence identity ranging from 55 
to 96 percent (81, 82). The virus was earlier classified as a subtype of EHV-1 
until 1981 when molecular evidence became available which allowed for the 
differentiation between the two viruses (433). Sequence information, therefore, 
substantiates the view that EHV-1 and EHV-4 are two closely related but distinct 
herpesviruses of the horse (434). The detailed pathogenesis of EHV-4 has not 
been well studied but the infection mirrors that of EHV-1 during the early onset. 
EHV-4 infection begins with virus replication in mucosal epithelial cells of the 
upper respiratory tract following inhalation of infectious aerosols or contact with 
infected fomites. However, the pathogenicity, extent of viral replication and tissue 
destruction in horses caused by EHV-4 are far lower than those observed for 
EHV-1 (434). It has been suggested that the biological difference in pathogenicity 
between EHV-1 and EHV-4 can be attributed to the difference in cellular tropism 
between the two viruses (5). While primary infection of EHV-4 has been reported 
to be limited mainly to the epithelial cells of the upper respiratory tract of a 
susceptible host (435), in vivo replication of EHV-4 in endothelial cells has also 
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been described (436). It has, however, been demonstrated that EHV-4 has less 
tropism for mononuclear cells and is less efficient in infecting these cells when 
compared to EHV-1 (5, 215). Consequently, leukocyte-associated viremia which 
is a prerequisite for the induction of abortion or neurologic disease in EHV-1 is 
not a common feature of EHV-4 infection (215).    
 The type-I IFN response is critical in restricting viral spread from infected 
to non-infected cells and several viruses have evolved mechanisms to evade this 
potent antiviral system. The action of EHV-1 on the host cell type-I IFN system 
during infection has been better studied than that of EHV-4. Recently, we have 
demonstrated in cell culture that an EHV-1 strain isolated from a 
neuropathogenic outbreak and possessing the neuropathogenic genotype, T953, 
has the ability to suppress type-I IFN response at 12 hpi when co-infected with 
either of the IFN inducers, Sendai virus or Poly-I:C (406). This virus strain was 
not only successful in downregulating the type-I IFN response but was also 
capable of inhibiting downstream type-I IFN mediated antiviral activity in vitro 
(31). Some of the mechanisms determined to be used by this EHV-1 strain to 
downregulate the type-I IFN response include interference with the nuclear 
translocation of STAT-1 protein (31) and the disruption of the interferon 
regulatory factor-3 (IRF-3) signaling pathways (402). Both STAT-1 and IRF-3 are 
important transcription factors that are indispensable for the sensitization and 
induction of type-I IFN. Thus it is clear that, in cell culture, the neuropathogenic 
T953 strain of EHV-1 can overcome the type-I IFN response of the host cell. For 
this reason, we hypothesized that neuropathogenicity is correlated with the 
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capacity for a reduced type-I IFN response in the host cell. If true, that would 
suggest that low type-I IFN induction in the host cell might be a contributing 
mechanism for neuropathogenicity. To test our hypothesis, here we compared 
the type-I IFN response between EHV-1 strains possessing the neuropathogenic 
genotype and those with the non-neuropathogenic genotype using our 
established cell culture system. We also compared the type-I IFN response 
following infection with the two closely related but different EHV subtypes: EHV-1 
and EHV-4. 
2.2 Materials and methods 
2.2.1 Cells and viruses  
 Equine pulmonary artery endothelial cells (EECs; (437)) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Mediatech Inc.) with 10% iron-
supplemented bovine calf serum (BCS, Hyclone Laboratories, Inc., Logan, UT), 
100 U/ml penicillin-streptomycin (Life Technologies, Carlsbad, CA), 1 mM sodium 
pyruvate, 0.1 mM non-essential amino acids and 200 mM L-glutamine (Life 
Technologies, Carlsbad, CA) in a humidified incubator at 37°C with 5% CO2. A 
total of 10 EHV-1 isolates including T953, a well-characterized, neuropathogenic 
strain also known as the Findlay strain isolated from a nasopharyngeal swab of a 
horse suffering from an EHV-1 neurologic disease (299), were included in the 
study. In addition to T953, the other EHV-1 isolates were: AB4, T313, T970, 
TX06, T75, T186, T220, T262, and T61. An isolate of EHV-4, T445, was also 
included. To prepare working virus stocks, confluent EECs were infected with 
EHV-1 at a multiplicity of infection (MOI) of 0.1. After the virus had produced 
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nearly 100% cytopathic effect (CPE), the tissue culture fluid (TCF) containing the 
virus was freeze-thawed three times and clarified at 2000 x g for 30 min at 4°C, 
filtered through 0.45 μm cellulose acetate membrane filters (Thermo Scientific 
Nunc, Pittsburgh, PA) and purified by ultracentrifugation at 100,000 x g for 4 h at 
4°C through a 20% sucrose cushion. The virus pellet was re-suspended in 
DMEM with 2% BCS, sonicated briefly, aliquoted in 100µl volumes and stored at 
-80°C until further use.  The infectious virus titer was determined by plaque assay 
in EECs as described (438) with slight modifications. Briefly, confluent EECs 
propagated in 6-well plates were infected with 10 fold serial dilutions of cell 
culture supernatant containing virus. For each dilution of the virus, duplicate wells 
were infected. The virus was let to adsorb for 1 h, at 37°C with 5% CO2. 
Unadsorbed viruses were removed by washing and 0.75% 
carboxymethylcellulose (CMC) media (Sigma-Aldrich, St. Louis, MO) was added 
to each well and the plates were further incubated in a humidified 5% CO2 
atmosphere at 37°C for 96 h. The CMC media was removed and the infected 
cells stained with 1% crystal violet (CV) solution in buffered formalin (10%) for 
plaque visualization. A total of 30 plaques were photographed for each virus 
strain and the plaque sizes were measured using ImageJ software (439).
 Genotyping of field isolates of EHV-1 was carried out as previously 
described (287) with slight modification. The viruses were grouped into either the 
neuropathogenic or the non-neuropathogenic genotype of EHV-1 based on the 
detection of either G2254 or A2254 in the viral DNA polymerase. 
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2.2.2 Viral infections 
EECs were plated into 6-well culture plates (Corning, NY) 48 h prior to 
infection to obtain more than 90% confluency at the time of infection. Monolayer 
cells were infected with the various virus strains at an MOI of 5 for 1 h in a 
humidified incubator at 37°C with 5% CO2. In parallel, cells were either mock-
infected with virus diluent (negative control) or treated with 80 µg/ml of Poly-I:C 
(positive control). The cells were then washed with D-PBS and incubated with 
complete growth medium for 12 h. All experiments were performed in duplicate 
and repeated on three independent days.  
2.2.3 RNA extraction and real-time RT-PCR assay 
Total cellular RNA was extracted using QiaAmp RNeasy plus mini kit 
(Qiagen Inc. Valencia, CA) from EHV-1-infected and control EECs at 12 hpi 
according to the manufacturer’s protocol. The quantity and quality of the cellular 
RNA were examined by OD260/OD280 measurement using the Synergy H1 hybrid 
plate reader (Biotek, Winooski, VT). One microgram of total cellular RNA was 
reverse transcribed as described (440) using 0.5 µg oligo dT primer. Equal 
amounts of cDNA were used for the transcription analysis of different genes by 
TaqMan real-time PCR using specific primers and probes in a ViiATM 7 Fast 
Real-Time PCR system (Applied Biosystems, Foster City, CA). The sequences of 
primers and probes used in this study are listed in Table 2.1. All reactions were 
performed in duplicate. The RT-PCR data were normalized using the equine 
ribosomal protein large P0 (RPLP0) transcript as an endogenous control. The 
PCR efficiency for all reactions was assessed by LinReg software (441). Fold 
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changes in the gene expression were calculated using the comparative ΔΔCT 
method for relative quantification (RQ) (442), using the average Ct value of 
mock-infected samples for each individual gene as the calibrator. 
2.2.4 IFN-β reduction score 
To quantify the degree of reduction of IFN-β transcription relative to 
positive control at 12 hpi, each virus was assigned a reduction score based on 
the algorithmic expression below. Reduction Score= [log10(Poly-I:C) - 
log10(Virus)] / [log10(Poly-I:C) - log10(Mock)]. Where each term (Poly-I:C, Virus, 
Mock) is the measured mean RQ value for IFN-β obtained by RT-PCR. Using 
this approach, we scored all the EHV-1 isolates based on their ability to induce 
IFN-β on a scale of 0 to 1. Scores approaching 0 indicate little reduction (IFN 
expression is similar to that stimulated by Poly-I:C), and scores approaching 1 
indicate strong reduction (IFN expression is markedly reduced compared to Poly-
I:C). 
2.2.5 Type-I interferon bioassay 
The inhibition of vesicular stomatitis virus (VSV)-induced cytopathic effect 
in Madin-Darby bovine kidney (MDBK) cells treated with the cell supernatants 
harvested at different hpi was measured using the type-I IFN bioassay as 
previously described (406, 443, 444). Briefly, confluent MDBK cells were treated 
with two-fold serially diluted supernatant for 24 hrs to stimulate type-I IFN protein 
secretion in the cell monolayer. Afterwards, the samples were removed and the 
cells infected with VSV at an MOI of 0.1. Each plate was incubated with virus and 
cell control wells respectively. Serially diluted recombinant EqIFN-α (Kingfisher 
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Biotech, Inc., Saint Paul, MN) was used as positive control. After 27 h of 
incubation, residual cells were fixed and stained with crystal violet for 2 h and the 
IFN bioactivity was read as an endpoint of a dilution providing 50% protection to 
cell monolayer expressed as Laboratory Units (LU)/ml. 
2.2.6 Statistical methods 
 Data from the study were analyzed either by Student’s t-test or by ANOVA 
with pairwise multiple comparison procedures by Tukey’s HSD test using 
GraphPad Prism version 6.04 (GraphPad Software, Inc., La Jolla, CA). P-Values 
less than 0.05 except otherwise stated were considered to be statistically 
significant. 
2.3 Results 
2.3.1  Identification and genotyping of EHV-1 strains  
 To ensure that the EHV-1 strains included in the study were properly 
classified into either the neuropathogenic or the non-neuropathogenic group, we 
genotyped each virus isolate. This was done using a standardized RT-PCR 
assay that is able to detect the presence of an A2254→G2254 SNP in the ORF 30 
gene of the virus (Equine Diagnostic Solutions, Lexington, KY). The strains 
possessing the neuropathogenic genotype, having an A2254→G2254 SNP in the 
ORF 30 gene of the virus, had lower melting temperatures when compared to the 
strains with A2254 classified as the non-neuropathogenic genotype (Fig. 2.1.A and 
2.1.B). 
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2.3.2  Effects of EHV-1 strains on IFN-β gene expression following in vitro  
infection of EECs 
 All the EHV-1 isolates included in the study, irrespective of their genotype, 
had reduced IFN-β mRNA expression level at 12 hpi compared to the positive 
control (Fig. 2.2.). We focused on IFN-β gene expression as the equine genome 
contains fewer alleles of this gene compared to IFN-α (307). The mean 
expression of IFN-β mRNA following 12 hpi was then compared between the two 
genotypes. The neuropathogenic group had a mean log10 RQ value for IFN-β 
mRNA expression of 0.90 ± 0.11 in EECs, while the non-neuropathogenic group 
had a mean log10 RQ value of 0.86 ± 0.21. Both the EHV-1 strains possessing 
the neuropathogenic genotype and the ones possessing the non-
neuropathogenic genotype showed low induction of IFN-β mRNA by about the 
same amount compared to Poly-I:C. 
 To quantitate the reduction of the type-I IFN response relative to positive 
control by individual EHV-1 strains following infection, we generated an 
algorithmic formula as detailed in Materials and Methods. With this, we were able 
to determine the RQ value of IFN-β mRNA from an EHV-1 infected cell with 
respect to those from the mock-infected and Poly-I:C-treated cells. We then 
compared the mean IFN-β reduction scores between the neuropathogenic and 
the non-neuropathogenic strains of EHV-1. The IFN-β reduction scores of the 
neuropathogenic strains ranged from 0.58 to 0.84 with a mean of 0.72 ± 0.04 and 
those of the non-neuropathogenic strains ranged from 0.55 to 0.86 with a mean 
of 0.74 ± 0.05 (Table 2.2.). Data from our study indicate no statistically significant 
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difference (p=0.76) in the type-I IFN reduction scores between the 
neuropathogenic and the non-neuropathogenic groups.  
2.3.3  Comparison of the plaques sizes of EHV subtypes (1 and 4)   
 Since the type-I IFN system plays an important role in restricting viral 
replication and viral cell-to-cell transmission (445), we compared the plaque sizes 
produced by the 10 neuropathogenic and the non-neuropathogenic strains of 
EHV-1 in EECs. With increased type-IFN production following EHV-1 infection, 
we would expect to see smaller plaques and vice versa. Our finding indicates no 
statistically significant difference in the sizes of the plaques produced by either 
group of EHV-1 (P=0.6) as both the neuropathogenic and the non-
neuropathogenic genotype produced plaque sizes of approximately 7.2 mm2 and 
7.0 mm2 respectively. Additionally, both EHV-1 genotypes produced similar viral 
titers in EECs (data not shown). 
 We also compared the sizes of plaques produced by the T953 strain of 
EHV-1 and the T445 strain of EHV-4 to gain insight into their cell-to-cell spread in 
EECs. The T953 strain of EHV-1 had a statistically significantly (P=0.0079) larger 
mean plaque size of about 8.6 mm2 compared to EHV-4, T445 strain with a 
mean plaque size of 5.30 mm2.                       
2.3.4 Comparison of IFN-β mRNA expression between EHV-1 (T953 strain) and 
EHV-4 (T445 strain). 
 We examined the association between pathogenicity and suppression of 
type-I IFN response by quantifying IFN-β gene transcription following infection of 
EECs with the EHV-1 T953 strain and the EHV-4 T445 strain. The pattern of 
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induction and suppression of IFN-β mRNA following infection with either EHV-1 
or EHV-4 is shown in Fig. 2.3.  Findings from our study, though not reaching 
statistical significance, showed a trend indicating that EHV-1 induced more IFN-β 
mRNA at 3 hpi than EHV-4 (Fig. 2.3.A). The maximum induction of type-I IFN 
was observed at 6 hpi for EHV-1 infection and this was followed by a decline at 
12 hpi. On the contrary, EHV-4 seemed to be a non-potent inducer of IFN-β 
mRNA at 3 hpi but the IFN response increased steadily at 6 and 12 hpi 
respectively. At 6 hpi, EHV-1 has induced twice as much IFN-β mRNA compared 
to EHV-4 in EECs. However, following 12 hpi, EHV-1 has caused a statistically 
significant (P=0.0087) decline in the IFN-β mRNA, whereas EHV-4 has 
stimulated increased IFN-β mRNA even further. By 18 hpi, the kinetics of IFN-β 
mRNA expression in EECs following EHV-1 infection indicated further reduction 
of IFN-β mRNA while the EHV-4 IFN-β mRNA level was unchanged (data not 
shown). 
 We previously showed that EHV-1 suppressed IFN-β responses even in the 
presence of an outside inducer such as Poly-I:C or Sendai virus (406).To 
evaluate the direct effect of either EHV-1 or EHV-4 on the induction of IFN-β 
mRNA stimulated by Poly-I:C treatment, we infected EECs with either EHV-1 or 
EHV-4 and also treated with Poly-I:C simultaneously. EHV-1 but not EHV-4 
infection in the presence of Poly-I:C treatment produced a significant increase in 
the transcription of IFN-β mRNA at 3 hpi compared to Poly-I:C only positive 
control (Fig. 2.3.B). However, there was no significant difference in the IFN-β 
transcription between the Poly-I:C only positive control and either EHV-1 or EHV-
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4 infection combined with Poly-I:C treatment at 6 hpi. By 12 hpi, EHV-1 
significantly reduced the IFN-β transcription in the presence of Poly-I:C treatment 
when compared to Poly-I:C only positive control as we have shown previously 
(Sarkar et al., 2015), whereas EHV-4 infection in the presence of Poly-I:C 
treatment significantly increased IFN-β mRNA transcription. 
2.3.5 Effect of EHV subtypes (1 and 4) on type-I IFN protein activity 
 To assess whether the IFN-β mRNA expression following infection are 
reflective of the type-I IFN protein activity, we performed a type-I IFN bioassay. 
This assay measures the protective effect of total type-I IFN protein in adjacent 
cells following VSV infection in MDBK cells. At 3 hpi (Fig. 2.4.A.), both EHV-1 
and EHV-4 produced less type-I IFN protein activity when compared to the 
positive control (Poly-I:C or Sendai Virus) with EHV-4 inducing the least IFN of 
all, although the differences were not statistically significant (P= 0.24). Following 
6 hpi (Fig. 2.4.B.), the most striking observation to emerge from the data 
comparison was that EHV-1 suppressed the type-I IFN protein activity induced by 
Sendai virus (P=0.03). Remarkably, by 12 hpi (Fig. 2.4.C.), EHV-1 had 
significantly suppressed the type-I IFN protein activity produced by Poly-I:C and 
Sendai virus respectively, whereas EHV-4 significantly enhanced type-I IFN 
protein activity produced by Poly-I:C. These results offer support for our IFN-β 
mRNA data, with EHV-1 but not EHV-4 capable of suppressing type-I IFN 
response by 12 hpi. Interestingly, while EHV-1 failed to induce any type-I IFN 
protein activity at 12 hpi, EHV-4 had induced more type-I IFN protein by 12 hpi. 
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2.4 Discussion  
 For a virus to be successful, it must possess factors that allow it to evade 
the key components of the host defensive structure: the physical and chemical 
barriers, the innate immunity and the adaptive immunity. EHV-1, like other 
herpesviruses, possesses an array of impressive immune evasive strategies 
(293, 446, 447) that are critical for the successful establishment of disease 
process once the virus perpetuates in the host cell. Here, we tested a hypothesis 
that neuropathogenicity is correlated to the host type-I IFN response. We also 
compared the suppression of type-I IFN between the EHV-1 T953 strain and a 
strain of EHV-4, T445, to further understand how widespread the IFN 
suppressive function is found among equine alpha herpesviruses. 
Firstly, we screened a panel of viruses of both the neuropathogenic and 
the non-neuropathogenic genotypes for their effect on host cell type-I IFN 
response. There was no statistical difference in the level of expression of IFN-β 
mRNA between the neuropathogenic and the non-neuropathogenic groups. This 
finding suggests that the neuropathogenic strains of EHV-1 do not cause a lower 
type-I IFN induction than the non-neuropathogenic group, refuting our hypothesis 
that a reduced IFN response may contribute to the neuropathogenic phenotype. 
A lower induction of type-I interferon appears to be an immune evasion strategy 
used commonly by all EHV-1 strains. It is apparent that both the G2254 and the 
A2254 genotypes of EHV-1 possess viral genes employed to escape the host 
innate immune response during infection. Like EHV-1, other herpesviruses 
including HSV, bovine herpesvirus, varicella-zoster virus, and mouse 
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cytomegalovirus, first induce and then inhibit IFN-α/β production (315, 448-451). 
For example, alpha herpesviruses like BoHV-1 and HSV-1 express an immediate 
early (IE) protein, infected cell protein 0  (ICP0), in the infected cells, which 
interferes with multiple steps of the type-I IFN response. EHV-1 also possess a 
homolog of this viral protein, EICP0, but its role with regards to interference with 
type-I IFN response in the equine host has not been documented. Further 
studies are, therefore, required to illuminate whether EICP0 exhibit similar roles 
on host type-I IFN response as observed in both BoHV-1 and HSV-1 ICP0. 
To confirm similarity of behavior between the 2 genotypes, we then 
evaluated the ability of both EHV-1 genotypes to produce visible plaques in 
EECs. Our results indicate no difference in the plaque sizes between the 
neuropathogenic and the non-neuropathogenic strains. Despite the presence of a 
non-synonymous mutation (A2254→G2254) in the DNA polymerase of the 
neuropathogenic group of EHV-1, which has been shown to affect virus 
replication based on titer (411), the plaque size remained unaltered in EECs. Our 
finding agrees with that of Goodman and co-workers who reported no difference 
in the replication properties of both genotypes of EHV-1 in equine fibroblasts in 
vitro (452). However, the G2254 genotype appears to play a key role in 
determining the level of viremia and endothelial cell infection in horses in vivo (5, 
452-454). A possible explanation for this difference compared to our study could 
be that in natural infection, viruses of the G2254 genotype due to their better 
replication efficiency (272), are effectively transmitted to the vasculature of 
pregnant uterus and CNS highlighting the limitation of our in vitro system. In the 
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future, we hope to extend our research along those lines in a different model of 
immediate relevance for the initial stage of EHV-1 pathogenicity. 
 Both EHV-1 and EHV-4 are successful viral pathogens of horses and their 
ability to inflict disease is influenced by their possession of unique biological 
features. Findings from our study indicate that the two virus types have a 
different pathogenic potential for stimulating and downregulating type-I IFN 
response. While EHV-1 was more competent both in inducing and shutting down 
the type-I IFN response of the host cell even in the presence of Poly-I:C or SeV, 
EHV-4 only weakly induced type-I IFN over a period of time without 
downregulating it. Our data suggest that the suppression of type-I IFN activity by 
EHV-1 may promote viral cell-to-cell spread during disease process more ably 
than EHV-4. This is corroborated by finding from another study (215) which 
reported a significantly increased plaque size in respiratory epithelial cells 
(RECs) infected with EHV-1 compared with EHV-4 at different time points, 
indicating a reduced lateral spread of EHV-4 compared to EHV-1 in vitro. Since 
EECs (equine endothelial cells) are specialized epithelial cells lining blood 
vessels, it is not inconceivable that different results could arise if our plaque 
assay had made use of a totally different cell line. While we have the complete 
sequence information of T953, we do not have the sequence of T445 used in this 
study. It will be interesting to compare the homology of both viruses to reveal the 
extent of similarity between both EHV subtypes. Taken together, there is 
evidence to suggest that the T953 strain of EHV-1 possess the gene(s) 
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responsible for suppression of host type-I IFN response while EHV-4, T445 
strain, either lacks the gene or the gene is silenced. 
 Type-I IFN plays an important role in triggering the transcription of a diverse 
set of genes known as IFN-stimulated genes (ISGs) that create a global antiviral 
environment within the host cell. A low induction of type-I IFN response by both 
genotypes of EHV-1 will prevent the production and further release of antiviral 
proteins (31), thus facilitating viral spread from infected to non-infected cells. 
Most viruses equipped with the ability to down-regulate the type-I IFN response 
use non-structural (NS) viral proteins for that purpose, which are otherwise non-
essential for virus growth. For example, the US11 protein of HSV-1 binds to 
retinoic acid-inducible gene I (RIG-I) and the melanoma differentiation-associated 
protein 5 (MDA-5) in order to inhibit their downstream signaling pathways, 
thereby preventing the production of IFN-β (395). For this reason, it is plausible 
that the viral factor responsible for the low induction of host IFN-β by EHV-1 is a 
non-structural protein other than the viral DNA polymerase. The putative EHV-1 
gene product that is involved in the reduction of host IFN-β still remains to be 
identified. However, our study has established that both the neuropathogenic and 
non-neuropathogenic genotypes of EHV-1 are equally competent to provoke a 
low induction of type-I IFN response. 
2.5 Conclusion  
 In this study, we provide evidence that the ability to evade a key component 
of the host innate immunity is not a unique feature of the neuropathogenic 
genotype of EHV-1 as both genotypes of EHV-1 were equally capable of 
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reducing IFN-β expression to low levels in vitro, which could contribute to viral 
spread to distant sites for disease manifestation. Further, while EHV-1 induced a 
type-I IFN response early during infection, it also rapidly reduced the IFN activity 
at late time points, unlike EHV-4 that weakly induced type-I IFN without 
suppressing it. Future studies should focus on identifying the key viral proteins 
that exert these effects on the type-I IFN response by EHV-1.  
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Tables. 
Table 2. 1 Primers and probes for RT-PCR. 
 
Target gene 
 
Sequences (5’-3’) 
 
EqRPLP0 
 
 Fwd: CTGATTACACCTTCCCACTTGCT 
 Rev: AGCCACAAATGCAGATGGATCA 
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ 
EqIFN-β  Fwd: AATGGCCCTCCTGCTGTGT 
 Rev: CCGAAGCAAGTCATAGTTCACAGA 
 Probe: FAM-CTCCACCACGGCTC-NFQ 
 
Table 2. 2 IFN-β reduction scores following EHV-1 infection. 
 
 
EHV-1 genotype 
 
EHV-1 strain 
 
IFN-β reduction score 
 
Neuropathogenic 
 
T953 
 
0.84 
AB4 0.72 
T313 0.73 
T970 0.75 
TX06 0.58 
 
Non-neuropathogenic 
 
T262 
 
0.86 
T75 0.73 
T186 0.55 
T220 0.77 
T61 0.80 
 Interferon reduction scores were calculated according to the equation:  
 [log10 (Poly-I: C) - log10 (Virus)] / [log10 (Poly-I: C) - log10 (Mock)]. 
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Figures. 
 
 
 
Figure 2. 1 Melting curves of EHV-1 isolates. (A). Viruses were screened for the 
presence or absence of an SNP in their DNA polymerase encoded by ORF 30 using a 
real-time PCR assay. (B). As controls, a neuropathogenic and a non-neuropathogenic 
plasmid of EHV-1 were included in the assay. 
B 
 
A 
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Figure 2. 2 Expression levels of IFN-β mRNA following EHV-1 infection. EECs were 
either infected with the indicated EHV-1 strain at an MOI of 5, or mock-infected (as 
represented by M) or Poly-I:C-treated (as represented by P). At 12 hpi, the cells were 
lysed and equine IFN-β mRNA was quantified by real-time PCR as described in Materials 
and Methods. Data were normalized to levels of the endogenous control equine RPLPO 
mRNA at the same time point. Each bar represents the mean and standard deviation 
from three independent experiments.   
 
  
Figure 2. 3 IFN-β mRNA expression levels following infection with EHV-1 and 
EHV-4. (A) EECs were either infected with the T953 strain of EHV-1 (E1) or with 
the T445 strain of EHV-4 (E4). As controls, cells were either mock-infected or 
treated with 80 µg/ml of Poly-I:C. After 3, 6 and 12 hpi, cells were lysed and 
equine IFN- β mRNA was quantified by real-time PCR. The expression levels of 
IFN-β mRNA were then compared between T953 and T445. (B) EECs were 
either stimulated with Poly-I:C (80 µg/ml) or both stimulated with Poly-I:C and 
infected with either EHV-1 T953 or EHV-4 T445 together for 3 h, 6 h, and 12 h. 
IFN-β mRNA was quantified as described. Each bar represents the mean and 
standard deviation from three independent experiments. Differences were 
significant at p<0.0001 (****) or p<0.01 (**) while ‘ns’ denotes non-significant 
differences. 
B A 
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Figure 2. 4 Effect of EHV-1 and EHV-4 infection on levels of type-I IFN biological 
activity. EECs were mock infected (M) or infected with T953 only (E1) at an MOI of 5 or 
infected with T445 only (E4) at an MOI of 5 or co-infected with T953 and Sendai Virus 
(SeV+E1), or co-incubated with T953 and Poly-I:C (P+E1) or co-infected with T445 strain 
and Sendai Virus (SeV+E4), or co-incubated with T445 and Poly-I:C (P+E4). As positive 
controls, EECs were either infected with Sendai virus (SeV) at an MOI of 5 or treated with 
80 µg/ml of Poly-I:C (P). At indicated times post-infection; (A) 3 hpi; (B) 6 hpi; and (C) 12 
hpi, harvested cell supernatants were tested for their type-I IFN bioactivity. Each bar 
represents the mean and standard deviation from three independent experiments. 
Differences were significant at p<0.0001 (****), p<0.01 (**), and p<0.05 (*) while ‘ns’ 
denotes non-significant differences.  
 
A B 
C 
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CHAPTER 3: EQUINE HERPESVIRUS TYPE 1 TARGETS THE 
SENSITIZATION AND INDUCTION STEPS TO INHIBIT TYPE-I 
INTERFERON RESPONSE IN EQUINE ENDOTHELIAL CELLS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Fatai S. Oladunni, Sanjay Sarkar, Stephanie Reedy, Udeni B.R. 
Balasuriya, David W. Horohov, Thomas M. Chambers. Submitted to Journal of 
Virology. 2019.  
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Abstract 
Equine herpesvirus type 1 (EHV-1) is a viral pathogen of horse 
populations worldwide spread by the respiratory route and is known for causing 
outbreaks of neurologic syndromes and abortion storms. Previously, we 
demonstrated that an EHV-1 strain of the neuropathogenic genotype, T953, 
downregulates the IFN-β response in vitro in equine endothelial cells (EECs) at 
12 h post-infection (hpi). In the current study, we explored the molecular 
correlates of this inhibition as clues towards an understanding of the mechanism. 
Data from our study revealed that EHV-1 infection of EECs significantly reduced 
both TLR3 and TLR4 mRNA expression at 6 hpi and 12 hpi. While EHV-1 was 
able to significantly reduce IRF9 mRNA at both 6 hpi and 12 hpi, the virus 
significantly reduced IRF7 mRNA only at 12 hpi. EHV-1 did not alter the cellular 
level of JAK1 at any time point. However, EHV-1 reduced the cellular level of 
expression of TYK2 at 12 hpi. Downstream of the JAK1-TYK2 signaling EHV-1 
blocked the phosphorylation and activation of STAT2 when co-incubated with 
exogenous IFN, at 12 hpi, although not at 3 or 6 hpi. Immunofluorescence 
staining revealed that the virus prevented the nuclear translocation of STAT2 
molecules confirming the virus-mediated inhibition of STAT2 activation. The 
pattern of suppression of phosphorylation of STAT2 by EHV-1 implicated viral 
late gene expression. These data help illuminate how EHV-1 strategically inhibits 
the host innate immune defense by limiting steps required for type-I IFN 
sensitization and induction.  
KEYWORDS: EHV-1, Type-I IFN, TLR, STAT2, TYK2, ISGF3, Innate immunity.  
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3.1 Introduction 
Equine herpesvirus type 1 (EHV-1) is a large DNA virus belonging to the 
genus Varicellovirus of the Herpesviridae family (76). The virion structure, size 
and replicative strategy of EHV-1 is similar to those of other herpesviruses such 
as human herpes simplex virus, varicella-zoster virus, and bovine herpesvirus-1 
(82). The virus is enzootic in the world’s horse population predisposing horses to 
high risk of infection. Most horses acquire the infection at a young age and 
become latent carriers throughout their life (5, 10), with recrudescence into active 
infection when the animals are under stress (10, 77). EHV-1 produces a 
constellation of disease syndromes including upper respiratory tract infection, 
early neonatal death in foals, sporadic or epizootic abortions in pregnant mares, 
and a devastating form of neurologic disease called equine herpesviral 
myeloencephalopathy (EHM) in adult horses that is fatal in 20-50% of cases 
(455-457). EHM has been associated with an A2254G2254 mutation in the viral 
DNA polymerase (ORF30). Generally, neuropathogenic strains such as the T953 
strain used here have aspartic acid at position 752 whereas non-
neuropathogenic strains possess asparagine (268, 269). In field outbreaks, this 
association is strong but not absolute, and there may be other factors that could 
contribute to neuropathogenicity (109, 270).  
Upon initial viral insult, many host cells rely on the non-specific effects of 
biological regulatory proteins called IFN to contain the viral spread and prevent 
infection of bystander cells (27). The induction of type-I IFN response following 
viral infection occurs in 3 phases- sensitization, induction, and amplification 
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(302). In the initial sensitization phase, viral motifs or pathogen associated 
molecular patterns (PAMPs) are detected by pattern recognition receptors 
(PRRs) such as Toll-like receptors (TLRs) present in the cells to initiate antiviral 
signal transduction, featuring coordinated activation of transcription factors 
including interferon regulatory factor 3 (IRF3), IRF7, and nuclear factor-κB (NF-
κB) which induce IFN-β at a very low level (329). In the context of a virus 
infection, TLR3, TLR4, and TLR9 are important for the signaling that initiates 
type-I IFN production. TLR3 recognizes double-stranded RNA (dsRNA), an 
intermediate of most DNA viruses during replication (458), while TLR4 and TLR9 
recognize viral glycoproteins and CpG DNA respectively (459, 460). Both TLR3 
and TLR4 signal through activation of IRF3, which then dimerizes, translocates 
into the nucleus, binds to the promoter of IFN-β, and induces its transcription 
(461, 462). On the other hand, TLR9 signals through the activation of IRF7 
whose subsequent nuclear translocation upon homodimerization results in 
upregulated type-I IFN genes (463). In the succeeding induction phase, secreted 
IFN-β binds to its cognate receptors present ubiquitously on cell surfaces, 
inducing phosphorylation-activation of receptor-associated Janus-activated 
kinases (JAKs) including tyrosine kinase 2 (TYK2) (21). Activated JAK1 and 
TYK2 phosphorylate signal transducer and activator of transcription-1 (STAT1) 
and STAT2 which bind to IRF9 forming the interferon-stimulated gene factor 3 
(ISGF3) heterocomplex (326). ISGF3 translocates into the nucleus and binds to 
the IFN-stimulated response elements (ISRE) of different IFN inducible genes 
including IRF7 which enhances their transcription (464-466). Activated IRF3 
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forms a heterodimer with IRF7, translocates into the nucleus, and binds to the 
promoter of IFN-α genes and stimulates their transcription (329, 462). In the 
amplification phase, the synergistic effect of IFN-α and IFN-β induces enhanced 
transcription of a diverse set of genes known as IFN-stimulated genes (ISGs) 
which create a global antiviral environment (467, 468).   
The impact of EHV-1 on host IFN responses has not been exhaustively 
studied. Previous studies from our group have revealed that in vitro in EECs, 
neuropathogenic T953 virus infection is capable of inhibiting host type-I IFN by 
12 hpi and it does so by blocking certain transcriptional factors required for type-I 
IFN response (31, 402, 406). More recently, we showed that EHV-1 strains with 
the neuropathogenic genotype as well as those with the non-neuropathogenic 
genotype are both able to inhibit type-I IFN production in EECs thereby enabling 
viral spread to neighboring cells (469). By suppressing the host type-I IFN 
response, we predict that T953 interferes with one or more transcription factors 
required for type-I IFN production. To test this hypothesis, here we investigated 
the impact of T953 on key molecules required for type-I IFN sensing and 
induction. We also investigated the involvement of viral gene expression on the 
type-I IFN pathway to gain insight on whether a productive viral replication cycle 
is required for type-I IFN inhibition. 
3.2 Materials and methods 
3.2.1 Cells and viruses  
Equine pulmonary artery endothelial cells (EECs; (437)) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Mediatech Inc.) with 10% iron-
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supplemented bovine calf serum (BCS, Hyclone Laboratories, Inc., Logan, UT), 
100 U/ml penicillin-streptomycin (Life Technologies, Carlsbad, CA), 1 mM sodium 
pyruvate, 0.1 mM non-essential amino acids, and 200 mM L-glutamine (Life 
Technologies, Carlsbad, CA) in a humidified incubator at 37 °C with 5% CO2. A 
well characterized EHV-1 strain T953 isolated from a case of equine herpesvirus 
myeloencephalopathy (EHM) at the Veterinary Medical Teaching Hospital, 
University of Findlay, Ohio in 2003 (299) was used for the study. To prepare 
working virus stocks, confluent EECs were infected with the virus at a multiplicity 
of infection (MOI) of 0.1. After the virus had produced nearly 100% cytopathic 
effect (CPE), the tissue culture fluid (TCF) containing the virus was freeze-
thawed three times and clarified at 2000 x g for 30 min at 4°C, filtered through 
0.45 μm cellulose acetate membrane filters (Thermo Scientific Nunc, Pittsburgh, 
PA), and purified by ultracentrifugation at 100,000 x g for 4 h at 4°C through a 
20% sucrose cushion. The virus pellet was re-suspended in DMEM with 2% 
BCS, sonicated briefly, aliquoted in 100µl volumes and stored at -80°C until 
further use. The infectious virus titer was determined by plaque assay in EECs as 
described (438) with slight modifications. Briefly, confluent EECs propagated in 
6-well plates were infected with 10 fold serial dilutions of cell culture supernatant 
containing virus. For each dilution of the virus, duplicate wells were infected. The 
virus was adsorbed for 1 h, at 37°C with 5% CO2. Unadsorbed viruses were 
removed by washing and 0.75% carboxymethylcellulose (CMC) media (Sigma-
Aldrich, St. Louis, MO) was added to each well and the plates were further 
incubated in a humidified 5% CO2 atmosphere at 37°C for 96 h. The CMC media 
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was removed and the infected cells stained with 1% crystal violet (CV) solution in 
buffered formalin (10%) for plaque visualization. 
3.2.2 Viral infections  
EECs were plated into 6-well culture plates (Corning, NY) 48 h prior to 
infection to ensure more than 90% confluency at the time of infection. Monolayer 
cells were infected with EHV-1, T953 strain, at an MOI of 5 for 1 h in a humidified 
incubator at 37 °C with 5% CO2. In parallel, cells were either mock-infected with 
virus diluent (negative control) or treated with 80 μg/ml of Poly-I:C (positive 
control) unless otherwise stated. The cells were then washed with D-PBS and 
incubated with complete growth medium for 3 h, 6 h, and 12 h respectively. All 
experiments were performed in duplicate and repeated on three independent 
days. 
3.2.3 RNA extraction and real-time RT-PCR assay  
Total cellular RNA was extracted using QiaAmp RNeasy plus mini kit 
(Qiagen Inc. Valencia, CA) from EHV-1- infected and controls’ EECs at 3 h, 6h, 
and 12 h according to the manufacturer’s protocol. The quantity and quality of the 
cellular RNA were determined by OD260/OD280 measurement using the Synergy 
H1 hybrid plate reader (Biotek, Winooski, VT). One µg of total cellular RNA was 
reverse transcribed as described (440) using 0.5 µg oligo dT primer. Equal 
amounts of cDNA were used for the transcription analysis of different genes by 
TaqMan real-time PCR using inventoried primers and probes (Thermo Scientific, 
Pittsburgh, PA) in a ViiATM 7 Fast Real-Time PCR system (Applied Biosystems, 
Foster City, CA). Details of the primers and probes used in this study are 
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provided in Table 1. All reactions were performed in duplicate. The RT-PCR data 
were normalized using the equine ribosomal protein large P0 (RPLP0) transcript 
as an endogenous control. The PCR efficiency for all reactions was assessed by 
LinReg software (441). Fold changes in the gene expression were calculated 
using the comparative ΔΔCT method for relative quantification (RQ) (442), using 
the average Ct value of mock-infected samples for each individual gene as the 
calibrator. 
3.2.4 Western immunoblotting assay  
EECs were infected with EHV-1, T953 strain, at an MOI of 5. At 30 
minutes prior to the end of experiment, infected cells were treated with rEqIFN-α 
at 1000 IU/ml following established protocols (31, 470, 471). Cells were then 
washed in cold PBS and solubilized in RIPA lysis buffer (Santa Cruz 
Biotechnology, Dallas, TX) enriched with phosphatase inhibitor (Thermo 
Scientific, Pittsburgh, PA) on ice. The protein concentration was measured using 
BCA protein assay kit (Thermo Scientific, Pittsburgh, PA) and measured using 
the Synergy H1 hybrid plate reader (Biotek, Winooski, VT). Equal amount of 
protein were then separated in 10% sodium dodecyl polyacrylamide resolving 
gels and transferred onto PVDF membranes (BioRad, Hercules, CA). Following 1 
h of blocking, membranes were incubated with the respective primary antibody 
(anti-JAK1, anti-TYK2, anti-phospho-STAT1, anti-phospho-STAT2, anti-β-actin, 
and anti-lamin A/C all used at 1:1000 dilution) in 5% bovine serum albumin at 
4˚C overnight. The membranes were then washed and incubated with 
corresponding secondary antibody for 1 h at room temperature (RT). Afterwards, 
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membranes were developed with the aid of an enhanced chemiluminescent 
substrate (Thermo Scientific, Pittsburgh, PA) and imaged immediately using 
Azure c600 (Azure Biosystems, Dublin, CA). The relative intensities of 
expression levels of the respective protein bands were quantified by 
densitometric analysis using ImageJ software (National Institute of Health, USA). 
3.2.5 Cytoplasmic and nuclear protein extraction 
To generate subcellular fractionation, cytoplasmic and nuclear proteins 
were extracted using Thermo Scientific NE-PER® Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Scientific, Pittsburgh, PA) according to the 
manufacturer’s protocol. Briefly, an ice-cold cytoplasmic extraction reagent I 
(CER I) was added to pelleted cells, vigorously vortexed, and incubated on ice 
for 10 min. This was followed by the addition of ice-cold cytoplasmic extraction 
reagent II (CER II). The solution was vortexed, incubated on ice for 1 min and 
centrifuged at 16,000 x g for 5 min. The supernatant containing the cytoplasmic 
protein extracts were stored at -80º C while pellets containing the nuclear 
proteins were re-suspended in ice-cold nuclear extraction reagent, vortexed 
every 10 min during a total of 40 min incubation on ice. The lysate was 
centrifuged at 16,000 x g for 10 min and the supernatant containing the nuclear 
proteins was immediately collected and stored at -80º C. Equal amounts of 
cytoplasmic and nuclear proteins were separated on 10% SDS-polyacrylamide 
gels, transferred to PVDF membranes and blotted with antibodies as described. 
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3.2.6 Indirect immunofluorescence assay 
Confluent EECs seeded on coverslips (Electron Microscopy Sciences, 
Hatfield, PA) in 24 well cell culture plates were infected with EHV-1, T953 strain, 
at an MOI of 3. To minimize rounding-up and clumping of EHV-1-infected cells at 
an MOI of 5 which may affect the quality of IF images, we decided to test a 
different infection condition using a lower MOI. At 30 minutes prior to fixation, 
both infected and uninfected cells were treated with rEqIFN-α at 1000 IU/ml 
(positive control) or equal volume of media (negative control). The cells were 
then fixed with 4% paraformaldehyde (PFA) at RT for 30 min and stained as 
described (31, 472, 473). After 3 washes with 10mM glycine-PBS, the cells were 
permeabilized with 0.1% Triton X-100 in PBS (Sigma, St. Louis, MO) for 10 min 
at RT and blocked with 5% normal goat serum in PBS for 30 min at RT. The cells 
were subsequently incubated with the primary antibodies (rabbit anti-STAT2, 
1:100 dilution; and mouse anti-EHV-1 gC, 1:200 dilution) at RT for 1 h. The 
unbound antibodies were washed off with 10mM glycine-PBS and the cells were 
incubated with the corresponding secondary antibody conjugated with either 
Alexa Fluor 488 at 1:200 dilution or Texas Red at 2 µg/ml dilution (Thermo 
Scientific, Pittsburgh, PA) for 1 h at RT. Finally, the cells were washed and 
mounted in VECTASHIELD Mounting Medium containing 4’, 6’- diamidno-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) and observed at X 40 
objective lens under an inverted fluorescence microscope (Nikon ECLIPSE Ti, 
Melville, NY). Images were captured using DS-QiMc-U3 camera, and nuclear 
STAT2 translocation was quantified using Nikon NIS-Elements software following 
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background subtraction and thresholding for each channel. The STAT2 
fluorescence was measured without prior knowledge of cells expressing EHV-1 
gC. 
3.2.7 Antibodies and other reagents  
Rabbit anti-STAT1 and rabbit anti-STAT2 primary antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, TX). Rabbit anti-β-actin 
primary antibody, rabbit anti-JAK1, rabbit anti-TYK2, rabbit anti-phospho-STAT1 
primary antibody, Lamin A/C, MEK1/2, and goat anti-rabbit IgG secondary 
antibody conjugated with horseradish peroxidase (HRP) were purchased from 
Cell Signaling Technology (Beverly, CA). Rabbit anti-phospho-STAT2 primary 
antibody was purchased from Rockland Immunochemicals Inc. (Limerick, PA). 
Donkey anti-goat IgG (H+L) secondary antibody, Texas Red, Goat anti-Rabbit 
IgG (H+L) secondary antibody, Alexa Fluor 488, and phosphonoacetic acid were 
purchased from Thermo Scientific (Pittsburgh, PA). Poly-I: C and LPS-RB 
ultrapure were purchased from Invivogen (San Diego, CA). Both the EHV-1 anti-
IE (474, 475) and EHV-1 anti-gD (476) primary antibodies were kindly provided 
by Dr. Dennis O’Callaghan (Louisiana State University). The EHV-1 gC specific 
primary antibody has been described elsewhere (477) while rEqIFN-α was 
purchased from Kingfisher Biotech, Inc. (Saint Paul, MN).  
3.2.8 Statistical methods  
Data from the study were analyzed by ANOVA with pairwise multiple 
comparison procedures by Tukey’s HSD test using GraphPad Prism version 6.04 
(GraphPad Software, Inc., La Jolla, CA) yielding a multiplicity adjusted P-value 
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for each comparison. P-Values less than 0.05 except otherwise stated were 
considered to be statistically significant. 
3.3 Results 
3.3.1 EHV-1 modulation of TLR3 and TLR4 transcription 
In order to assess the impact of T953 on selected pattern recognition 
receptors, we quantified TLR3 and TLR4 mRNA following infection in EECs. 
Findings from our study revealed that following 3 hpi, T953 induced about the 
same amount of TLR3 mRNA as in mock-infected cells and showed no 
suppressive effect on TLR3 mRNA when co-incubated with the IFN inducer, 
polyinosinic acid: polycytidylic acid (Poly-I:C) (Fig. 3.1.A). At 6 hpi, the kinetics of 
induction of TLR3 mRNA were not statistically significantly different (P = 1.0) 
between EHV-1- and mock-infected cells, but T953 exerted a statistically 
significant (P < 0.0001) suppressive effect on TLR3 mRNA when co-incubated 
with Poly-I:C at this time-point. At 12 hpi, T953 infection did not induce any TLR3 
mRNA and the virus infection in the presence of Poly-I:C statistically significantly 
(P < 0.0001) down-regulated TLR3 mRNA by about 54 fold compared to the 
positive control (Poly-I:C). The pattern of induction of TLR4 revealed no 
statistically significant (P = 0.76) difference between the treatment groups at 3 
hpi (Fig. 3.1.B). At 6 hpi, the virus had induced about the same amount of TLR4 
mRNA when compared with mock-infected cells. In the presence of a TLR4 
agonist, lipopolysaccharide (LPS), T953 infection had a statistically significant (P 
= 0.0016), suppressive effect on TLR4 mRNA when compared to the positive 
control at this time-point. At 12 hpi, there was no difference in the induction of 
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TLR4 mRNA between mock-infected and T953-infected cells, but the virus in the 
presence of LPS suppressed TLR4 mRNA by about 27 fold compared to the 
positive control (LPS). To demonstrate the specificity of EHV-1-mediated 
downmodulation of TLR3 and TLR4, we evaluated the impact of EHV-1 on 
equine -glucuronidase using RT-PCR. Our data revealed that at all studied 
time-points, EHV-1 did not alter the expression of this cellular gene (data not 
shown). 
3.3.2 EHV-1 suppression of IRF7 and IRF9 mRNA transcription 
The IRF7 transcription factor plays an important role in regulating the 
transcriptional activation of virus inducible cellular genes like IFN-α. On the other 
hand, IRF9 forms a complex termed ISGF3 with activated STAT1 and STAT2 
proteins to drive the induction of ISGs following viral infection. To study the 
impact of T953 on IRF7 and IRF9 transcription factors, we evaluated IRF7 and 
IRF9 mRNA in EECs following in vitro infection using RT-PCR. The kinetics of 
transcription of IRF7 mRNA following infection with T953 was similar to that of 
the mock-infected cells at 3hpi and 6 hpi (Fig. 3.2.A). At these time points, the 
expression of IRF7 mRNA induced by Poly-I:C was unchanged by T953 
infection. However, at 12 hpi, T953 infection statistically significantly (P < 0.0001) 
suppressed IRF7 mRNA transcription induced by Poly-I:C. Similarly, T953 
infection had no statistically significant (P = 0.44) effect on the IRF9 mRNA 
transcription induced by Poly-I:C at 3 hpi (Fig. 3.2.B). However, at 6 hpi, T953 
infection caused a statistically significant (P < 0.0001) reduction of IRF9 mRNA in 
the presence of Poly-I:C. At 12 hpi, the kinetics of transcription of IRF9 mRNA 
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revealed that T953 had statistically significantly (P < 0.0001) suppressed IRF9 
mRNA by about 40 fold compared to levels with Poly-I:C alone.  
3.3.3 EHV-1 degrades cellular levels of TYK2 but not JAK1 during infection  
Upstream of the signaling cascades leading to type-I IFN production are 
the JAK1 and TYK2 proteins which play key roles in the phosphorylation and 
activation of STAT1 and STAT2. To evaluate whether the inhibitory effects of 
T953 on the type-I IFN response is reflective of the virus’ ability to disrupt these 
upstream signaling events, we quantitated the cellular levels of JAK1 and TYK2 
following T953 infection and also in response to exogenous recombinant equine 
interferon-α (rEqIFN-α) treatment following infection. Western blot analysis 
revealed that T953 had no downregulating effect on TYK2 at 3 hpi (Fig. 3.3.A) 
and 6 hpi (Fig. 3.3.B) either with or without IFN treatment. However, at 12 hpi, 
the cellular abundance of TYK2 was reduced either in cells infected with T953 
alone or in cells infected with T953 and co-incubated with exogenous IFN-α (Fig. 
3.3.C). Densitometric analysis revealed that while T953 failed to alter the cellular 
levels of JAK1 at all the time-points in the study (Fig. 3.3.D), the virus 
demonstrated an ability to inhibit TYK2 protein (P = 0.0006) in the presence of 
IFN treatment at 12 hpi (Fig. 3.3.E). These data suggested the possibility of a 
consequent downstream inhibition of IFN-induced STAT2 phosphorylation. 
3.3.4 EHV-1 alters the cellular levels of phosphorylated STAT1 and STAT2 
during infection 
Both JAKs and STATs are frequently targeted by virally encoded 
antagonists to inhibit their activation (478). Given the role of ISGF3 in the 
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downstream signaling events leading to type-I IFN induction, we hypothesized 
that T953 is capable of blocking the formation of ISGF3 complex in vitro over the 
course of infection. Here we evaluated the phosphorylation of both STAT1 and 
STAT2 by Western immunoblotting assay after infection of EECs with T953 in the 
presence or absence of rEqIFN-α. We previously showed that T953 infection 
interferes with STAT1 phosphorylation in EECs at 12 hpi (31). We confirmed this 
result (Fig. 3.4.A) and also found that STAT2 is also inhibited (Fig. 3.4.B-D). Data 
revealed that T953 infection did not prevent exogenous IFN-induced STAT2 
phosphorylation at either 3 hpi (Fig. 3.4.B) or 6 hpi (Fig. 3.4.C) but the virus 
infection reduced IFN-induced STAT2 phosphorylation in EECs at 12 hpi (Fig. 
3.4.D). In the absence of an exogenous IFN stimulation, T953 infection triggered 
only a small amount of STAT2 phosphorylation in EECs at 6 (Fig. 3.4.C) and 12 
hpi (Fig. 3.4.D). The suppressive effect of T953 on both STAT1 and STAT2 
phosphorylation when co-incubated with exogenous IFN at 12 hpi did not alter 
the endogenous abundance of either total STAT1 or total STAT2 molecule. This 
finding was corroborated by the densitometric analysis of the phosphorylated 
STAT relative to total STAT proteins. The analysis showed that T953 at 12 hpi 
only, statistically significantly (P < 0.0001) reduced the phosphorylation of STAT1 
and STAT2 proteins when co-incubated with exogenous IFN (Fig. 3.4.E and 
3.4.F).  
3.3.5 EHV-1 blocks nuclear translocation of STAT2 during infection 
The above experiments showed that T953 inhibited the phosphorylation of 
STAT1 and STAT2 at 12 hpi in the presence of IFN- treatment. We further 
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investigated the anti-STAT effect of T953 by using indirect immunofluorescence 
imaging. Our previous publication showed that T953 blocked nuclear 
translocation of STAT1 even in the presence of exogenous IFN (31). We 
hypothesized that T953 also blocks the activation of STAT2, which would be 
evidenced by cytosolic localization of STAT2 in virus-infected cells and also in 
virus-infected cells co-incubated with exogenous IFN. By using 
immunofluorescence, as expected we found an exclusively cytoplasmic retention 
of STAT2 molecules in a majority of uninfected cells when stained with anti-
STAT2 antibody (Fig. 3.5.A). Treatment of the uninfected cells with exogenous 
IFN- resulted in redistribution STAT2 molecules leading to nuclear accumulation 
of these molecules in a majority of cells as expected (Fig. 3.5.B). In contrast, a 
majority of EHV-1 infected cells exhibited cytoplasmic retention of STAT2 both in 
the absence (Fig. 3.5.C) and presence (Fig. 3.5.D) of exogenous IFN- indicating 
that STAT2 molecules were not efficiently activated. Moreover, nuclear STAT2 
quantification of IF images revealed that even in the presence of exogenous IFN-
 treatment, EHV-1 infection of EECs produced a statistically significant 
reduction of nuclear STAT2 when compared to uninfected cells treated with 
exogenous IFN- (Fig. 3.5.E). To confirm these findings, we carried out 
subcellular fractionation following infection or treatment with exogenous IFN- 
and quantitated the level of STAT2 molecules in the nuclear and cytoplasmic 
compartments by Western immunoblotting. Consistent with our 
immunofluorescence data, T953 reduced the nuclear accumulation of 
phosphorylated and total STAT2 (Fig. 3.5.F) in infected cells when co-incubated 
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with exogenous IFN-. This result provides a plausible mechanistic insight into 
how T953 blocks the type-I IFN signaling cascade when stimulated by 
exogenous IFN-. 
3.3.6 Suppression of type-I IFN signaling molecules is mediated by an active 
EHV-1 gene 
We previously showed that active viral replication is necessary for STAT1 
interference by T953 (31), and show above that the virus also inhibited STAT2 
phosphorylation and subsequent activation. In the above experiments, the 
downregulation of these signal-transduction molecules in the IFN induction 
pathway by T953 was demonstrable by 12 hpi. For this reason, we tested the 
hypothesis that these suppressive effects required active virus gene expression 
during T953 replication in EECs. To evaluate whether a productive viral infection 
in EEC is essential for the above effects, we performed similar experiments using 
UV-inactivated T953 virus. We UV-inactivated T953 by irradiating the virus with 
7.2 × 104 J of 254 nm UV from a distance of 10 cm using a UV Stratalinker 800 
(Stratagene, La Jolla, CA). As a control to examine whether this level of UV-
inactivation of T953 inactivated virion proteins as well as DNA-directed 
transcription, we evaluated for T953 gD before and after UV-inactivation. We 
found that gD of UV-inactivated T953 was still recognized by a gD-specific 
antibody suggesting that gD likely retained activity and the virus can enter 
infected EECs (data not shown). The inactivation of T953 was demonstrated by 
absence of cytopathic effect when used to infect RK-13 cells following 24 h of 
incubation. EECs were then infected with UV-inactivated T953 at an equivalent 
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dilution to the infectious T953, and both cellular RNA for RT-PCR and protein for 
Western immunoblotting were subsequently harvested. Mock infected cells 
stimulated with either 80 μg/ml of Poly-I:C or 1000 IU/ml of rEqIFN-α were 
included as positive controls. Results showed that by comparison with Figures 1 
and 2, UV-inactivated T953 was unable to statistically significantly downregulate 
TLR3 and TLR4 mRNA at 3, 6, and 12 hpi compared with the positive control 
(Fig. 3.6.A and 3.6.B). Similarly, UV-inactivated T953 failed to inhibit IRF7 and 
IRF9 mRNA at 3, 6, and 12 hpi when compared with the positive control (Fig. 
3.6.C and 3.6.D). UV-inactivated T953 also failed to suppress STAT2 
phosphorylation (Fig. 3.6.E) when co-incubated with rEqIFN-α at 12 hpi. Since 
these phenotypes of UV-inactivated T953 contradicted those of the infectious 
virus, we conclude that an active viral replication was required for suppression of 
key molecules of type-I IFN signaling by T953 including TLR3/4, and IRF7/9. 
3.3.7 A late viral gene of EHV-1 blocks STAT2 activation 
Like other herpesviruses, the EHV-1 transcriptome is temporally 
expressed as immediate early (IE), early (E), and late genes (L) in that sequence 
respectively (128, 129, 133). The L gene expression is partially or completely 
dependent on the viral DNA replication (479). Our data thus far indicated that the 
suppression of key factors for type-I IFN production does not set in until after 
DNA synthesis by T953. We previously showed that blockage of T953 late gene 
expression eliminated the viral suppressive effect on type-I IFN induction (406). 
For this reason, we hypothesized that one or more late viral genes of T953 are 
involved in switching off phosphorylation of STAT2 molecules. In order to 
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investigate this phenomenon, we blocked the T953 viral late gene expression 
with a chemical inhibitor, phosphonoacetic acid (PAA) (Acros Organics, NJ). We 
then compared the cellular abundance and phosphorylation of STAT2 in T953-
infected EECs in the presence or absence of PAA (300 g/ml). The effectiveness 
of the PAA-mediated blockage of T953 was demonstrated by analysis of 
expression of a viral L protein gD, in comparison with the expression of viral IE 
protein. We observed that at 3 hpi, EHV-1 gD was not expressed either in the 
presence or absence of PAA treatment (data not shown). This was expected 
because gD is one of the L proteins of EHV-1 that is not synthesized during early 
infection. Consistent with previous findings, phosphorylated STAT2 was not 
detected in mock-infected EECs, but was readily detectable 30 min after rEqIFN-
α treatment in the positive control. In the absence and presence of PAA, T953 
failed to either induce or block the phosphorylation of STAT2 at 3 hpi and 6 hpi 
(Fig. 3.7.A and 3.7.B). In contrast with untreated cells, T953 infection in the 
presence of PAA was unable to prevent rEqIFN-α-induced phosphorylation of 
STAT2 at 12 hpi (Fig. 3.7.C). This data indicates that inhibition of STAT2 
phosphorylation involves one or more late viral genes of T953, whose expression 
is blocked in the presence of PAA.  
3.4 Discussion  
In natural outbreaks, EHV-1 has a predilection for the epithelial cells of the 
upper respiratory pathway, but cell-associated virus can eventually be 
transmitted to EECs lining the blood vessels of the uterus and those of the CNS. 
When this happens, these cells can mount an immediate innate immune 
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response by activating the type-I IFN signaling cascade. EHV-1 is capable of 
employing a variety of ways to escape the early innate immune response at least 
in vitro and presumably also in vivo. Here, we explored some molecular 
mechanisms by which EHV-1 renders the host type-I IFN signaling ineffective 
during the infection process, using our already established EEC model. 
Most viral intruders are recognized by PRRs such as the TLRs which initiate 
signaling cascades leading to type-I IFN production (361). The ability to 
immediately counteract recognition by these PRRs enables virus replication in 
host cells and facilitates an effective viral infection. Our study revealed that EHV-
1 interferes with the host cell’s ability to recognize viral invasion by suppressing 
the expression of TLR3 and TLR4 mRNA by 6 and 12 hpi in EECs. Many viruses 
impede the expression of TLRs in order to escape the antiviral effect of type-I 
IFN. For instance, respiratory syncytial virus strain A2 and a measles virus strain 
block type-I IFN production in a plasmacytoid dendritic cell model and this is 
mediated by inhibition of both TLR7 and TLR9 (480). Since TLR3 recognizes 
dsRNA (458) while TLR4 recognizes viral glycoprotein (459), it is plausible that 
by reducing TLR3 and TLR4 expression in EECs, EHV-1 is able to evade cellular 
PAMP recognition, thereby enhancing its effective replication. Individual TLR 
signaling is dependent on a set of TIR domain-containing adaptors such as 
Myd88, TRIF, TIRAP/MAL or TRAM for a robust innate immune response 
including type-I IFN production (481). Another possibility is that by inhibiting 
TLR3 and TLR4 expression in EECs, EHV-1 may block the recruitment of these 
adaptor proteins thereby compromising the antigen-induced signal transduction 
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needed for a potent type-I IFN response. Although our study did not investigate 
the effects of EHV-1 on cytosolic PRRs such as RIG-I-like receptors, we 
speculate, based on our TLR3 and TLR4 data, that the same EHV-1 viral factors 
similarly interfere with their sensitivity during infection. 
Transcription factors involved in IFN production are activated when a virus 
is initially detected by PRR. Activated transcription factors subsequently 
translocate to the nucleus and interact with IFN promoter sequences, leading to 
the upregulation of IFN genes. It has been shown that herpesviruses and other 
viruses can down-regulate IRF3, IRF7 or IRF9 signaling to suppress IFN-α/β 
production (482-487). Recently, we determined that the molecular mechanism for 
EHV-1 suppression of type-I IFN induction involves disruption of the IRF-3 
signaling pathways (402). Whether EHV-1 is able to directly affect the cellular 
abundance of IRF7 and IRF9 remained poorly understood. Here we show that 
consistent with our earlier results, EHV-1 significantly downregulated IRF7 
mRNA by 12 hpi and IRF9 mRNA by 6 and 12 hpi in EECs. These are the same 
time-points in our previous studies where suppression of type-I IFN was 
observed following EHV-1 infection of EECs (31, 402, 406, 469). Since both IRF7 
and IRF9 play significant roles along with IRF3 in the induction phase of type-I 
IFN production, it seems plausible that EHV-1 blocks type-I IFN induction in the 
infected cell by preventing the expression of these transcription factors. One of 
the limitations of our study is the lack of equine specific anti-TLR3, anti-TLR4, 
anti-IRF7, and anti-IRF9 antibodies. This hindered our ability to investigate 
whether EHV-1 effects on TLR3, TLR4, IRF7, and IRF9 gene expressions extend 
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to the respective translated protein components. We hope such reagents will 
become available for study of the effect of EHV-1 on TLR3, TLR4, IRF7, and 
IRF9 protein products during infection of EECs. 
In this study, we found that EHV-1 disrupts the JAK/STAT signaling 
pathway by degrading the cellular levels of TYK2 at 12 hpi. Interestingly, EHV-1 
exerted no significant effect on the cellular abundance of JAK1 at all studied 
time-points. Since TYK2 helps phosphorylate STAT2 (320), which in turn creates 
a docking site for STAT1 phosphorylation (324, 488), it is possible that EHV-1 
specifically targets TYK2 to prevent the interaction between the two STAT 
proteins in order to block type-I IFN induction. Several other viruses have 
evolved mechanisms to prevent the activation of STAT2 proteins by TYK2. One 
such example is Epstein-Barr virus that negatively regulates TKY2 
phosphorylation and IFN signaling in human B cells using a latent membrane 
protein 1 (489). Although we do not understand the exact mechanism employed 
by EHV-1 to degrade TYK2, we hypothesize that certain viral proteins may act to 
target TYK2 for proteosomal degradation as has been reported for human 
metapneumovirus (21).  
As expected, our study revealed that EHV-1 prevents IFN-induced 
phosphorylation of the STAT1/STAT2 molecule by 12 hpi. EHV-1 seems to 
induce only the downregulation of STAT1 phosphorylation without affecting JAK1 
whereas a reduced cellular abundance of TYK2 leads to the downstream 
inhibition of STAT2 phosphorylation in response to EHV-1 infection. One major 
consequence of the lack of phosphorylated STAT1/STAT2 is the exclusion of 
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these STAT molecules from the nucleus of EHV-1 infected EECs. Previously, we 
demonstrated STAT1 occlusion from the nucleus in EHV-1 infected cells even in 
the presence of an exogenous IFN stimulant (31). Our new data revealed that 
EHV-1 was able to prevent STAT2 activation/translocation, thereby resulting in 
sequestration in the nucleus. Since EHV-1 also inhibits IRF9 mRNA at this time 
point, we believe that EHV-1 blocks the nuclear accumulation of the ISGF3 
heterocomplex as one of the ways of preventing type-I IFN induction. The 
efficient inhibition of type-I IFN production by EHV-1 may be a consequence of 
coordinated cytoplasmic sequestration of STAT2 proteins or narrowing of nuclear 
pore complex to occlude STAT2 into the nucleus during infection as has been 
reported for Nipah virus (490). This finding further explains why EHV-1 is able to 
prevent the transcription of ISGs as we previously reported (31). Our data also 
suggest that despite inhibiting IFN-induced STAT1/STAT2 phosphorylation, EHV-
1 did not alter the total cellular level of STAT1/STAT2 during infection. These 
data, including that of JAK1, add to the body of evidence that the inhibitory 
effects of EHV-1 on the other key factors of type-I IFN signaling are not a result 
of the global shutdown of host macromolecular synthesis during infection (491). 
Our data revealed an elevated lamin A/C with EHV-1 infection when compared to 
uninfected controls. In a recent study, Banati and co-workers also reported up-
regulated lamin A/C in Epstein-Barr virus immortalized lymphoblastoid cell lines 
and in group III Burkitt lymphoma lines (492). An up-regulated lamin A/C, as seen 
in our study, may facilitate viral gene transcription/replication in the nucleus of 
EHV-1- infected cells. Although it appeared that the cytoplasmic portion of total 
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STAT2 was affected in virus-infected cells, densitometric analysis of Western blot 
images revealed no difference between total STAT2 in EHV-1-infected cells and 
uninfected controls (data not shown).   
We showed that the ability to suppress key molecules of the type-I IFN 
response, including IFN-induced STAT2 phosphorylation, involves the de novo 
synthesis of viral genes. UV-inactivation of EHV-1 abolished the suppressive 
effects that were present during active EHV-1 infection in EECs. Thus, it appears 
that viral DNA synthesis and some viral protein synthesis were required for the 
inhibition. Also, the only striking difference in the phenotypes of STAT2 
phosphorylation in EECs infected with EHV-1 either in the presence or absence 
of PAA treatment occurred at 12 hpi. PAA-mediated blockage of late viral gene 
expression at this time-point resulted in no suppressive effect on IFN-induced 
STAT2 phosphorylation. Therefore, as we suggested previously (406), EHV-1 
encodes one or more late viral genes that target host factors needed for type-I 
IFN response. These viral factors responsible for the inhibitory effect on host 
type-I IFN response remain to be identified. It has been reported that HSV-1 
utilizes a late viral protein, UL41, to mediate inhibition of STAT1 phosphorylation 
(493). Another late protein, US3 (a serine-threonine kinase), of HSV-1 is also 
involved in the evasion of the type-I IFN response by interfering with the TLR3-
mediated immune response (398, 399). EHV-1 encodes homologs of HSV-1 
UL41 and US3 proteins (434). However, their effects in an equine host in the 
context of STAT2 phosphorylation and TLR3-mediated type-I IFN response are 
yet to be explored. Further studies are, therefore, required to elucidate whether 
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the roles of EHV-1 homologs of HSV-1 UL41 and US3 proteins are functionally 
conserved between both alphaherpesviruses. 
Our results are contrary to the finding of Edington et al. (494) that EHV-1 
induces a type-I IFN response in the horse. Also, Wagner et al. (495) showed 
that equine PBMCs infected with EHV-1 strains including the neuropathogenic 
strain Ab4 robustly secreted IFN-α at 48 hpi, and Holz et al. (496) detected IFN-α 
in nasal secretions from Ab4-infected horses on days 1 and 2 post infection; 
interestingly this was much reduced in horses that went on to develop EHM. On 
the other hand, IFN-α was not detected in cerebrospinal fluid of Ab4-infected 
horses (496). Our results also should be seen in the light of those of Soboll 
Hussey et al. (497) who found that in cultured equine respiratory epithelial cells 
(ERECs), there was no significant IFN-α/β production at 12 hpi but considerably 
more at 24 hpi. In another similar study, Poelaert et al. (498) reported that both 
the abortigenic EHV-1 and the neurovirulent EHV-1 competently induced IFN- 
in equine respiratory mucosa and ERECs, although, the abortigenic strains show 
more anti-IFN effect. These differences in observed response may be 
characteristic of the particular model being used and also to the kinetics of the 
infectious process in each model relevant to pathogenicity.  The correspondence 
of EECs with ERECs with regards to type-I production following EHV-1 infection 
has not been previously studied. We are currently investigating this effect to 
further understand whether the kinetics of type-I IFN response during EHV-1 
infection correlates with cell type. We hypothesize that the virus-mediated IFN 
suppression effect does not operate on neighboring cells but only on the infected 
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cell. Also, the effect may be more consequential in some cell types (endothelial) 
than others. This effect may be more related to facilitating virus replication in the 
face of exogenous IFN stimulation as the IFN-α receptor also signals in part 
through the JAK/STAT pathway. Finally, we have shown that EHV-1 can repress 
host type-I IFN response by specifically targeting the sensitization and the 
induction phase of type-I IFN during infection. This information could be useful in 
identifying the specific viral protein involved in host type-I IFN inhibition enabling 
the development of a future therapeutic target against EHV-1. Therapies that 
would synergistically improve both host cells’ recognition of the virus and IFN 
signaling would be more beneficial in preventing field outbreaks of more 
devastating EHV-1 diseases.  
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Table. 
Table 3. 1 Primers and probes for RT-PCR. 
Target gene Sequences (5’-3’) / Assay ID 
EqRPLP0 
Fwd: CTGATTACACCTTCCCACTTGCT 
Rev: AGCCACAAATGCAGATGGATCA 
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ 
(406) 
EqTLR3 Ec03467747_m1 
EqTLR4 Ec03468994_m1 
EqIRF7 AJBJX9T 
EqIRF9 ARMFXCF 
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Figures. 
Figure 3. 1 Effect of EHV-1 infection on TLR mRNA transcription. Mock-infected 
EECs (M, solid bars) were either treated with 80 µg/ml of Poly-I:C for A or 10 µg/ml of 
LPS for B (both labelled as P, clear bars) or infected at an MOI of 5 with T953 in the 
presence (P+E1, diagonal-striped bars) or absence of P (E1, checker board bars). At 
indicated time-points, the cells were lysed and equine TLR3 (A) and TLR4 (B) mRNA 
were quantified by real-time RT-PCR as described in the text. Data were normalized to 
the levels of endogenous control equine RPLPO mRNA at the same time point. Each bar 
represents the mean and standard deviation from three independent experiments. Data 
were significant at P < 0.05 (*), P < 0.01 (**), and P < 0.0001 (****) while non-significant 
data is denoted by ns. 
Figure 3. 2 Effect of EHV-1 infection on IRF mRNA transcription. EECs were either 
mock infected (M in solid bars) or Poly-I:C-treated (P in clear bars) or infected at an MOI 
of 5 with T953 in the presence (P+E1 in diagonal-striped bars) or absence of P (E1 in 
checker board bars). At indicated time-points, the cells were lysed and equine IRF7 (A) 
and IRF9 (B) mRNA were quantified by real-time RT-PCR as described in the text. Data 
were normalized to the levels of endogenous control equine RPLPO mRNA at the same 
time point. Each bar represents the mean and standard deviation from three independent 
experiments. **** shows statistical significance at P < 0.0001 while ns indicates non-
significant data. 
A B 
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Figure 3. 3 Effect of EHV-1 infection on cellular abundance of endogenous JAK1 and 
TYK2. EECs were either mock-infected (M) or infected with T953 (E1) at an MOI of 5 for 
3 h (A), 6 h (B) or 12 h (C). The cells were then treated or left untreated (+/- in figure) with 
equine rEqIFN-α at 1000 IU/ml for 30 min before lysis at indicated time points. 
Abundance of total JAK1 and TYK2 was analyzed by Western blot and band intensities 
were normalized to the endogenous levels of β-actin. Densitometric analysis of Western 
blot images for JAK1 (D) and TYK2 (E) normalized against β-actin were done by ImageJ 
(NIH). The Western blot images were representative of 3 different blots from independent 
experiments. 
A B 
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E
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Figure 3. 4 Effect of EHV-1 infection on IFN-induced STAT1/STAT2 phosphorylation. 
EECs were either mock-infected (M) or infected with T953 (E1) at an MOI of 5 and cells 
were either treated or left untreated (+/- in figure) with equine rEqIFN-α at 1000 IU/ml for 
30 min before lysis. Abundance of phosphorylated versus total STAT1 at 12 h (A), and 
phosphorylated versus total STAT2 at 3 h (B), 6 h (C), or 12 h (D) were then quantified 
using Western blot analysis. Membranes were stripped and reprobed with β-actin as a 
control for equal loading of samples. Densitometric analysis of Western blot images for 
phosphorylated STAT1, total STAT1 (E), and phosphorylated STAT2, total STAT2 (F) 
normalized against β-actin were done by ImageJ (NIH). The Western blot images were 
representative of 3 different blots from independent experiments. 
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Figure 3. 5 Effect of EHV-1 infection on nuclear accumulation of STAT2. EECs, grown 
on coverslips in 24-well plates were either infected with T953 at an MOI of 3 or mock-
infected. The cells were either stimulated with equine rEqIFN-α at 1000 IU/ml or equal 
volume of plain media for 30 min prior to fixation in 4% PFA at 12 hpi. Cells were stained 
with anti-STAT2 (1:100 dilution) and anti-EHV-1 gC antibody (1:200 dilution). N  300 
cells from different fields were examined for each treatment using an inverted fluorescent 
microscope. (A) Mock-infected EECs treated with plain media and stained for STAT2. (B) 
Mock-infected cells stimulated with equine rEqIFN-α and stained for STAT2 (C) T953 
infected cells stained for STAT2. (D) T953 infected cells stimulated with equine rEqIFN-α 
and stained for STAT2. 4,6-diamidino-2-phenylindole (DAPI: blue) served as a 
counterstain. Solid arrowheads indicate representative cells without nuclear STAT2 
translocation whereas open arrowheads indicate representative cells with nuclear STAT2 
translocation. Scale bar: 50 µm. (E) Quantification of nuclear STAT2 intensity of IF 
images using Nikon NIS-Elements software as described in Materials and Methods. (F) 
EECs were either mock infected (M) or infected with T953 (E1) at an MOI of 3 and cells 
were either treated or left untreated (+/- in figure) with equine rEqIFN-α (1000 IU/ml) for 30 
min before fractionation into nuclear (N) or cytoplasmic (C) compartment. Separated 
cellular fractions were probed for phosphorylated STAT2 and total STAT2 to determine 
their cellular distribution following T953 infection. Lamin A/C and MEK1/2 were used as 
nuclear and cytoplasmic loading controls respectively. 
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Figure 3. 6 Effect of UV-inactivation on type-I IFN molecules. Mock-infected EECs (M, 
solid bars) were either treated with 80 µg/ml of Poly-I:C for A, C, and D or 10 µg/ml of 
LPS for B (both labelled as P, clear bars) or infected with UV-inactivated T953 in the 
presence (P+E1, diagonal-striped bars) or absence of P (E1, checker board bars) as 
described in the text. At indicated time-points, the cells were lysed and equine TLR3 (A), 
TLR4 (B), IRF7 (C), and IRF9 mRNA (D) were quantified by real-time RT-PCR. Data 
were normalized to the levels of endogenous control equine RPLPO mRNA at the same 
time point. Non-significant data is denoted by ns. (E) EECs were either mock-infected (M) 
or infected with UV-inactivated T953 (E1) at an MOI of 5 and cells were either treated or 
left untreated (+/- in figure) with 1000 IU/ml of equine rEqIFN-α for 30 min prior to lysis. 
Following 12 hpi, cells were lysed and equal amounts of proteins were separated on 10% 
SDS-PAGE and probed using phospho-STAT2 or STAT2. Images were representative 
of 3 independent biological experiments. 
E 
A B 
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Figure 3. 7 Effect of viral late gene blockage on STAT2 activation. EECs were infected 
with T953 (E1) either in the presence (left columns) or absence of PAA (300 µg/ml). 
Mock-infected EECs (M) were either treated or left untreated (+/- in figure) with equine 
rEqIFN-α at 1000 IU/ml for 30 min before lysis. Abundance of phosphorylated versus total 
STAT2 at 3 h (A), 6 h (B), or 12 h (C) were then quantified using Western blot analysis. 
Membranes were stripped and reprobed with β-actin as a control for equal loading of 
samples. As controls for effective PAA-mediated blockage of T953 L proteins, both the 
EHV-1 IE and EHV-1 gD were also quantified. The Western blot images were 
representative of 3 different blots from independent experiments. 
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CHAPTER 4: THE EFFECT OF EQUINE HERPESVIRUS TYPE 4 ON 
TYPE-I INTERFERON SIGNALING MOLECULES. 
Adapted from: Fatai S. Oladunni, Stephanie Reedy, Udeni B.R. Balasuriya, David 
W. Horohov, Thomas M. Chambers. Submitted to Veterinary Immunology and 
Immunopathology. 2019. 
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Abstract 
Equine herpesvirus type 4 (EHV-4) is mildly pathogenic but is a common 
cause of respiratory disease in horses worldwide. We previously demonstrated 
that unlike EHV-1, EHV-4 is not a potent inducer of type-I IFN and does not 
suppress that IFN response, especially during late infection, when compared to 
EHV-1 infection in equine endothelial cells (EECs). Here, we investigated the 
impact of EHV-4 infection in EECs on type-I IFN signaling molecules at 3, 6, and 
12 hpi. Findings from our study revealed that EHV-4 did not induce nor suppress 
TLR3 and TLR4 expression in EECs at all the studied time points. EHV-4 was 
able to induce variable amounts of IRF7 and IRF9 in EECs with no evidence of 
suppressive effect on these important transcription factors of IFN-α/β induction. 
Intriguingly, EHV-4 did interfere with the phosphorylation of STAT1/STAT2 at 3 
hpi and 6 hpi, less so at 12 hpi. An active EHV-4 viral gene expression was 
required for the suppressive effect of EHV-4 on STAT1/STAT2 phosphorylation 
during early infection. One or more early viral genes of EHV-4 are involved in the 
suppression of STAT1/STAT2 phosphorylation observed during early time points 
in EHV-4-infected EECs. The inability of EHV-4 to significantly down-regulate key 
molecules of type-I IFN signaling may be related to the lower severity of 
pathogenesis when compared with EHV-1. Harnessing this knowledge may 
prove useful in controlling future outbreaks of the disease.  
Key words: EHV-4, STAT1, STAT2, innate immunity, type-I interferon. 
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4.1 Introduction 
Equine herpesvirus 4 (EHV-4) is a ubiquitous virus relevant for its ability to 
cause clinically significant upper respiratory tract (URT) disease in horse 
populations worldwide. This virus, along with EHV-1, has been found for over 80 
years to be the most common herpesviruses impeding successful breeding, 
competition, and recreational horse industries all around the world (499). EHV-4 
belongs to the genus Varicellovirus of the subfamily Alphaherpesvirinae (74). The 
virus was considered as subtype 2 of EHV-1 and known as the same virus until 
1981 when DNA sequence information indicated otherwise (433, 500). EHV-4 
has a genome size of about 146-kbp and encodes 76 ORF, with three of those 
genes duplicated (81). The genomic architecture of EHV-4 comprises a linear 
double-stranded, DNA organized into a long unique segment (UL , 112,398 bp) 
flanked by a short inverted repeat sequence (TRL/IRL, 27 bp) and a short unique 
segment (US, 12,789 bp) that is flanked by a large inverted repeat sequence 
(TRS/IRS, 10,178 bp) (81, 499). The level of nucleotide identity between EHV-1 
and EHV-4, within individual homologous genes, ranges from 55-84% while the 
amino acid sequence identity ranges from 55-96% (81, 82). Despite the close 
relatedness of EHV-4 to EHV-1, the genetic differences between the two viruses 
are sufficient to affect their host range and disease phenotypes. EHV-4 mostly 
infect the URT of horses causing respiratory syndromes, whereas EHV-1 has a 
more diverse host range and causes pathologies including respiratory disease, 
abortion and equine herpesviral myeloencephalopathy (EHM) (105). 
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Unlike EHV-1, EHV-4 has a streamlined host range and the virus can 
efficiently infect only equine cells; it replicates only poorly in a few other cell lines 
(501). Lytic infection by EHV-4 is thought to mainly occur in the epithelial cells of 
the URT, although equine endothelial cells (EEC) are also permissive to EHV-4 
infection (5). Alphaherpesviruses have been demonstrated to enter different cell 
types by different pathways that, mostly, utilize similar viral glycoproteins, 
namely, glycoprotein D (gD), gB, gH, and gL, in conjunction with host cellular 
receptors and coreceptors (502-506). The major viral component that defines the 
differential cellular tropism between EHV-1 and EHV-4 has been found to be gD. 
An exchange of gD of EHV-1 for that of EHV-4 was able to enhance EHV-4 entry 
in an originally non-permissive cell (507). Unlike many alphaherpesviruses that 
enter endothelial cells via viral envelope fusion with the plasma membrane, EHV-
4 does so by an endocytic pathway which is reportedly dependent on dynamin-II, 
cholesterol, caveolin-1, and tyrosine kinase (507).  
The detailed pathogenesis of EHV-4 has not been fully uncovered but the 
infection mirrors that of EHV-1 at the initial stage in which the virus infects the 
epithelial cells of the URT and its associated lymphoid system. However, the 
pathogenicity, extent of virus spread and invasiveness in an infected horse are 
not as severe when compared to EHV-1 infection. The sequence similarity of 
EHV-4 with EHV-1 makes a detailed examination of EHV-4 pathogenesis useful, 
as this can provide clues to the molecular basis of pathogenesis of both viruses. 
Usually, the extent of EHV-4 infection and viral cell-to-cell spread does not occur 
beyond the infection of regional lymph nodes of the URT (206). The virus is 
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normally unable to attain the level of viremia in circulating lymphocytes needed to 
initiate the process of abortion and neurologic syndromes seen in many cases of 
EHV-1 infection. However, cell-associated viremia as a result of EHV-4 has been 
reported (508) and in rare cases, EHV-4-induced abortion has been documented 
(509). The ability of EHV-4 to induce abortion, although rare, suggests that the 
virus can sometimes overcome host immune activity that normally limits the 
infection process. Over the years, many studies have focused on the evasion of 
host immune protection by EHV-1 in equine hosts. However, in comparison, 
relatively little is known about the immune evasion strategies of EHV-4. Recently, 
we were able to demonstrate that EHV-4 reduced type-1 IFN production at the 
early onset of infection but lost this ability over time (469). Here, we investigated 
the impact of EHV-4 on host type-1 IFN signaling molecules in order to gain 
insight into the immune evasion strategies of EHV-4 during infection using an 
EEC model. 
4.2 Materials and methods 
4.2.1 Cells and viruses 
Equine pulmonary artery endothelial cells (EECs; (437)) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Mediatech Inc.) with 10% iron-
supplemented bovine calf serum (BCS, Hyclone Laboratories, Inc., Logan, UT), 
100 U/ml penicillin-streptomycin (Life Technologies, Carlsbad, CA), 1 mM sodium 
pyruvate, 0.1 mM non-essential amino acids and 200 mM L-glutamine (Life 
Technologies, Carlsbad, CA) in a humidified incubator at 37 °C with 5% CO2. 
The EHV-4 strain T445 (hereafter EHV-4) was previously isolated and archived 
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by the late Dr. George P. Allen at the Maxwell H. Gluck Equine Research Center, 
University of Kentucky. Virus stocks of EHV-4, were prepared by infection of 90 
to 100% confluent EECs at a multiplicity of 0.5 in DMEM in the absence of BCS 
as described (469). After the virus has produced nearly 100% cytopathic effect 
(CPE), the tissue culture fluid (TCF) containing the virus was freeze-thawed three 
times and clarified at 2000 x g for 30 min at 4°C, filtered through 0.45 μm 
cellulose acetate membrane filters (Thermo Scientific Nunc, Pittsburgh, PA) and 
purified by ultracentrifugation at 100,000 x g for 4 h at 4°C through a 20% 
sucrose cushion. The virus pellet was re-suspended in DMEM with 2% BCS, 
sonicated briefly, aliquoted in 100µl volumes and stored at -80°C until further 
use. The infectious virus titer was determined by plaque assay in EECs as 
described (438).  
4.2.2 Viral infections 
EECs were seeded in 6-well culture plates (Corning, NY) 48 h prior to 
infection to obtain more than 90% confluency at the time of infection. Monolayer 
cells were thereafter infected with EHV-4 at an MOI of 5 for 1 h in a humidified 
incubator at 37 °C with 5% CO2. In parallel, cells were either mock-infected with 
virus diluent (negative control) or treated with 80 μg/ml of polyinosinic acid: 
polycytidylic acid (Poly-I:C) (positive control). The cells were then incubated with 
complete growth medium for 3 h, 6 h, and 12 h respectively. Cell lysates were 
collected at these time points to evaluate target mRNAs and proteins using RT-
PCR and western blot assay respectively. All experiments were performed in 
duplicate and repeated on three independent days. 
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4.2.3 RNA extraction and real-time RT-PCR assay 
Total cellular RNA was extracted using the QiaAmp RNeasy plus mini kit 
(Qiagen Inc. Valencia, CA) from EHV-4 infected and control EECs at 3 h, 6h, and 
12 h respectively according to the manufacturer’s protocol. The quantity and 
quality of the cellular RNA were examined by OD260/OD280 measurement using 
the Synergy H1 hybrid plate reader (Biotek, Winooski, VT). One microgram of 
total cellular RNA was reverse transcribed as described (440) using 0.5 µg oligo 
dT primer. Equal amounts of cDNA were used for the transcription analysis of 
different genes by TaqMan real-time PCR using primers and probes (Thermo 
Scientific, Pittsburgh, PA) in a ViiATM 7 Fast Real-Time PCR system (Applied 
Biosystems, Foster City, CA). Details of the primers and probes used in this 
study are provided in Table 1. All reactions were performed in duplicate. The RT-
PCR data were normalized using the equine ribosomal protein large P0 (RPLP0) 
transcript as an endogenous control. The PCR efficiency for all reactions was 
assessed by LinReg software (441). Fold changes in the gene expression were 
calculated using the comparative ΔΔCT method for relative quantification (RQ) 
(442), using the average Ct value of mock-infected samples for each individual 
gene as the calibrator. 
4.2.4 Western blot analysis 
Confluent EECs were infected with EHV-4 at an MOI of 5. At 30 minutes 
prior to the end of experiment, infected cells were treated with recombinant 
equine interferon-α (rEqIFN-α) at 1000IU/ml to stimulate phosphorylation of 
STAT proteins following established protocols (31, 470). Cells were then washed 
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in cold PBS and solubilized in RIPA lysis buffer system (Santa Cruz, Dallas, TX) 
enriched with phosphatase inhibitor (Thermo Scientific, Pittsburgh, PA) on ice. 
Protein concentrations were determined using the BCA protein assay kit (Thermo 
Scientific, Pittsburgh, PA) and measured using the Synergy H1 hybrid plate 
reader (Biotek, Winooski, VT). Equal amount of proteins were then separated in 
10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred onto polyvinylidene difluoride membranes (BioRad, Hercules, 
CA). Membranes were blocked with 5% milk, 0.1% Tween-20 in Tris-buffered 
saline (TBS), and incubated overnight with the appropriate primary antibodies 
according to the manufacturer’s direction. The membranes were then washed 
and incubated with corresponding secondary antibody for 1 h at room 
temperature (RT). Protein bands were detected by enhanced 
chemiluminescence (Thermo Scientific, Pittsburgh, PA) and imaged immediately 
using Azure c600 (Azure Biosystems, Dublin, CA).  
4.2.5 Antibodies and other reagents 
Rabbit anti-STAT1 and rabbit anti-STAT2 primary antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, TX). Rabbit anti-β-actin 
primary antibody, rabbit anti-phospho-STAT1 primary antibody, and goat anti-
rabbit IgG secondary antibody conjugated with horseradish peroxidase (HRP) 
were purchased from Cell Signaling Technology (Beverly, CA). Rabbit anti-
phospho-STAT2 primary antibody was purchased from Rockland 
Immunochemicals Inc. (Limerick, PA). Polyinosinic acid: polycytidylic acid (Poly-
I:C) and lipopolysaccharide (LPS) were purchased from Invivogen (San Diego, 
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CA) and Phosphonoacetic acid (PAA) was purchased from Fisher Scientific 
(Pittsburgh, PA). Recombinant equine interferon (rEqIFN-α) was purchased from 
Kingfisher Biotech, Inc. (Saint Paul, MN). 
4.2.6 Statistical analysis 
Data from the study were analyzed by ANOVA with pairwise multiple 
comparison procedures by Tukey’s HSD test using GraphPad Prism version 6.04 
(GraphPad Software, Inc., La Jolla, CA). P-Values less than 0.05 were 
considered to be statistically significant. 
4.3 Results 
4.3.1 Effect of EHV-4 on TLR expression in EECs 
One of the mechanisms by which the innate immune system senses 
impending invasion by pathogenic microorganisms is through cellular Toll-like 
receptors (TLR) which recognize conserved small molecular motifs known as 
pathogen-associated molecular patterns (PAMP) (510). We first evaluated the 
impact of EHV-4 infection on TLR3 and TLR4, based on their reported prominent 
roles in the viral replication cycle (458, 511) and their relative abundance in 
EECs. The kinetics of induction of TLR3/TLR4 mRNA following EHV-4 infection 
in EECs revealed a manner similar to the expression observed in mock-infected 
cells at 3, 6, and 12 hpi (Fig. 4.1.A and Fig. 4.1.B). In the presence of either 
TLR3 agonist (Poly-I:C) or TLR4 agonist (LPS), EHV-4 was unable to statistically 
significantly reduce TLR3/TLR4 mRNA at all studied time-points. These findings 
suggest that EHV-4 can neither induce nor inhibit TLR3/TLR4 expression in 
EECs at the studied time-points. An antagonistic effect of EHV-4 on TLR3 and 
137 
TLR4, part of a key host cell innate immune sensing apparatus, was not evident 
which is in accord with our previous finding of elevated IFN-β levels in EHV-4 
infected EECs at later time points (469). 
4.3.2 Effect EHV-4 on interferon (IFN) transcription factors (IRF) 
Interferon regulatory factors (IRF) 3, 7, and 9 are essential factors needed 
for efficient transcription of diverse IFN-α/β genes which in turn promote robust 
antiviral immune responses (309, 483, 512, 513). We examined the effect of 
EHV-4 on IRF7 and IRF9 mRNA following infection in EECs. EHV-4 induction of 
IRF7 mRNA was similar to what was observed in mock-infected cells at 3, 6, and 
12 hpi (Fig. 4.2.A). The virus was also unable to statistically significantly alter 
IRF7 mRNA in cells stimulated with Poly-I:C at these time-points. The pattern of 
induction of IRF9 mRNA following EHV-4 infection was slightly different. Although 
not statistically significant, EHV-4 appeared to induce IRF9 mRNA at 3 hpi, 
however this induction had declined at 6 and 12 hpi respectively (Fig. 4.2.B). In 
the presence of Poly-I:C, EHV-4 was unable to statistically significantly inhibit the 
expression of IRF9 mRNA at all three time-points. 
4.3.3 Effect of EHV-4 on STAT1/STAT2 phosphorylation 
Activated STAT1 in conjunction with activated STAT2 and IRF9 form an 
IFN activated transcription factor, ISGF3, which is a heterocomplex involved in 
IFN-α/β gene induction (514-516). We recently demonstrated that EHV-1 has the 
ability to interfere with the phosphorylation and activation status of STAT1/STAT2 
in infected EECs ((31); Oladunni et al., manuscript submitted). To investigate 
whether EHV-4 may interfere with the cellular abundance and activation status of 
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STAT1/STAT2, EECs were infected at an MOI of 5 and then treated with 1000 
IU/ml of rEqIFN-α for 30 min prior to cell lysis for western blot assay. Findings 
from our study revealed that EHV-4 infection failed to induce the phosphorylation 
of STAT1/STAT2 at 3 hpi (Fig. 4.3.A and Fig. 4.3.D). The virus also reduced 
phosphorylation of STAT1/ STAT2 when cells were stimulated with exogenous 
IFN at this time-point. By 6 hpi, EHV-4 had induced a small but detectable level 
of STAT1/STAT2 phosphorylation (Fig. 4.3.B and Fig. 4.3.E). However, virus 
infection also suppressed phosphorylation of STAT1/STAT2 that was stimulated 
by exogenous IFN at 6 hpi. By 12 hpi, EHV-4 infection had stimulated 
phosphorylation of STAT1/STAT2 in infected EECs to levels comparable to 
exogenous IFN stimulation (Fig. 4.3.C and Fig. 4.3.F). At 12 hpi, there was little 
sign of viral suppression of exogenous IFN-stimulated phosphorylation of 
STAT1/STAT2. The endogenous level of total STAT1/STAT2 remained 
unchanged at all the three time points. Findings from our study revealed a trend 
of a progressive increase in the cellular abundance of phosphorylated 
STAT1/STAT2 in EHV-4-infected cells either in the presence or absence of an 
exogenous IFN treatment which differs from the pattern observed in EHV-1 
infection ((31); Oladunni et al., manuscript submitted). 
4.3.4 Effect of UV-inactivated EHV-4 on STAT1/STAT2 phosphorylation 
The data above indicate that EHV-4 infection exerted a suppressive effect 
on endogenous levels of phosphorylated STAT1/STAT2 early in the infection 
process. For this reason, we next tested the hypothesis that the suppression of 
phosphorylated STAT1/STAT2 is dependent on an active viral replication of 
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EHV-4 in EECs. We performed similar experiments as above, using UV-
inactivated EHV-4. Briefly, purified EHV-4 was UV-inactivated in a 33 mm petri 
dish placed 10 cm from a 40-watt UV lamp (UV Stratalinker 1800, CA) for 30 min. 
The inactivation of UV-treated EHV-4 was demonstrated by the absence of 
cytopathic effect when this was used to infect RK-13 cells. EECs were then 
infected with UV-inactivated EHV-4 at an equivalent dilution as the wild type 
(WT) EHV-4. Total cell lysates were then prepared for western immunoblotting. 
Mock-infected cells stimulated with 1000 IU/ml of rEqIFN-α were included as the 
positive control. Following 3hpi, EECs infected with UV-inactivated EHV-4 
induced a level of phosphorylated STAT1/STAT2 similar to that of mock-infected 
cells (Fig. 4.4.A and Fig. 4.4.D). The UV-inactivated virus also failed to 
downregulate phosphorylated STAT1/STAT2 when cells were co-incubated with 
exogenous IFN at 3 hpi. Similarly, EECs infected with UV-inactivated EHV-4 
neither induced nor suppressed phosphorylation of STAT1/STAT2 in the 
presence of rEqIFN-α at 6 hpi (Fig. 4.4.B and Fig. 4.4.E). This trend continues at 
12 hpi. EECs infected with UV-inactivated EHV-4 induced a similar level of 
phosphorylated STAT1/STAT2 when compared with mock-infected cells (Fig. 
4.4.C and Fig. 4.4.F). The UV-inactivated EHV-4 did not hinder the 
phosphorylation of STAT1/STAT2 in the presence of an exogenous IFN at 12 
hpi. UV-inactivated EHV-4 infection also did not alter the cellular abundance level 
of total STAT1/STAT2 at 3, 6, and 12 hpi. These findings suggest that active viral 
replication is required for EHV-4 to affect the cellular abundance of 
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phosphorylated STAT1/STAT2 in EECs during an infection, and that proteins 
associated with the infecting virion particles are not responsible. 
4.3.5 Effect of EHV-4 late gene expression on STAT1/STAT2 phosphorylation 
The suppression of phosphorylated STAT1/STAT2 exhibited in EHV-4-
infected cells was prominent at 3 hpi and 6 hpi, but not at 12 hpi. This pattern 
suggests a mechanism involving one or more viral early genes. To rule out 
dependence on EHV-4 late gene expression, we used a chemical inhibitor, 
Phosphonoacetic acid (PAA) (Acros Organics, NJ), to block the EHV-4 late gene 
expression as previously described (406, 517). We then evaluated the cellular 
abundance and phosphorylation of STAT1/STAT2 in EECs infected with EHV-4 
in the presence or absence of PAA at different time-points by western blot. In the 
presence of PAA, EHV-4 failed to induce phosphorylated STAT1/STAT2 at 3 hpi 
(Fig. 4.5.A and Fig. 4.5.D). The PAA-treated EHV-4 also exerted a 
downregulating effect on phosphorylated STAT1/STAT2 in the presence of 
exogenous IFN at 3 hpi. Following 6 hpi, PAA-mediated blockage of EHV-4 late 
gene expression induced a modest level of phosphorylated STAT1/STAT2 in 
infected EECs (Fig. 4.5.B and Fig. 4.5.E). Also, at this time-point, PAA-treated 
EHV-4 suppressed the phosphorylation of STAT1/STAT2 in infected cells in a 
manner observed with the WT virus. At 3 and 6 hpi, the patterns observed in 
untreated and PAA-treated EHV-4-infected EECs were similar, indicating the 
involvement of early rather than late viral factors. Interestingly, PAA-treated EHV-
4 induced a small level of phosphorylated STAT1/STAT2 but reduced the 
phosphorylation of STAT1/STAT2 stimulated by rEqIFN-α at 12 hpi (Fig. 4.5.C 
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and Fig. 4.5.F). The endogenous level of total STAT1/STAT2 remained 
unchanged at all the three time-points studied. These data suggest to us that 
possibly some late viral genes of EHV-4 have a counteracting effect on viral 
suppression of phosphorylated STAT1/STAT2. This finding is in contrast to that 
of EHV-1 virus that utilizes late viral genes to repress STAT1/STAT2 
phosphorylation in infected EECs ((31); Oladunni et al., manuscript submitted). 
4.4 Discussion 
The primary cellular targets of most respiratory virus infections are 
epithelial cells of the respiratory tract. They play an active role in the production 
and release of IFN-α/β which mediates antiviral innate immune 
responses (518) to inhibit viral replication in infected cells (519). Within the lower 
respiratory tract, alveolar epithelial cells are in close proximity to the underlying 
endothelium which is thus susceptible to infection by virus particles produced by 
infected and damaged epithelial cells (520). Previously we have demonstrated 
that there is a difference in the induction kinetics of IFN-β between EHV-1 and 
EHV-4 in EECs (469), a cell line related to the endothelial cells lining all blood 
vessels. Here, we explored the influence of EHV-4 infection on important host 
cell signaling molecules needed for type-I IFN production using our already 
established EEC model. 
Our present study revealed that EHV-4 lacked the potency to stimulate 
TLR3 and TLR4 transcription following infection in EECs. Since TLR3 and TLR4 
expression is not up-regulated, it is possible IFN induction by EHV-4 utilizes 
other sensors than the TLR family, such as those triggered by cytoplasmic 
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recognition of viral replication; retinoic acid-inducible gene I (RIG-I), or 
melanoma differentiation-associated protein 5 (MDA-5) to initiate type-I IFN 
signaling pathways in EECs. All DNA viruses, including EHV-4, are known to 
produce dsRNA by convergent transcription and thus could activate IFN-
inducible dsRNA-dependent protein kinase R (PKR), and possibly RIG-I or MDA-
5 (521). In addition, EHV-4 did not have the capacity to suppress TLR3 and 
TLR4 transcription. This is unlike most other herpesviruses. For example, we 
demonstrated that the molecular mechanism of suppression of type-I IFN 
induction by EHV-1, a virus closely related to EHV-4, involves the virus first 
downregulating TLR3 and TLR4 transcription in EECs (Oladunni et al., 
manuscript submitted). Also, TLR4 mRNA levels and protein expression are 
significantly downregulated upon primary Kaposi sarcoma-associated 
herpesvirus (KSHV) infection of human lymphatic endothelial cells (522). EHV-4 
did not inhibit TLR3 and TLR4 expression, so we do not envisage an antagonistic 
response to the effectiveness of synthetic TLR agonists like Poly-I:C were such 
to be administered as immune adjuvants when vaccinating against EHV-4 
infection. 
Transcription factors involved in IFN production are activated when a virus 
is initially detected. Activated transcription factors, such as IRF7, subsequently 
translocate to the nucleus and interact with IFN promoter sequences, leading to 
the upregulation of IFN genes (523). Data from our study showed that EHV-4 
was unable to affect IRF7 transcription. These data suggest that during EHV-4 
infection of EECs, the endogenous level of IRF7 remained fairly abundant and 
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capable of transactivating type-I IFN inducible genes. Our finding is in contrast to 
that of Zhu et al., who found that the ORF45 of KSHV interacts with IRF-7 and 
inhibits its phosphorylation and nuclear accumulation (523). It is also dissimilar to 
herpes simplex virus type1 (HSV-1) which blocks IFN regulatory factor IRF3- and 
IRF7-mediated activation of IFN-stimulated genes using its ICP0 RING finger 
domain (524). These examples are pointers to the anti-IFN mechanisms utilized 
by other herpesviruses to promote virus replication in their respective hosts. 
EHV-4, however, apparently lacks a similar capacity due to its inability to inhibit 
IRF7 which is required, together with IRF3, for inducing type-I IFN genes. Our 
data also showed that EHV-4 was unable to downregulate IRF9 mRNA when 
cells were stimulated with Poly-I:C at all time points. Degradation of the cellular 
level of IRF9 and subsequent blocking of its nuclear translocation to prevent the 
formation of IFN stimulated gene factor3 (ISGF3) complex is an IFN-evasive 
mechanism utilized by many other herpesviruses (486, 487). Since both IRF7 
and IRF9 play significant roles in the induction phase of type-I IFN production, we 
speculate that the inability of EHV-4 to downregulate these two key transcription 
factors may account for its lack of suppressive effect on type-I IFN in EECs 
(469). 
Importantly, EHV-4 failed to induce any significant phosphorylation of 
STAT1/STAT2 early during infection at 3 h. At this same time-point, the virus had 
statistically significantly suppressed the phosphorylation of STAT1/STAT2 when 
cells were co-incubated with exogenous IFN. However, our data did show that 
induction of phosphorylation of STAT1/STAT2 in response to EHV-4 infection 
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increased over time while the viral suppressive effect on phosphorylated 
STAT1/STAT2 by exogenous IFN was lost as infection progressed. We believe 
that the inability of EHV-4 infected cells to induce STAT1/STAT2 phosphorylation 
at both 3 and 6 hpi even in the presence of exogenous IFN will down-regulate 
IFN induction at early time-points, as we previously observed (469). We also 
showed that the ability to inhibit the phosphorylation of STAT1/STAT2 by EHV-4 
requires de novo viral DNA synthesis. UV-inactivation of EHV-4 abolished the 
suppressive effects on STAT1/STAT2 phosphorylation that were profoundly 
present during the early onset of WT virus infection at 3 and 6 h. The striking 
difference in the phenotypes of STAT1/STAT2 phosphorylation in EECs infected 
with EHV-4 either in the presence or absence of PAA treatment occurred at 12 
hpi. Data suggested that one or more early viral genes of EHV-4 were needed for 
suppression of STAT1/STAT2 phosphorylation, but by the later period this 
activity has worn off. 
One major shortfall of our study is our inability to demonstrate whether 
EHV-4 alters the protein levels of studied TLRs and IRFs due to lack of equine-
specific antibodies. We hope that future studies will be able to address this 
limitation to uncover the impact of EHV-4 on post-transcriptional levels of these 
factors. The inability of EHV-4 to exert a negative influence on key molecules of 
type-I IFN response may also be directly related to its reduced pathogenicity 
when compared to EHV-1 explaining why EHV-4 infection is mostly restricted to 
the URT. In a different study, Vandekerckhove et al., (215) reported a reduced 
lateral spread of EHV-4 in nasal mucosal epithelium when compared to EHV-1 
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suggesting the inability of EHV-4 to inhibit the antiviral effects of type-I IFNs in 
mucosal epithelial cells. This striking difference in the pathogenic potential 
between EHV-1 and EHV-4 provides additional evidence for the lesser severity of 
respiratory signs observed, in vivo, during EHV-4 infection (105, 525, 526). 
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Table. 
Table 4. 1 Primers and probes for RT-PCR. 
Target gene Sequences (5’-3’) / Assay ID 
EqRPLP0 
Fwd: CTGATTACACCTTCCCACTTGCT 
Rev: AGCCACAAATGCAGATGGATCA 
Probe: FAM-AAGGCCTTGACCTTTTC-NFQ 
(406) 
EqTLR3 Ec03467747_m1 
EqTLR4 Ec03468994_m1 
EqIRF7 AJBJX9T 
EqIRF9 ARMFXCF 
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                                             Figures. 
 
Figure 4. 1 Effect of EHV-4 infection on TLR mRNA transcription. Mock-infected 
EECs (M, solid bars) were either treated with 80 µg/ml of Poly-I:C for A or 10 µg/ml of 
LPS for B (both labelled as P, clear bars) or infected at an MOI of 5 with EHV-4 in the 
absence (E4, checker board bars) or presence of P (P+E4, diagonal-striped bars). At 
indicated time-points, the cells were lysed and equine (A) TLR3 and (B) TLR4 mRNA 
were quantified by real-time RT-PCR as described in the text. Data were normalized to 
the levels of endogenous control equine RPLPO mRNA at the same time point. Each bar 
represents the mean and standard deviation from three independent experiments. Non-
significant data is denoted by ns. 
 
 
Figure 4. 2 Effect of EHV-4 infection on IRF mRNA transcription. EECs were either 
mock infected (M in solid bars) or Poly-I:C-treated (P in clear bars) or infected at an MOI 
of 5 with EHV-4 in the absence (E4, checker board bars) or presence of P (P+E4, 
diagonal-striped bars). At indicated time-points, the cells were lysed and equine (A) IRF7 
and (B) IRF9 mRNA were quantified by real-time RT-PCR as described in the text. Data 
were normalized to the levels of endogenous control equine RPLPO mRNA at the same 
time point. Each bar represents the mean and standard deviation from three independent 
experiments. Non-significant data is denoted by ns. 
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Figure 4. 3 Effect of EHV-4 infection on IFN-induced STAT1/STAT2 phosphorylation. 
EECs were either mock-infected (M) or infected with EHV-4 (E4) at an MOI of 5 and cells 
were either treated or left untreated (+/- in figure) with equine rEqIFN-α at 1000 IU/ml for 
30 min before lysis. Abundance of phosphorylated versus total STAT1 at (A) 3 h, (B) 6 h, 
and (C) 12 h or phosphorylated versus total STAT2 at (D) 3 h, (E) 6 h, and (F) 12 h were 
then quantified using western blot analysis. Membranes were stripped and reprobed with 
β-actin as a control for equal loading of samples. The western blot images were 
representative of 3 different blots from independent experiments. 
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Figure 4. 4 Effect of UV-inactivated EHV-4 on STAT1/STAT2 phosphorylation. EECs 
were either mock-infected (M) or infected with UV-inactivated EHV-4 (E4) at an MOI of 5 
and cells were either treated or left untreated (+/- in figure) with 1000 IU/ml of equine 
rEqIFN-α for 30 min prior to lysis. Abundance of phosphorylated versus total STAT1 at 
(A) 3 h, (B) 6 h, and (C) 12 h or phosphorylated versus total STAT2 at (D) 3 h, (E) 6 h, 
and (F) 12 h were then quantified using western blot analysis. Membranes were stripped 
and reprobed with β-actin as a control for equal loading of samples. Images were 
representative of 3 independent biological experiments. 
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Figure 4. 5 Effect of viral late gene blockage of EHV-4 on STAT1/STAT2 
phosphorylation. EECs were infected with EHV-4 (E4) either in the presence (left 
columns) or absence of PAA (300 µg/ml). Mock-infected EECs (M) were either treated or 
left untreated (+/- in figure) with equine rEqIFN-α at 1000 IU/ml for 30 min before lysis. 
Abundance of phosphorylated versus total STAT1 at (A) 3 h, (B) 6 h, and (C) 12 h or 
phosphorylated versus total STAT2 at (D) 3 h, (E) 6 h, and (F) 12 h were then quantified 
using western blot analysis. Membranes were stripped and reprobed with β-actin as a 
control for equal loading of samples. The western blot images were representative of 3 
different blots from independent experiments.  
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CHAPTER 5: GENERAL DISCUSSION 
5.1 Summary 
Equine herpesvirus-1 (EHV-1), a DNA virus under the genus 
Varicellovirus, subfamily alphaherpesvirinae, is one of the most important and 
prevalent viral pathogens of horses and a major threat to the equine industry 
(499). Features of this viral infection involves the destruction of either the 
epithelial cells of the URT or the endothelial cells lining the small blood vessels of 
the pregnant uterus or the CNS which leads to outbreaks of sporadic abortions or 
CNS disorders as sequelae of an initial respiratory illness in affected horses 
(456, 527, 528). Prior research in the field has overwhelmingly focused on the 
impacts of the EHV-1 on the adaptive arm of the immune system of an infected 
horse. Certainly, such studies provide valuable insights, as the typical immune 
response to an intracellular pathogen requires a strong cell-mediated and 
humoral-immunity to clear the invading pathogens. However, such studies fail to 
provide a nuanced understanding of the distinct roles of an important arm of 
innate immunity- the type-I IFN system, which act as the ‘first responder’ of the 
host against an invading viral pathogen. EHV-1, like many other successful 
viruses, can circumvent this important host innate immunity but yet, only few 
studies have looked into the direct impacts of the virus infection on the host type-
I IFN response. Here, our goal was to examine the alterations in the biology of 
the host type-I IFN response during equine alphaherpesviruses’ infection using a 
relevant cell culture model (EEC) chosen to attempt to mimic natural infection of 
the blood vessels of the uterus/CNS.  
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5.2 Major findings 
5.2.1 Pathogenic EHV subtypes have inherent ability to shut down type-I IFN 
response in host cells.  
Field outbreaks of EHV-1 vary in pathogenicity, and some but not all field 
isolates are highly neuropathologic (246, 411, 527). As a result, isolates of EHV-
1 that exist in the field can be broadly classified as neuropathogenic and non-
neuropathogenic, based on presence of a DNApol SNP which influences whether 
a horse develops a neurologic syndrome or not. Although it is believed almost all 
strains of EHV-1 can induce abortion in pregnant mares, in general the strains 
with an A2254 → G2254 mutation in the viral DNApol leading to a change from 
asparagine to aspartic acid at amino acid position 752 (N752→D752) are the 
strains with the strongest potential to cause neurologic disease (272, 452, 454). 
In chapter 2 of this dissertation, we hypothesized that EHV-1 strains vary in their 
ability to suppress IFN-β response and that this variation is associated with 
variation in viral neuropathogenicity. Our data revealed that all the studied 
isolates (both neuropathogenic and non-neuropathogenic based on D or N at 
752) of EHV-1 had reduced induction kinetics of IFN-β mRNA at 12 hpi when 
compared to poly-I:C-treated controls (Fig. 2.2). No statistically significant 
correlations were observed between the IFN-β mRNA induced in infected EECs 
and neuropathogenic genotype of EHV-1 isolates. This data implied that the host 
cells’ release of IFN-β following EHV-1 infection is not determined by the 
presence of a mutation in the virus DNA polymerase. Indeed, both EHV-1 strains 
with the neuropathogenic genotype and non-neuropathogenic genotype have 
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viral factors mediating an inhibition of IFN-β response in host cells following 
infection. The classification of EHV-1 isolates into either neuropathogenic or non-
neuropathogenic genotypes based on presence of a DNApol SNP is overly 
simplistic as factors other than viral factors may influence neuropathogenicity 
(109). Our data refutes our hypothesis, and it is possible that both genotypes of 
EHV-1 possess similar pathological relevance within a host resulting in similar 
patterns of antigenic stimulation and IFN-β response observed in vitro. This 
possibility is also supported by our data revealing that the presence of a DNApol 
SNP in the neuropathogenic genotype of EHV-1, previously demonstrated to 
affect virus load in vivo (411), exerts no influence in the extent of virus’ cell-to-cell 
spread in EECs as measured by plaque assay. With influenza virus, defects in 
the viral gene (NS1) responsible for IFN suppression are correlated with reduced 
plaque size and attenuated replication in IFN-competent cells (529). It is, 
therefore, deducible from our study that the DNA polymerase of EHV-1 encoded 
by ORF30 is not the viral factor mediating type-I IFN shutdown in EECs during 
infection.  
We next modified our hypothesis to investigate whether there is a 
correlation between pathogenicity of EHV subtypes and type-I IFN inhibition that 
we observed with EHV-1 field isolates. For this study, we compared the well 
characterized T953 strain of EHV-1 isolated from a previous neurologic outbreak 
with the T445 strain of EHV-4 which has reduced pathogenicity mainly confined 
to the URT. Data revealed that these two EHV subtypes produced different 
patterns of IFN-β induction in EECs with EHV-1 being a more potent inducer of 
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IFN-β mRNA early in infection (Fig. 2.3.A). This finding correlates with EHV-1 
being more virulent than EHV-4 therefore, eliciting an immediate IFN response 
from infected host cell during infection. Interestingly, EHV-1 but not EHV-4 
produced an antagonistic effect on type-I IFN production in EECs later in 
infection at 12 hpi. Consistent with our hypothesis, our data revealed that 
suppression of type-I IFN activity is a correlate of the pathogenicity of EHV 
subtype with the more pathogenic EHV-1 being able to inhibit type-I IFN in host 
cells. Although the magnitude and duration of viremia produced by EHV-1 have 
been described as critical factors enabling the delivery of EHV-1 to distant 
tissues (109), we opine that EHV-1 specifically shuts down host type-I IFN 
responses in endothelial cells of the pregnant uterus and CNS in order to aid 
virus cell-to-cell spread and replication. This eventually leads to the damage 
observed in the microvasculature of the small blood vessels around these 
secondary target organs leading to severe symptoms such as abortion and CNS 
disorders. We deduced that inhibition of type-I IFN is not a neuropathogenic 
phenomenon but rather a pathogenic attribute of EHV-1, irrespective of its 
genotype, that enhances virus spread and replication in host cells. 
5.2.2 EHV-1 negatively regulates host factors required for type-I IFN production 
Type-I IFN induction by virus-infected cells occurs in 3 phases- 
sensitization, induction, and amplification (302). Our findings together with others 
from our lab (31, 402, 406, 418) revealed that EHV-1 can inhibit type-I IFN 
responses, in the host cell, but there is still an open question of how the virus 
achieves this. We next explored the effect of EHV-1 infection on type-I IFN 
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signaling pathways with the aim of identifying the steps targeted for inhibition 
(chapter 3). At the beginning of the signaling events leading to type-I IFN 
production are a family of innate immune-recognition receptors called TLRs. 
TLRs recognize conserved molecular patterns (PAMPs) that are associated with 
microbial pathogens, and induce anti-microbial immune responses including 
type-I IFN (530, 531). In addition to stimulating TLR signaling events, other 
viruses (both RNA and DNA virus) have been demonstrated to inhibit TLR 
expression and signaling thereby, counteracting IFN production in the process 
(480, 532). We hypothesized that EHV-1 down-regulates the cellular expression 
levels of TLRs so as to dampen the innate immune response to infection. Our 
study demonstrated a statistically significant reduction of both TLR3 and TLR4 
mRNA in EHV-1-infected EECs at 6 hpi and 12 hpi (Fig. 3.1). Downregulating the 
expression of TLR3 and TLR4 probably helps EHV-1 to escape being recognized 
as a pathogen favoring virus replication within host cells. Our study of TLR 
expression did not investigate the impact of EHV-1 on specific TLR signaling 
owing to poor performance of the TLR ligands we tested (TLR7 and TLR9 
ligand). However, we believe that by inhibiting TLR3 and TLR4 expression, EHV-
1 would have a negative effect on downstream signaling events which will hinder 
type-I IFN production. Although we did not test the hypothesis that EHV-1 
similarly inhibits other cytosolic PRRs such as RLR, we speculate, based on our 
TLR data that EHV-1 utilizes same viral factors to evade cytosolic detection. 
Among the nine members of the IRFs (IRF1-9), four have been associated 
with the transcriptional induction of IFN-α/β genes (533-535). Previously, our 
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laboratory reported that the T953 strain of EHV-1 inhibits host type-I IFN 
response by antagonizing IRF3 activation and subsequent nuclear translocation 
in EECs during infection (402). We next hypothesized that EHV-1 down-regulates 
IRF7 and IRF9 as part of its mechanism of IFN-α/β suppression. Our data 
supports this hypothesis (Fig. 3.2) indicating that EHV-1 specifically inhibits 
cellular levels of both IRF7 and IRF9 to block the induction of IFN-α/β genes 
during infection. Both IRF7 and IRF9 play distinct and essential roles which 
together ensure transcriptional efficiency and diversity of IFN-α/β genes for a 
robust antiviral response. While IRF3 and IRF7 form a complex-virus activated 
factor (VAF) that binds IFN-β promoter in the nucleus (536), IRF9 is a subunit of 
IFN-activated transcription factor termed ‘ISGF3’ which is involved in IFN-α/β 
induction (537-539). Inhibition of these important IFN transcription factors 
demonstrates a downstream effect of EHV-1 on efficient TLR signaling enabling 
the virus to avoid host antiviral response. 
As described in the Introduction, IFN antiviral activity depends upon 
successful JAK-STAT signaling for induction of IFN-α/β. Some viruses including 
herpesviruses disrupt the JAK-STAT signaling pathways at different steps (404, 
540, 541). Recently, our laboratory also demonstrated high resistance of EHV-1 
to rEqIFN-induced phosphorylation and nuclear translocation of STAT1 
molecule in infected EECs (31). We hypothesized that EHV-1 has a similar effect 
on STAT2 during infection. Consistent with the previous result, our data showed 
that EHV-1 infection of EECs reduced phosphorylation of STAT2 and promoted 
cytosolic retention of STAT2 even in the presence of an exogenous IFN 
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stimulation (Fig. 3.4.A and Fig. 3.4.D). The possibilities are that either EHV-1 is 
directly preventing the nuclear accumulation of STAT2 by physically interacting 
with STAT2 or the virus is blocking the upstream activators of STAT2 molecule. 
We next hypothesized that EHV-1 blocks both STAT1 and STAT2 activation by 
interfering with the upstream kinases responsible for STAT1 and STAT2 
phosphorylation. The Janus kinases, JAK1 and TYK2, are important upstream 
factors required for the phosphorylation-activation of STAT1 and STAT2 
molecules (324, 325, 488). Our data revealed that while the cellular abundance 
of JAK1 remained constant with infection, EHV-1 infection degrades the cellular 
abundance of TYK2 at 12 hpi (Fig. 3.3). By down-regulating the cellular level of 
TYK2, we suggest that EHV-1 indirectly blocks the phosphorylation-activation of 
STAT1/STAT2 molecule. Other viruses such as human metapneumovirus have 
been shown to direct both JAK1 and TYK2 for proteosomal degradation, thereby, 
interfering with STAT1 and STAT2 phosphorylation (21). We are at this time 
unable to confirm whether an EHV-1 viral factor physically interacts with STAT2 
molecule as is reported for HSV ICP27 (470). However, our data support the 
hypothesis that EHV-1 mediated inhibition of IFN-α/β induction comes by way of 
an ineffective JAK-STAT pathway. We also found that UV-inactivated EHV-1 is 
not able to block the phosphorylation of STAT1/STAT2 indicating that de novo 
viral gene expression or viral replication is required for reduced phosphorylation 
of STAT1/STAT2. Similarly, blocking the late gene expression by EHV-1 
abolishes its suppressive effects on STAT1/STAT2 phosphorylation. The 
inhibitory effects of EHV-1 on IFN-α/β induction occurs at different levels of the 
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signaling cascade, as the virus blocks TLR3 and TLR4 gene transcription, 
inhibits IRF7 and IRF9 gene transcription, and facilitates TYK2 degradation, 
ultimately leading to inhibition of STAT2 activation. As a result, we speculate that 
the ability of EHV-1 to interfere with outside-in signal transduction and the JAK-
STAT pathway will be consequential on the host type-I IFN response. Therefore, 
it is reasonable to hypothesize that EHV-1 encodes one or more viral proteins, 
presumably encoded by late genes, responsible for the sequential events 
targeted at achieving a reduced IFN-α/β induction in the infected host cell. 
Acquisition of these mechanisms for IFN evasion that can subdue multiple steps 
of IFN pathway may be one of the reasons why EHV-1 remains a successful 
pathogen of horses. 
5.2.3 EHV-4 is unable to block host factors of type-I IFN production 
In chapter 2, we showed that the ability to shut down the host type-I IFN 
response is not pathogenicity dependent among EHV-1 strains. EHV-1 and EHV-
4 share 55 to 84 % nucleotide identity within the individual homolog genes and 
55 to 96% homology exists between their amino acid sequences (77, 81). So, an 
EHV-1-coded IFN-suppressive factor might possibly be shared by EHV-4. In 
chapter 4, we investigated whether EHV-4 exerts similar effects as EHV-1 on 
type-I IFN induction steps during infection of EECs. EHV-4 replicates in EECs 
although endothelial cells are not its normal site of replication in the horse. EHV-
4 failed to either induce or inhibit TLR3 and TLR4 mRNA even in the presence of 
a positive inducer (Fig. 4.1). These findings suggest that unlike EHV-1 which is 
more pathogenic, EHV-4 should not be able to evade recognition and oppose 
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downstream TLR signal transduction needed for IFN-α/β induction. Similarly, our 
data showed that EHV-4 was unable to down-regulate the expression of both 
IRF7 and IRF9 mRNA. Similarly, we do not expect EHV-4 to interfere with IFN-
α/β induction at any time during infection due to lack of inhibition of IRF7 and 
IRF9 mRNA. Interestingly, EHV-4 suppressed the phosphorylation of 
STAT1/STAT2 molecules but progressively lost this suppressive effect with time. 
By blocking phosphorylation-activation of STAT molecules early during infection, 
EHV-4 might prevent a robust IFN-α/β gene induction during early infection. 
These data are in contrast to our EHV-1 data and may be related to the relative 
inability of EHV-4 to replicate outside of the URT. Suppression of IFN-induced 
STAT1/STAT2 phosphorylation is dependent on an active viral gene expression 
by EHV-4. UV-inactivation of EHV-4 abolished these effects (Fig. 4.4). 
Intriguingly, unlike EHV-1, viral late gene expression was not required for the 
inhibition of STAT1 and STAT2 phosphorylation by EHV-4. PAA-mediated 
blockage of EHV-4 late gene did not abolish the suppressive effect on STAT1 
and STAT2 phosphorylation at 3 hpi and 6 hpi (Fig 4.5.A, Fig. 4.5.B, Fig. 4.5.D, 
and Fig 4.5.E). We speculate that EHV-1 and EHV-4 utilize different viral genes 
or pathways for interfering with STAT1 and STAT2 phosphorylation. It would be 
interesting to find out the effect an EHV-1-EHV-4 chimera, expressing only EHV-
4 late genes, would have on type-I IFN in vitro. We predict a reduced IFN-
suppressive effect from such chimera in infected EECs. Individual field isolates of 
EHV-1 and EHV-4 exhibit wide variations in virulence in horses (206, 213). 
Hypervirulent strains of EHV-1, such as the ones in this study, are highly 
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endotheliotropic causing high rates of abortion and neurologic syndromes (213, 
229). However, EHV-4 primarily causes respiratory disease and normally does 
not lead to abortion and neurologic disease due to reduced endothelial cell 
replication and cell-associated viremia (77). Our data show that EHV-1 but not 
EHV-4 has the inherent ability to shut down the host IFN-α/β response in infected 
cells. This exerts a major influence on the diverse replication and invasion 
strategies exhibited by the two EHV subtypes. In vivo, we therefore expect EHV-
1 to be able to avoid triggering an immediate IFN-α/β alert and also be able to 
inhibit IFN-α/β response induced by other co-infecting unrelated pathogens 
enabling the virus to promote secondary pathologies. This provides further 
explanation of the differential pathogenic potentials that exist between EHV-1 
and EHV-4 during natural outbreaks of infection. 
5.3 Limitations 
One of the caveats of our EEC model employed for this project is a direct 
extrapolation of our novel findings to reflect natural events in an intact animal 
model or a horse. The complexity in the architecture and organization of different 
organs within a horse may influence the outlook of our study were it conducted in 
vivo. In an intact horse, a robust induction of the full complement of the host 
immune response may have an overlapping role in moderating EHV-1 disease 
establishment which may make an exaggeration of our in vitro results. Although 
we were able to establish EHV-1 and EHV-4 infections in EECs, direct infection 
of the endothelial cells with free virus particle may not be reflective of a natural 
infection in field outbreaks. Both EHV-1 and EHV-4 are primarily respiratory 
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pathogens with tropism for equine respiratory mucosal epithelium that permits 
efficient viral entry into the horse (77), and indeed, most respiratory pathogens 
are disposed of by the mucociliary escalator even if they evade nasal filtering and 
end up in the trachea (542). Therefore, care must be taken in interpreting our 
results as it may be seemingly unlikely for free virus particles, in high titers, to 
have direct access to the endothelium of different tissues after an initial escape 
from the URT in a healthy horse.  
The lack of expression of certain TLRs in EEC also places limitations on 
the scope of this dissertation. Although thirteen mammalian TLRs have been 
recognized, only TLRs 2-4 and 6-9 have been found to be expressed in equine 
cells (543-547). While TLR7 recognizes viral ssRNA, TLR9 detects non-
methylated viral CpG-containing DNA motifs in dsDNA viruses (548). Our EEC 
model failed to show induction of the expression of TLR7 and TLR9 even when 
stimulated with the corresponding TLR7 (tlrl-gdq-5) and TLR9 (tlrl-dsl03) agonists 
(Invivogen, CA). While other researchers have demonstrated the expression of 
these two genes in different horse studies (547, 549), it is possible that their 
expression is cell-type specific. A few other studies have also reported low level 
expression or lack of expression of both TLR7 and TLR9 mRNA in equine and 
human epithelium tissue samples (550, 551). Our results suggest that both TLR7 
and TLR9 are not required for sensing EHV-1 genetic material in EECs. The 
overlapping nature of the TLR signaling pathway may help compensate for any 
lack of TLR7 and TLR9 expression in EECs ensuring that viral pathogens do not 
escape detection. 
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Another limitation of this study is our inability to evaluate the 
posttranslational cellular abundance of TLR3, TLR4, IRF7, and IRF9 proteins 
following EHV-1 infection of EECs. Evaluating the biological effects of EHV-1 on 
host gene expression without a protein data may present an incomplete 
description of the mechanism being studied. It is possible that certain 
posttranslational modifications occur following gene transcription during EHV-
infection of EECs which may directly influence the global picture of our data were 
protein data available. During the course of this study, we were confronted at one 
point or the other with either lack of availability of an equine-specific antibody 
reagent, or ineffectiveness of the available equine-specific antibody. This limited 
the scope of our study and restrained us from asking other fundamental 
questions that would have provided additional details to the current findings. 
Future work should focus on delineating the impact of EHV-1 on protein products 
of TLR3, TLR4, IRF7, and IRF7 mRNA following infection. When useful equine-
specific antibodies are available, it will also be fascinating to investigate whether 
EHV-1 targets TLR-mediated recruitments of adaptor proteins during infection. 
5.4 Future directions 
This dissertation has provided valuable insights into the previously unknown 
mechanisms employed by EHV-1 to circumvent type-I IFN responses in host cell. 
It is our hope that this work encourages future exploration into the lifecycle of 
EHV-1 and host-pathogen interactions affecting the quality of innate immunity, 
particularly the type-I IFN response. Perhaps one of the crucial unanswered 
questions of this project is identifying the exact viral factor utilized by EHV-1 to 
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inhibit the host type-I IFN response. Throughout the course of our study, EHV-1-
mediated inhibition of host factors (e.g. STAT, TYK2) required for type-I IFN 
response occurred predominantly at 12 hpi. Coincidently, the observed timing 
corresponds to when EHV-1 significantly down-regulates type-I IFN in host cells 
(Fig. 2.3.B). This implies that the viral factor responsible for type-I IFN inhibition 
in the host cell is expressed by 12 h during the virus lytic life cycle. In chapter 3, 
we also presented data that supports our hypothesis that the viral factors 
responsible for anti-IFN response in host cells are late-expressed factors 
(Fig.3.7.C). Similarly, a previous study had also reported the involvement of a 
late protein of pseudorabies virus, another alphaherpesvirus, in the blockage of 
IFN-mediated phosphorylation of STAT1 (552). We, therefore, propose that the 
following selected late genes of EHV-1 be screened for their inhibitory effect on 
type-I IFN response in host cells. Studies on HSV-1 have revealed that important 
viral proteins, such as ICP34.5, US11, ICP0, ICP27, UL13, and UL41, target 
different steps of the type-I IFN system including production of IFN, IFN 
signaling, and the functioning of ISG products (470, 524, 553-556). While EHV-1 
encodes functional homologs of HSV-1 ICP0, ICP27, UL13, and UL41 proteins, it 
lacks both ICP34.5 and US11 (Table 1.2). Future work in our laboratory will seek 
to characterize the functional relevance of EHV-1 ORF 63 (HSV-1 ICP0 
homolog), EHV-1 ORF5 (HSV-1 ICP27 homolog), EHV-1 ORF49 (HSV-1 UL13 
homolog), and EHV-1 ORF19 (HSV-1 UL41 homolog), on type-I IFN pathway in 
equine cells. This might be achieved by evaluating the impact of infectious clones 
of EHV-1, containing mutations of reported IFN-suppressing HSV-1 homologs, 
 164 
 
on type-I IFN response in infected EECs using reporter assays. We also hope to 
screen selected EHV-4 IE and E genes that are possibly functional homologs of 
documented HSV-1 genes involved in STAT1/STAT2 phosphorylation-inhibition. 
The advent of next generation sequencing (NGS) has revolutionized our 
abilities to formulate scientific questions and advance knowledge. NGS has 
predominantly been used in studying infectious pathogens such as HIV (557-
559) and hepatitis B virus (560-562) but it is now gaining traction for other viruses 
including HSV-1 (563-565). In the future, we propose to conduct a 
comprehensive transcriptome profiling of the host type-I IFN response to EHV-1 
through NGS. The first approach of this study would be accomplished in vitro in 
EHV-1 target cells such as equine RECs and EECs. A second approach would 
be to directly address the host mediated anti-EHV-1 innate immune responses in 
vivo, using an experimentally infected horse model. Using both in vitro and in 
vivo approaches would provide a better picture of what is going on in arm races 
between EHV-1 and its host as infection progresses. We predict that using this 
approach would reveal key host innate immune transcriptomes that are either 
downregulated or upregulated during EHV-1 infection. This could potentially be 
used to identify host factors that contributes to the development of EHM. 
Similarly, modern technologies such as generation of an infectious EHV-1 clone 
system and CRISPR-Cas9 can be used for making many mutations in a short 
form to tease out EHV-1 protein functions and host response once a specific viral 
gene target has been identified. 
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Another fascinating area of future research is to delineate the role of the 
respiratory microbiome during EHV-1 infection. There is now a global shift of how 
animal and human disease conditions are managed in terms of minimizing 
therapeutic interventions while at the same time obtaining an optimal result. A 
study on the alterations in the upper respiratory tract biota in EHV-1-infected 
horses can provide a viable approach to managing the initial stage of the 
respiratory disease. Since EHV-1 gains entry and first replicates in the 
respiratory epithelial cells, we would like to study how EHV-1 affects the diversity 
of the respiratory tract microbiome in infected horses. The phenotypes of the 
upper respiratory tract microbiome from EHV-1 infected horses could be 
compared with those from healthy control horses using NGS. Recent reports 
have indicated that the gastrointestinal microbiota exerts an essential role in 
maintaining intestinal epithelial cell integrity and development of the mucosal 
immune system (566-570). We propose that there would be a reduced diversity 
of the respiratory tract microbiome in EHV-1-infected horses when compared to 
healthy uninfected controls. This study would reveal the identity and possible 
roles of missing microflora in the respiratory tract of the EHV-1-infected horses. 
Restoration of the respiratory tract flora population by microbiota transplant can 
potentially help improve the health of EHV-1-infected horses by reviving the lost 
mucosal immunity during infection. The major advantage of this approach is that 
it removes the risk of adverse effects of administering medicine or that of 
vaccination. This approach has been tried with great success for managing 
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gastrointestinal diseases and can also be adapted as a potentially viable 
approach for managing the initial respiratory disease associated with EHV-1. 
Other compelling questions, with accompanying speculation, include:  
1. Does EHV-1 equally antagonize type-III IFN? 
Three classes of IFN, Type-I, II and III, have been characterized (571). 
Functionally, type-III IFN (IFN-λ) produces effects very similar to IFN-α. These 
include induction of antiviral, anti-proliferative, anti-tumor, and other innate 
immune responses (572). Although the IFN-λ receptor complex is unique, once 
activated by ligand binding it signals through the same intracellular pathways as 
IFN-α/β which accounts for its producing much the same functional effects 
including antiviral activity (571, 573, 574). Our current data revealed that EHV-1 
is equipped with viral factors which mediate an anti-type-I IFN response in EECs. 
By extension, similar questions can be asked about the impact of EHV-1 on IFN-
λ response at the mucosal epithelium of the URT. This will offer a supportive 
detail on how EHV-1 is able to manifest and establish infection in its initial 
primary replication site. We predict that EHV-1 will block type-I IFN responses as 
well, by using the same mechanisms as for type-I IFN. 
2. Does EHV-1 inhibits type-I IFN response in uninfected bystander cells? 
In chapter 2, we demonstrated that inhibition of type-I IFN response in host cells 
is a pathogenic property of all EHV-1 pathotypes. The ability to evade the type-I 
IFN response of the host facilitates virus cell-to-cell spread during EHV-1 
infection. This raises another question: is EHV-1-mediated anti-IFN response 
restricted to only virus-infected cells? In the future, we intend to carry out single 
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cell studies that will look at host responses to EHV-1 effects in both virus-infected 
cell and virus-uninfected cell populations. This would provide a global picture of 
the extent of IFN suppressive effect that is present during EHV-1 infection. If 
EHV-1 did suppress IFN response in uninfected cells, we would be interested in 
delineating the steps in the type-I IFN system pathways that are likely targeted as 
a result. We predict that EHV-1-mediated IFN suppression effect does not affect 
neighboring bystander cells. 
3. What host factors contribute to the development of EHM? 
The factors that can be directly linked to the development of EHM in 
horses are ill defined. While some studies have attributed this phenomenon to 
the presence of an SNP in the ORF30 encoding DNA polymerase in EHV-1 (272, 
452), there is still some debates about this explanation. Furthermore, our data 
suggest that both EHV-1 with the neuropathogenic genotype and EHV-1 strains 
with the non-neuropathogenic genotype behave similarly in vitro in affecting the 
type-I IFN response. It has also been reported that older horses are more 
susceptible to the development of EHM (411, 575), suggesting that, possibly, 
host factors may be responsible for the development of this phenotype. It is also 
noteworthy that only the endothelial cells of some selected organs such as 
conjunctiva, pregnant uterus, and CNS are EHV-1-affected. Future studies may 
characterize the cell surface adhesion molecules or markers on these EHV-1 
target organs relative to other organs to answer if, indeed, there are certain host 
determinants of EHM. 
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5.5 Conclusions 
Here, we gathered evidence in support of our hypothesis that pathogenic 
strains of EHV-1 encode viral factors that allow them to overcome the potent 
antiviral effects of the host type-I IFN response during infection. During natural 
outbreaks in horses, EHV-1 particularly targets endothelial cells of important 
organs such as the respiratory tract, the conjunctiva, pregnant uterus, and the 
CNS. Our data suggest that suppression of the type-I IFN response in host cells 
is among the first important steps needed by virulent strains of EHV-1 to produce 
diseases in vivo. The data herein provide compelling evidence identifying some 
of the underlying, novel, molecular pathways targeted by EHV-1 in order to 
down-regulate host type-I IFN response during infection. The inability of EHV-4 to 
inhibit type-I IFN responses in host cells may partly explain why the virus rarely 
produces fatal outcomes such as abortion and neurologic diseases. These data 
support our central hypothesis and provides valuable insights into how 
pathogenic EHV-1 manipulate the type-I IFN signaling pathway in order to 
promote disease (Fig. 5.1). Our data has provided the groundwork for the 
identification of therapeutic target(s) of EHV-1. Further investigation to identify 
the viral protein(s) utilized by EHV-1 to resist host type-I IFN response may help 
fuel the discovery of novel therapeutic that will be effective against EHV-1 
disease outbreaks. 
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Figure. 
 
Figure 5. 1 Schematic illustration of our proposal of how EHV-1 T953 strain blocks the 
key molecules required for type-I IFN production. (A) During the sensitization phase of 
host type-I IFN production, EHV-1 blocks the expression of TLR3 and TLR4 mRNA 
thereby enabling the virus to avoid host detection. (B) In the subsequent induction phase, 
EHV-1 specifically degrades the cellular level of TYK2 protein. This consequently blocks 
the abundance of cellular levels of phosphorylated/activated STAT1 and STAT2 
molecules in infected cells. At the same time, EHV-1 blocks the transcription of IRF9 
mRNA and thus prevents the formation of ISGF3 complex needed to transactivate ISRE 
for ISG production. EHV-1 also inhibits the transcription of IRF7 mRNA, exerting a 
negative effect on IFN-α production. The overall effect of EHV-1 renders the host cell 
unable to restrict viral spread by direct cell-to-cell contact during infection. 
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